T-lymphocyte/monocyte interactions in relation to inflammatory joint diseases by Al-Shukaili, Ahmed Khalifa Ali
        
University of Bath
PHD
T-lymphocyte/monocyte interactions in relation to inflammatory joint diseases







Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 13. May. 2019
T-lymphocyte/monocyte interactions in 
relation to inflammatory joint diseases
Submitted by 
Ahmed Khalifa Ali Al-Shukaili
For the degree o f Doctor o f Philosophy 
of the University of Bath
2004
Copyright
Attention is drawn to the fact that the copyright of this thesis rests with the author. 
This copy of the thesis has been supplied on the condition that anyone who consults 
its understood to recognise that its copyright rests with author and that no quotation 
from the thesis and no information derived from it may be published without the prior 
written consent of the author. This thesis may be made available for consultation 





INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a complete manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
Dissertation Publishing
UMI U177315
Published by ProQuest LLC 2013. Copyright in the Dissertation held by the Author.
Microform Edition © ProQuest LLC.
All rights reserved. This work is protected against 
unauthorized copying under Title 17, United States Code.
ProQuest LLC 
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106-1346
I • .‘ .•(VER-SiTV OF BATH 1 
j LIBRARY
j 4 -0  2 9 JUL 2004
5
%  . * - . . . .........
Acknowledgements
Throughout the course of this thesis, I have been supported, advised and encouraged 
by my supervisor, Dr Nick Hall. I would like to thank him very much for his 
continuous encouragement and support, and I will always be extremely grateful for 
the opportunities and help provided.
Likewise, my thanks must go to Dr Gavin Lyndon for practical guidance throughout 
this project. Also, I wish to thank Dr Pauline Wood, Dr Malcolm Watson, and Dr 
Steve Ward and his group for their help in some parts of this thesis.
Finally, I would like to thank all the blood donors (at the Department of Pharmacy 
and Pharmacology, University of Bath) for their generous donation o f blood.
II
ABSTRACT
Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease affecting the 
synovial membranes of multiple joints. Elevated levels of proinflammatory cytokines 
such as tumour necrosis factor-alpha (TNF-a) and interleukin-1-beta (IL-1 (3) have 
been detected in RA and are considered to be key mediators of the disease process. 
Hypoxia up-regulates TNF-a and IL-lp; therefore, considerable research interest has 
been focused on the biological consequences of the hypoxic nature of the rheumatoid 
synovium. A hydrogen peroxide tolerant Jurkat cell line (HJ16) was generated to 
study the mechanisms of cytokine production under oxidative stress. HJ16 and 
normal Jurkat (J16) cells were co-cultured with a monocyte cell line (THP-1) or 
peripheral blood mononuclear cells (PBMCs). IL -ip  and IL-1 receptor antagonist 
(IL-lra) production by THP-1 cells or PBMCs was measured.
HJ16 cells exhibited different characteristics to J16 cells. HJ16 cells were slightly 
activated at resting conditions, manifested by low expression of CD69. Also HJ16 
cells have higher level of glutathione (GSH) compared to J16 cells. HJ16 cells were 
more sensitive to PHA-L than J16 cells, manifested by higher expression of CD2 and 
low proliferation rate after activation. In co-culture, activated unfixed HJ16 cells 
stimulated more IL-lp production by both PBMCs and THP-1 cells, although they 
exhibited reduced calcium signalling. Activated fixed T cells (J16 and HJ16 cells) 
failed to stimulate (to significant levels) both IL -lp and IL-lra production by 
PBMCs, but significantly stimulated IL-lra production by THP-1 cells, compared to 
unfixed activated T cells. Activated fixed HJ16 cells induced slightly higher levels of 
IL-lra production by THP-1 cells. Depletion of GSH in J16 and HJ16 cells 
augmented the stimulation of IL -ip and IL-lra production by THP-1 cells, but 
reduced calcium signalling and proliferation. Enhancement of GSH levels in J16 or 
HJ16 cells had no effect on the stimulation of IL -lp or IL-lra production by THP-1 
cells.
Chronic exposure to oxidative stress such as H2O2, and decreased antioxidants (GSH) 
in T cells have altered their characteristics, and enhanced their stimulation of 
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Rheumatoid arthritis (RA) is a chronic systemic inflammatory disorder that affects 
approximately 1% of the population, in a female/male ratio of 3/1. The disease can 
occur at any age, but it is most common among those aged 40-70 years. Despite many 
years of study, the aetiology of RA is still undefined. However, with increased 
understanding of the immune system the pathogenesis of RA has become clearer. A 
large bulk of data suggests that T lymphocytes and macrophages play a critical role in 
the initiation and perpetuation of synovial inflammation (McCarty, 1989; Sewell & 
Trentham, 1993; Snowden & Kay, 1995; Panayi, 1999; Weyand, 2000).
Recently, the cytokine profile of T helper cells has been associated with the disease, 
the cytokine repertoire of inflamed synovia is categorised as that of T helper 1 
response. Moreover, in RA elevated levels of proinflammatory or inflammatory 
cytokines such as TNF-a and IL-1 (3 have been detected. Hypoxia up-regulates TNF-a 
and IL-1; therefore, considerable research interest has been focused on the biological 
consequences of the hypoxic nature of the rheumatoid synovium. Hypoxia might 
underlie the functional polarization of the T cells and cytokine production, and thus 
may contribute to the progression and persistence of the disease (reviewed by Dayer 
& Fenner, 1992; Feldman et al, 1996; Miossec & Berg, 1997; Bodamyali et al, 1998).
In addition, cellular antioxidants such as glutathione (GSH) regulate lymphocyte 
function. GSH is known to mediate lymphocyte growth and activation as well as their 
responsiveness to cytokines, (Suthanthiran et al, 1990; Staal et al, 1994; Maurice et al, 
1997; Verhasselt et al, 1999; Hehner et al, 2000; Sido et al, 2000; Roozendaal et al, 
2002; Monick et al, 2003). For example, treatment with buthionine sulfoximine
1
(BSO) to deplete GSH and N-acetyl-L-cysteine (NAC) to enhance GSH, caused a 
decrease and increase in lymphocyte proliferation respectively (Maurice et al, 1997). 
Moreover, NAC-treatment resulted in upregulation of IL-4 (Th2 cytokine) and down 
regulation of IFN-y(Thl cytokine) production, thus GSH may mediate T cell 
phenotype (Monick et al, 2003).
Direct cell contact with T lymphocytes is a potent mechanism, which induces the 
production of proinflammatory cytokines by monocytes-macrophages. This 
interaction represents an important mechanism for initiation of the inflammation and 
mediates tissue destruction. Through this interaction, mononuclear phagocytes are 
capable of mediating tissue destruction directly by secreting matrix 
metalloproteinases (MMPs) or indirectly by releasing cytokines such as IL -lp and 
TNF-a, which in turn induce the production of MMPs by connective tissue cells. In 
vitro, T cell-induced contact-dependent activation of macrophages is a potent 
mechanism to induce IL-lp, TNF-a (Dayer et al, 1985; Chizzolini et al, 1997; Vey et 
al, 1997) and MMPs (Lacraz et al, 1994; reviewed by Burger & Dayer, 2002).
The aim of this research is to determine whether oxidative stress or redox regulation 
alters the behaviour of the T cells and their interactions with monocytes-macrophages 
in relation to inflammatory joint disease.
2
1.1 Rheumatoid arthritis
Rheumatoid arthritis (RA) is a chronic recurrent, systemic inflammatory disease 
primarily involving the synovial membranes of multiple joints, followed by cartilage 
and bone destruction, which eventually lead to joint deformities and loss of articular 
functions. The clinical course of the disorder is extremely variable, ranging from 
mild, self-limiting arthritis to rapidly progressive multi-system inflammation with 
profound morbidity and mortality.
The predominant symptoms of RA are pain, stiffness, and swelling of peripheral 
joints. These symptoms are accompanied by signs of articular inflammation, including 
swelling, warmth, erythema, and tenderness on palpation. At the onset of the disease 
small joints of the hand and feet are involved. Large joints such as knees, hips, 
elbows, ankles and shoulders commonly become involved later in the course of the 
disease. In the most severe cases, symptoms can include lesions of tendons, skeletal 
muscle, peripheral nerves and arteries (McCarty, 1989; Sewell & Trentham, 1993; 
Snowden & Kay, 1995).
1.1.1 Aetiology of RA
The cause of RA remains obscure. Over the years, a number of potential etiologic 
agents have been proposed. Some of these agents are illustrated in Table 1. Although 
many of these suggested pathogens could cause RA, to date no etiologic agent has 
been conclusively confirmed for RA (Venables, 1989; Hyrich & Inman, 2001).
3














The mechanism by which any microorganisms may cause RA also remains unclear. 
However, there are some proposed mechanisms such as (1) the direct infection into 
the synovium or retention of microbial products may trigger the chronic inflammatory 
response, (2 ) the infection or the host response may alter articular structures and they 
become immunogenic (Tarkowaski et al, 1989), (3) the etiologic agent might prime 
the host to a cross- reactive determinant expressed in the joint as a result of molecular 
mimicry (Winchester et al, 1988) and (4) superantigens might play a role in initiation 
o f the disease. Superantigens are proteins that can bind to major histocompatibility 
complex (MHC) class II and certain V(3 segments of the heterodimeric T cell receptor. 
Because of this binding, superantigens are potent stimulators of T cells (Choi et al, 
1990).
Auto-antigens may also be involved in the initiation of RA, including the cartilage 
proteoglycan component aggrecan, human cartilage glycoprotein (HCgp-39) and p78. 
Aggrecan has been found in the synovial fluid of RA patients (Lohmander et al, 1993; 
Boots et al, 1997), can induce inflammatory arthritis in murine models (Giant et al,
4
1987), and exhibits multiple sites capable of binding to peptide motifs for HLA-DR1 
and HLA-DR4 (Boots et al, 1997). HCgp-39 was detected in PBMCs and synovial 
samples in RA patients but not in normal subjects (Baeten et al, 2000; reviewed by 
Corrigall & Panayi, 2002).
There is a convincing association between the expression of certain class II MHC 
gene products (Human Leukocyte Antigen (HLA)-DR) and the development and 
severity of RA. A large body of evidence has shown that, there is a strong association 
between RA and the presence of DR4 (Gregersen et al, 1987; Scott, 2000). In 
addition, there is association between MHC haplotype and disease severity o f RA. For 
example, patients with homozygous DR4 tend to have more extra-articular 
manifestations as well as more destructive joint involvement than those with only one 
allele. However, those patients with one allele, in turn tend to have more severe 
disease than those patients with other MHC haplotypes (Gregersen et al, 1987; 
Wordsworth et al, 1989; Oilier & MacGregor, 1995; Singeal et al, 1999; Patil et al, 
2001).
The HLA-DR molecule is composed of an invariant a-chain and a highly 
polymorphic (3-chain. The antigen-binding cleft formed by a  and p chains of the 
molecules contains the amino acid sequence known as the shared epitope in the p i 
chain of DR4 and also on p i chain encoded by some other DR genes, such as DR1. 
The epitope common to those HLA-DR molecules is found from amino acid 70-74. 
The shared epitope may serve as the binding site for an arthritogenic peptide or may 
itself be the autoantigen that activates T cells (Gregersen et al, 1987; Singeal et al, 
1999, Smith & Haynes et al, 2002).
5
Moreover, the MHC class II role may predispose to disease by positively selecting for 
auto reactive clones of T cells or by negatively selecting against immuno-regulatory 
clones (reviewed by Kinne et al; 1997, Smith & Haynes et al, 2002).
1.1.2 Pathogenesis of RA
The initial stage in rheumatoid synovial inflammation involves some replication of 
cells in the synovial membrane to form a multi-cellular layer, which thickens 
primarily due to the simultaneous recruitment to this area of large numbers of 
macrophages, although T cells (CD4+, CD45RO+) are also present (Sewell & 
Trentham, 1993).
In the chronic phase of RA, infiltration of lymphocytes and macrophages becomes 
more abundant. Moreover, the chronic synovial inflammation in RA results in the 
formation of the pannus. This highly vascularized granulation tissue is composed of a 
variety of cell types, including not only lymphocytes and macrophages but also 
fibroblast synoviocytes and mast cells. Pannus is found at the marginal areas of 
diarthrodial joints, where it impinges upon articular cartilage and subchondral bone 
(Allard et al, 1987; Sewell & Trentham, 1993; Palmer, 1995; Tak et al, 1997).
The role o f T cells and macrophages in RA is discussed in more detail in sections 1.4 
and 1.5. However, it is likely that mature T cells (CD4+/CD45RO+) are capable of 
triggering several factors responsible for rheumatoid symptoms, including cytokine 
release and immunoglobulin (Ig) production by B cells (Panayi et al, 1992). IgM (the 
most prominent isotype) and IgG rheumatoid factors (RFs), together with anti-type-II- 
collagen activity and antibodies to collagen types V, VI and IX have been detected in
6
the synovium of RA patients (Tarkowaski et al, 1989). The binding of such immune 
complexes to cartilage could exacerbate the immune response by activating 
complement and triggering further cellular inflammatory response (Sewell & 
Trentham, 1993).
The maintenance of the integrity of cartilage and other extracellular matrix (ECM) 
tissue is a dynamic process. In the normal state, the synthesis of ECM components by 
chondrocytes and fibroblasts is counterbalanced by a specific degradation of these 
molecules. Degradation is mediated by a family of proteolytic enzymes (Matrix 
Metalloproteinases, MMPs), produced by both macrophages and activated fibroblasts 
in response to proinflammatory cytokines such as interleukin- 1-p (IL-lp) and tumour 
necrosis factor-a (TNF-a). Important enzymes in this category include collagenase 
(MMP-1), gelatinase (MMP-2) and stromelysin-1 (MMP-3) (Manicourt et al, 1995; 
Honda et al, 2001; Vincenti et al, 2002) These enzymes are secreted as proenzymes, 
which are later activated by proteolytic activity of other enzymes, such as trypsin and 
plasmin, these activated enzymes are regulated by inhibitory proteins such as tissue 
inhibitor of metalloproteinases (TIMPs). These are also released by macrophages and 
fibroblasts forming the pannus (Nemoto et al, 1996). In addition, there are other 
proteases that probably play an important role in tissue damage in RA include elastase 
and cathepsin G, secreted by macrophages and other inflammatory cells (Wright et al, 
1991; Mauviel, 1993; Vincenti et al, 1994; Feldmann et al, 1996).
Cytokines play a crucial role in mediating tissue damage (see section 1.3). IL-1, IL- 6  
and TNF-a may directly activate osteoclasts, stimulate cyclooxygenase-2 (COX-2) 
resulting in increased prostaglandin E2 (PGE2) production and may cause ECM
7
degradation via their ability to stimulate collagenase and stromelysin production by 
synoviocytes and chondrocytes (reviewed by Dayer & Fenner, 1992, Masferrer et al, 
1994; van de Loo et al, 1995; Feldman et al, 1996; Feldman & Maini, 1999).
The increase in intercellular adhesion molecules-1 (ICAM-1) expression, which 
accompanies the thickening o f the pannus, is also enhanced by the action o f IL-1(3, 
IL-6 , and IFN-y (Dayer & Fenner, 1992; Koch et al, 1992; Arias-Negrete et al, 1995; 
Lee et al, 1995; Van de Loo et al, 1995; Burmester et al, 1997). The pathogenesis of 
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Figure 1: Pathogenic pathways of jo in t destruction in RA patients. Rheumatoid 
arthritis is characterized by neo-vascularization and mononuclear cell infiltration. 
Infiltrating mononuclear and synovial cells are activated and contribute to the 
perpetuation of rheumatoid inflammation mediated by the cytokine network. 
Eventually, joints are destructed by various enzymes produced by theses activated 
cells.
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1.2 Hypoxia, oxidative stress and RA
The rheumatoid synovial cavity has a positive intra-articular pressure, in contrast to a 
normal joint, which has negative pressure. In RA synovium, the cavity pressure is 
raised and upon movement this pressure exceeds the capillary perfusion pressure, 
causing collapse of the blood vessels. This leads to the production of multiple 
episodes of hypoxic reperfusion injury, which consequently generates reactive oxygen 
species (ROS) (Mapp et al, 1995).
The earliest view of the redox concept is that of the addition of oxygen molecules 
(oxidation) to from an oxidant, or removal of oxygen (reduction) to form a reductant. 
Alternative approach of redox concept is to describe the oxidation as the loss of 
hydrogen, and reduction as the gaining of hydrogen. Furthermore, another alternative 
view is to describe oxidation as the losing of electrons and reduction as gaining of 
electrons (Haddad et al, 2002b).
ROS such H2O2 , superoxide (O2 ) and the hydroxyl radical (OH*), are generated in 
cells by several pathways: cellular energy metabolism to generate ATP in 
mitochondria involves the electron transport reaction in which O2 accepts electrons 
and H+ to yield water, in this process a single electron may leak out resulting in the 
production of O2'. Another site of electron transport is the endoplasmic reticulum, 
where O2" is released from NADPH cytochrome P450 reductase (reviewed by Kamata 
& Hirata, 1999). O2" is also generated by hypoxanthine/xanthine oxidase (Figure 2) 
(Mapp et al, 1995; reviewed by Kamata & Hirata, 1999).
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Figure 2: Generation of ROS:
1.Generation of Superoxide anion.
Xanthine Oxidoreductase 
Xanthine + 02+H20  ^  Uric acid+ O' +2H+
2. Generation of Ferrous irons
Fe3* + O'2 ________________ ^  Fe2\ 0 2
3. Generation o f H20 2: Trauma cau sed  b y  m ovem ent o f the jo in t leads to H20 2 release  
b y  neutrophils: 20  2+ 2hC Superoxide oxidoreductase dismutas^  H20 2
4.R elease o f hydroxyl radicals: Fe2" + H20 2 ______________________ ^.0H'+ Fe3+
There are several pieces of evidence that indicate the hypoxic nature o f RA synovium, 
including: direct measurement of O2 in synovium revealed low O2 and raised levels o f 
CO2, decreased synovial pH, raised lactate, 3-D-hydroxybutyrate, acetate levels, and 
ketone body formation. Increased enzyme activity such as glyceraldehyde-3 
phosphate dehydrogenase, glucose 6 -phosphate dehydrogenase and lactate 
dehydrogenase (major enzymes o f the glycolytic pathway) confirmed the hypoxic 
nature o f the RA synovium. Moreover, increased intracellular but decreased 
extracellular sulphydryl content within the inflamed synovium is a strong indication 
of redox imbalance (reviewed by Bodamyali et al, 1998).
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The hydroxyl radicals are very highly reactive, attacking a wide range of targets 
including hyaluronic acid in the synovial fluid, causing loss of lubricant properties 
and consequently mechanical damage to the joint (Blake et al, 1989; Schett et al, 
2001). The hydroxyl radicals break single and double stranded DNA. Moreover, ROS 
activate nuclear factor kB (NF-kB), a transcription factor that mediates expression of 
certain cytokines genes such as TNF-a and IL-1 (Tacchini et al, 1995; Chandel et al, 
2000). Hydroxyl radicals attack amino acids, and thus may be involved in the 
formation of rheumatoid factors (IgG, IgM and IgA). Proteins modified by hydroxyl 
radicals, could induce autoimmune responses and release of autoantibodies by B cells 
(Blake et al, 1989; Stevens et al, 1991; Fairbum et al, 1993; Mapp et al, 1995; 
Bodamyali et al, 1998).
Oxidative stress also has an effect on T cells; it has been observed that addition of an 
antioxidant resulted in reduction of T cell proliferation, IL-2R expression and IL-2 
production (Chandhri et al, 1988). Hypoxia transcriptionally upregulates TNF-a and 
IL-1 (Ghezzi et al, 1991; Naldini et al, 2001) but down regulates IL-2, therefore 
hypoxia might underlie the functional polarization of Thl/Th2 cells and so favour 
proinflammatory cytokines such as IL-1 and TNF-a (Blake et al, 1989; Stevens et al, 
1991; Fairbum et al, 1993; Mapp et al, 1995; Bodamyali et al, 1998). Moreover, low 
concentration of H2O2 caused activation of T cells (reviewed by Ginne-Pease & 
Whisler, 1998), and down-regulation of CD3 expression (Kono et al, 1996).
In addition, PKC activity is susceptible to oxidative stress or H2O2 (Whisler et al, 
1995; reviewed by Gopalakrishna & Jaken, 2000). MAPKs, PTK, PLCyare also 
activated by H2O2 and oxidative stress (Goldstone et al, 1997; Kamata & Hirata,
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1999; Devadas et al, 2002). The transcription factor NF-kB mediates the LPS-induced 
release of cytokine gene transcription. One common mechanism for the activation of 
NF-kB is requirement for an increase in ROS. Exposure to H2O2 or hypoxia can 
rapidly activate NF-kB (Brennan & O’Neill, 1995; reviewed by Ginn-Pease & 
Whisler, 1998; Janssen-Heininger et al, 1999; Chandel et al, 2000).
As protection against oxidative stress, cells possess anti-oxidants that maintain the 
intracellular redox environment. Glutathione (GSH) is a major cellular anti-oxidant 
(see section 1.2.1) found in all eukaryotic cells. Cellular H2O2 is eliminated in the 
cytoplasm by GSH-peroxidase-catalysed reduction, with GSH as a substrate. As a 
result of this reaction, oxidised GSH (GSSG) is formed, and then the GSSG is 
restored to GSH by GSH reductase. Thioredoxin (TRX) is a small multifunctional 
cellular protein that is also capable of reducing some ROS including H2O2 . Moreover, 
H2O2 can be eliminated by the enzyme catalase in the peroxisomes (reviewed by 
Mapp et al, 1995; Bodamyali et al, 1998; Kamata & Hirata 1999).
1.2.1 Glutathione and redox balance
Glutathione (L-y-Glutamyl-L-cysteinylglycine, GSH) is a major intracellular non­
protein sulphydryl anti-oxidant, and plays a central role in defending cells against free 
radicals and electrophiles and maintaining cellular oxidation-reduction (redox) 
equilibrium. The protective role of GSH consists of four components: 1) chemical 
reaction with intracellular targets (in most cases DNA); 2) enzymatic reduction of 
peroxides to prevents their decomposition; 3) enzymatic detoxification of 
electrophiles, as a coenzyme for formaldehyde dehydrogenase and glyoxylase and as
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a substrate for the GSH S-transferase, and 4) maintenance of the redox state of 
cellular thiols. Most cell types can metabolise extracellular GSH by an ectoenzyme, 
y-glutamyl transpeptidase (GGT), which transfers glutamate to amino acid acceptors. 
The rate of transport and the intracellular availability of cysteine appear to control the 
rate of GSH synthesis (Kavanagh et al, 1988 & 1994; Shrieve et al, 1988; Cook et al, 
1991; Ublacker et al, 1991; van der Ven et al, 1994; reviewed by Anderson, 1998; 
Seres et al, 2000).
The balance between reduced and oxidized glutathione is an important mechanism for 
balancing the effect of reactive oxygen species and alkylating agents. Oxidized 
glutathione can modify selected proteins in a process referred to as S-glutathiolation 
and is used as a means of minimizing oxidative damage. These reversible disulfide 
bonds are an effective means of protecting modified proteins against irreversible 
oxidative damage. Redox signalling involves modification of cellular proteins, and it 
leads to a decrease in the cellular glutathione levels [glutathione depletion has an 
effect on gene expression] (Coan et al, 1992; Park et al, 1998).
On one hand, GSH depletion is associated with augmentation of an oxidative stress- 
mediated production of proinflammatory cytokines. It has been shown that pre­
treatment with L-buthionine (S-R) sulfoximine (BSO), a specific inhibitor of y- 
glutamylcysteine synthetase, prior to exposure to LPS, augmented in a dose- 
dependent manner LPS-induced TNF-a and IL- 6  biosynthesis in alveolar epithelial 
cells, an effect associated with the induction of intracellular accumulation of reactive 
oxygen species (ROS) (Haddad, 2001a/b), and reduced IL-12 production by human
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alveolar macrophages (Dobashi et al, 2001). Moreover, BSO treatment of bronchial 
epithelial cells (BECs) facilitated TNF-a-induced mitogen-activated protein kinase 
(MAPK) p38 activation and RANTES production (Hashimoto et al, 2001). Pre­
treatment of monocytes with maleic acid diethyl ester (DEM) to reduce GSH levels 
also resulted in a decrease in IL-12 generation (Utsugi et al, 2002).
On the other hand, antioxidant drugs can in turn act as modulators of the immune 
response. In particular, N-acetylcysteine (NAC), through interfering with or 
counteracting ROS-induced subcellular changes can modulate several cell functions. 
This drug in fact works as a free radical scavenger, as a GSH precursor via a thiol 
supplier activity, or as structural analogue of GSH, enriching the GSH pool in the 
cellular environment (reviewed by Zafarullah et al, 2003). NAC treatment induced a 
significant upregulation of IL-1 (3, IL-2, IL-15 (Viora et al, 2001), and IL-12 
production (Dobashi et al, 2001; Viora et al, 2001). In addition, pre-treatment with 
NAC reduced LPS-mediated secretion of TNF-a and IL-6 , incubation of cells with 
NAC induced intracellular accumulation of GSH (Haddad, 2001b). Moreover, NAC 
attenuated TNF-a-induced IL- 8  production, and also attenuated TNF-a-induced 
activation of MAPK, p38 (Hashimoto et al, 2001). Furthermore, in contrast to BSO, 
which activates NF-kB, antioxidants such as NAC inhibit the activation of NF-kB and 
AP-1, and consequently block transcription of cytokine genes (reviewed by Ginn- 
Pease & Whisler, 1998; Chandel et al, 2000).
It is now well documented that oxidative stress triggers several intracellular pathways 
that lead to activation of certain transcription factors and expression of specific genes
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as mentioned above. Signal transduction via MAPK is involved in this process. 
MAPKs include the c-Jun N-terminal kinases (JNKs), p38 kinases and extracellular 
signal-regulated kinases (ERK1/2). JNK and p38 are induced by stress responses and 
mediating responses to inflammatory cytokines (Hale et al, 1999; Rincon et al, 2000).
MAPK cascades are involved in inflammation and tissue destruction in RA. In 
particular JNK is highly activated in RA fibroblast-like synoviocytes and synovium 
(reviewed by Vincenti et al, 2001). MAPK specificity may exist with respect to 
MMP-1 and MMP-13 gene expression. Although all three MAPK pathways can 
contribute to MMP-1 expression in synovial fibroblasts, cytokine activation of MMP- 
13 in chondrocytes appears to be primarily p38-dependent, since it is blocked with the 
p38 kinase inhibitor SB203580 (reviewed by Vincenti et al, 2001). In addition, Han 
et al found that administration of SP600125 (JNK inhibitor) decreased the rat paw 
swelling in rat-adjuvant-induced arthritis, and near-complete inhibition of 
radiographic damage that was associated with decreased AP-1 activity and 
collagenase-3 gene expression (Han et al, 2001).
NAC attenuated TNF-a induced p38 MAPK activation and RANTES production and 
BSO facilitated TNF-a/LPS-induced p38 MAPK activation (Haddad, 2001b; 
Hashimoto at al, 2001). These observations indicate an association between the 
cellular reduction/oxidation (redox) state and p38 MAPK-mediated cytokine 
expression.
Lymphocyte function is particularly dependent on GSH levels. GSH is known to 
influence lymphocyte growth and activation as well as their responsiveness to
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cytokines. RA synovial fluid T cells contain decreased GSH levels compared to cells 
isolated from peripheral blood o f RA patients or healthy people (Maurice et al, 1998). 
However, synovial T cells show features of hyporesponsiveness. This 
hyporesponsiveness is reflected by low proliferative responses (Maurice et al, 1997, 
1998), as well as low calcium responses upon stimulation (Carruthers et al, 1996; 
2000). It has been shown that depletion of intracellular GSH levels in T lymphocytes 
through treatment with BSO results in hyporesponsiveness due to the abrogation of 
the proximal TCR-mediated signalling (Staal et al, 1994) and displacement of the 
adaptor protein Linker for Activation of T cells (LAT) from the plasma membrane 
(Gringhuis et al, 2000). This has been also observed in SF T cells in RA, may be due 
to subjection to chronic oxidative stress and decreased GSH levels in these cells 
(Gringhuis et al, 2000 & 2002).
Antigen presenting cells (APC), macrophages, dendritic cells and B cells are central 
to the development of either T helper 1 (Thl) or T helper 2 (Th2) immunity. GSH 
depletion in APC inhibited Thl-associated cytokine production (IFN-y) (Peterson et 
al, 1998). Furthermore, decreased intracellular GSH levels in macrophages resulted 
in upregulation of the production IL- 6  and IL-10 (critical effector cytokine of Th2), 
and down regulated IL-12 (Thl cytokine), thus GSH plays an important role in the 
polarization of Thl/Th2 balance (Murata et al, 2002). However, increasing 
intracellular thiol pools with NAC in splenocytes resulted in upregulation of IL-4 
production (Th2 cytokine) after anti-CD3 stimulation (Monick et al, 2003).
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1.3 Cytokines and RA
Rheumatoid arthritis is associated with an increased production of a wide range of 
cytokines (Firestein et al, 1990; Dayer & Fenner, 1992; Kunkel et al, 1996; Feldmann 
et al, 1996 &1999; Steiner et al, 1999). Cytokines such as IL-1 and TNF-a produced 
by activated synoviocytes, mononuclear cells or by articular cartilage significantly up- 
regulate matrix metalloproteinase (MMP) gene expression. MMPs form a family of 
enzymes capable of degrading various extracellular matrix (ECM) components 
(Mauviel, 1993; Feldmann et al, 1996), as mentioned above in section 1.1.2.
High levels of IL-1, TNF-a, IL-6 , IL-8 , IL-15, IL-18, transforming growth factor-beta 
(TGF-p), granulocyte-macrophage colony stimulating factor (GM-CSF), macrophage 
inflammatory protein (MIP-1), and monocyte-chemoattractant protein (MCP-1) are 
detected in RA synovial tissue. TNF-a may be the major cytokine involved in the 
inflammatory process, whereas IL -lp  is a key mediator with regard to cartilage and 
bone destruction (Firestein et al, 1990; Dayer & Fenner, 1992; Kunkel et al, 1996; 
Feldmann et al, 1996 &1999; Steiner et al, 1999). Analysis of the synovial cell 
infiltrate in early RA revealed a positive correlation between the disease activity, the 
number of macrophages, IL-6 , and TNF-a expression in the synovium, suggesting 
that macrophage-derived cytokines play an important role in progression of the 
disease (Tak et al, 1997). Successful drug treatment of patients with RA resulted in a 
decrease in inflammatory cytokine levels such as TNF-a and IL -lp (Chang et al, 
1992; Thomas & Carrol, 1993; Arend & Dayer, 1995; Seitz et al, 1995; Moreland et 
al, 1997; Dolhain et al, 1998).
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Anti-inflammatory cytokines are also present in RA synovium, including IL-1 
receptor antagonist (IL-lra), soluble TNF receptor (sTNFR), IL-10, IL-11, and IL-13, 
and T cell-derived cytokines such as IL-17 and interferon beta (IFN-(3) and low level 
of IL-4 (Firestein et al, 1990; Dayer & Fenner, 1992; Kunkel et al, 1996; Feldmann et 
al, 1996 & 1999; Steiner et al, 1999).
1.3.1 Proinflammatory cytokines: INTERLEUKIN-1 & TUMOUR 
NECROSIS FACTOR-a
Interleukin-1 (IL-1) and tumour necrosis factor-a (TNF-a) are thought to play a key 
role in the inflammation and joint damage that occur in RA. The pathologic effects 
caused by these cytokines include leukocytic infiltration leading to synovial 
hyperplasia, cell activation, cartilage breakdown, and inhibition of cartilage matrix 
synthesis. Moreover, IL-1 and TNF-a increase the expression of adhesion molecules 
(such as intracellular adhesion molecule-1 (ICAM-1), prostaglandin E2 (PGE2), 
MMPs (such as, collagenase, stromelysin and gelatinases) (Mauviel et al, 1993) 
chemokines (such as IL-8 ), and other pro-inflammatory cytokines (such as IL-6 ) 
(Dayer & Fenner, 1992; Arend & Dayer, 1995; Feldman et al, 1996; Mino et al, 
1998). IL-1 shares many biological functions with TNF-a and is a potent factor in 
inducing damage to cartilage and bone, because it induces proteoglycan degradation 
and inhibits proteoglycan synthesis. Proteoglycans are important structural 
constituents of connective tissue, particularly of cartilage (van de Loo et al, 1995). 
Two distinct TNF-a receptor (TNF-aR) types have been demonstrated, 55-kDa 
(TNF-R1) and 75-kDa (TNF-R2) (Loetscher et al, 1991; Dayer and Fenner, 1992). 
Similarly, two types of IL-1 receptor (IL-1R) have been well studied in great detail 
(discussed in section 1.3.1.3).
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In addition to the function of IL-1 in disease states, IL-1 has a wide range of normal 
functions. It is involved in proliferation and differentiation of T cells, B cells and 
fibroblasts and also stimulates vascular endothelial cells to secrete colony-stimulating 
factors. IL-1 may cause lymphocytes to release IL-12 and other cells to release IL- 6  
and also may induce IL-2 receptor on T cells. Moreover, IL-1 up regulates other 
inflammatory cytokines such as lymphocyte growth factors, chemokines, and 
mesenchymal growth factors (Arend & Dayer, 1995; van de Loo et al, 1995; 
Dinallero, 1996; Crofford et al, 1997; Arend, 2002 Vervoordeldonk & Tak, 2002).
Macrophages are the principal cells producing IL-1 and TNF-a. It is not clear yet 
which mechanism controls this production, however at least two major pathways 
exist: 1) induction of cytokine release by T and B lymphocytes, mast cells, or soluble 
factors (e.g. immune complex or other cytokines) and 2 ) induction by direct contact 
between the macrophages and activated T-lymphocytes (discussed later) (Firestein et 
al, 1990; Vey et al, 1992; Isler et al, 1993; Lacraz et al, 1994; Kunkel et al, 1996; 
Feldmann, 1996 & 1999; Steiner et al, 1999; Arend, 2002; Vervoordeldonk, and Tak,
2002). IL-1 and TNF-a are usually synthesised and secreted simultaneously, although 
their production is controlled by different mechanisms (Dayer & Fenner, 1992).
TNF-a is one of the proinflammatory cytokines that plays a pivotal role in RA. It is 
produced intracellularly (by macrophages, monocytes, lymphocytes and transformed 
cell lines of haemopoietic and non haemopiotic origin) as a 26-kDa propeptide and is 
also present in the cell membrane in an active form. The active form is a trimer with a 
subunit of 17-kDa. Like IL-1 (I, LPS induces the production of TNF-a and TNF-p. 
TNF-a/p can also be stimulated by other cytokines such as IFN-y, IL-1, CSF and IL-
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17 (Jovanonic et al, 1998). TNF-a has a wide range of functions; it induces IL-1 (3 
and other proinflammatory cytokines such as GM-CSF, IL- 6  and IL- 8  production. 
Moreover TNF-a up regulates expression of HLA-DR and IL-2R (Brennan et al, 
1989; Feldman et al, 1996). There are two TNF-a inhibitors that have been found in 
urine of some febrile patients, 33kDa and 23 kDa named as TNF-a-INH (Seckinger et 
al, 1989; Abe et al, 2001).
Therapeutic approaches in RA have focused mainly on TNF-a; anti-TNF-a therapy 
shows efficacy in controlling signs and symptoms in most patients with RA. Clinical 
investigation in which the activity of TNF-a in RA patients was blocked by 
intravenously administrated Infliximab (monoclonal antibody against TNF- 
a )  provided evidence that TNF-a regulates IL-1, IL-6 , IL-8 , MCP-1, vascular 
endothelial growth factor production, recruitment of immune and inflammatory cells 
into the joints, angiogenesis, and reduction of serum levels of MMP-1 and 3. Anti- 
TNF-a, when used in combination with methotrexate, resulted in significant 
improvement compared to methotrexate alone, (Brennan et al, 1989; Maini et al, 
1998; Breedveld, 1999; Feldmann & Maini, 1999; Harriman et al, 1999; LaDuca et al, 
2001).
1.3.1.1 IL-1 family
Three members of the IL-1 family have been studied intensively, including IL-1 a, 
IL-1 (3 and IL-1 receptor antagonist (IL-lra) (reviewed by Dinarello, 1996). The genes 
for all three members of the IL-1 family, as well as for IL-1 receptors (IL-1R) type I 
and type II are located on the long arm of chromosome 2. The genes of IL-1 a , IL-1 (3 
and IL-lra show differential expression; for example, the IL-1 (3 gene possesses a
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TATA box, whereas IL-1 a  does not (Arend, 1993). IL-1 (3 is regulated by at least two 
different signalling pathways, as demonstrated by differential induction with LPS or 
phorbol ester. Stimulation with LPS provokes a transient expression of IL-1 (3 mRNA, 
while stimulation with phorbol ester gives rise to a more stable mRNA (Fenton et al,
1988). Moreover, complement component C5a also acts as an inducer of IL-1 (3 
transcription, however, the gene translation requires additional stimulus, such as LPS 
(Schindler et al, 1990). IL-1 (3 gene transcription has been extensively investigated in 
response to LPS stimulation, as an immediate and potent inducer of IL-1 (3 from 
monocytes (reviewed by Dinarello, 1996).
Both IL-1 a  and IL-1 (3 are synthesized as intracellular proteins and released to act on 
target cells by binding to cell surface receptors (IL-1R). IL-1 (3 requires proteolytic 
cleavage to produce the active form of the ligand; IL-1 (3 is initially synthesised as a 
31-kDa-precursor peptide, which is converted to the active form (17.5-kDa) by IL-1 
converting enzyme (ICE, caspase-1) (Kostura et al, 1989; Cerretti et al, 1992). ICE 
acts to cleave the pro-IL-ip molecule specifically between the aspartic acid 116 and 
alanine 117 residues, thus releasing the 153 amino acid COOH terminal that 
constitutes the active cytokine (Black et al, 1989; Kostura et al, 1989).
ICE activity has been detected in monocytes and the human monocytic cell line THP- 
1 (Miller et al, 1993). Although stimulation of cells with lipopolysaccharide (LPS) or 
other stimuli is required for secretion of IL-ip, the enzyme activity has been 
identified in both stimulated and un-stimulated cells. LPS is one stimulus capable of 
inducing ICE activity in addition to increasing pro-IL-lp transcription. The mRNA 
for the enzyme has been detected in several non-monocytic cell types, including T
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cells, B cells, and neutrophils. Because some of these cell types do not contain 
detectable IL-1 (3 mRNA, it has been suggested that the enzyme may have other 
substrates in addition to pro-IL-lp (Black et al, 1989; Kostura et al, 1989; Thombury 
et al, 1992; William et al, 1998). There is more recent evidence that demonstrates that 
ICE is required for the production of the mature form of the distant IL-1 family 
member, IL-18 (Ghayur et al, 1997).
In addition, stimuli such as LPS that initiate synthesis of pro-IL-lp from monocytes 
and macrophages are not necessarily sufficient to produce the active form, but in fact 
few of the pro-IL-1 are externalised as mature active molecules (Hogquist et al, 1991; 
Chin & Kostura, 1993). Efficient post-translational processing requires that LPS- 
activated cells encounter a secondary stimulus such as ATP (Perregaux et al, 1996, 
1998a,b and 2000) cytolytic T cells (Hogquist et al, 1991), or bacterial toxins (Walev 
et al, 1996). All these secondary effectors promote major change to the ionic 
composition of the IL-1-producing cell and these changes appear to be essential for 
productions of active cytokine (Perregaux et al, 1996, 1998a,b and 2000). Moreover, 
ATP is shown to promote formation of mature caspase-l(ICE) subunits in addition to 
mature IL -ip and to elicit release of mature products (Laliberte et al, 1999).
1.3.1.2 Regulation of interleukin-1
The activity of mature IL-lp, once released, is regulated by several mechanisms, 
including IL-lra, soluble IL-1 type II receptors that are cleaved from the surface of 
the cells (IL-lsRII), a decoy receptor (IL-1RII), which lacks an intracellular domain 
and is therefore, not capable of signal transduction, (discussed later), (Colotta et al,
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1993) and by natural autoantibodies to IL-1, particularly to IL-1 a  (Forslind et al, 
2001).
IL-lra is the most important physiological regulator of synovial IL-1 activity. It has 
very high affinity for IL-1RI; thus it blocks the access of IL-1 a  and IL-1 (3 to the 
receptor, (discussed in section 1.3.3). Cleaved fragments of the IL-1RII receptor (IL- 
lsRII), also inhibits the action of IL-1 by binding to circulating IL-1. Furthermore, IL- 
1 can be trapped on the cell surface by the membrane-bound decoy receptor, IL-1RII. 
Addition of IL-lra and soluble IL-lsRII to human synoviocytes dramatically inhibited 
IL-1-induced MMP and PGE2 release (Colotta et al, 1994; Burger et al, 1995; 
reviewed by Burger and Dayer, 1995; Neumann et al, 2000). Moreover, TGF-p blocks 
IL-1 dependent proliferation of T cells and B cells (cited in Wright et al, 1991). IFN-P 
does not inhibit IL -lp directly but it stimulates IL-lra production (Coclet-Ninin et al, 
1997). Anti-TNF-a also has been shown to inhibit IL-1 production (Brennan et al, 
1989).
1.3.1.3 Interleukin-1 receptors
The IL-1 receptor (IL-1R) family consists of a number of related receptor molecules; 
IL-1RI and IL-1RII are most important to be mentioned in this section. IL-1R1 is an 
80-kDa protein, found mainly on T cells and fibroblasts. This receptor forms a 
complex with IL-1R accessory protein (IL-1R AcP) to bind IL-lp with high affinity. 
Antibodies to IL-1R AcP, which block binding to IL-1R1, also block IL -lp binding 
and signal transduction (Greenfeder et al, 1995). IL-1R acts as the primary effector 
receptor, after ligation with its ligand (IL-1) initiates an efficient amplification of
24
signal transduction and a rapid activation of NF-kB (Akahoshi et al, 1988, Ye et al,
1993).
IL-1RII is a 6 8 -kDa protein, found in neutrophils, B cells, monocytes, and bone 
marrow cells (Chizzonite et al, 1989, reviewed by Dinarello, 1996). There is evidence 
to suggest that IL-1RII acts as decoy receptor, as there is no triggering o f NF-kB 
induction when IL-1 binds to it (Sims et al, 1993; Colotta et al, 1994; Attur et al, 
2000). It has been found that soluble IL-1RII significantly inhibited IL-l(3-induced 
nitric oxide (NO) and / or PGE2 production in chondrocytes, synovial and epithelial 
cells (Attur et al, 2000). Furthermore, IL-lra was found to bind with high affinity to 
type IIL-1R, but not to the type II receptor (Stylianou et al, 1992), and also IL-1RII, 
but not IL-1RI is susceptible to proteolytic shedding, a finding consistent with the 
decoy function of this molecule (Orlando et al, 1999).
Other members of the IL-1R family, which do not bind to IL-1, include IL-1 receptor 
related protein (IL-lRrp), and accessory protein-like receptor (AcPL), (Kumar et al, 
1995; Bom et al, 1998).
1.3.2 OTHER PROINFLAMMATORY CYTOKINES
IL- 6  is a multifunctional cytokine that plays an important role in immune and 
inflammatory responses as it is elevated in inflammatory diseases. IL- 6  activates T 
and B cells, and induces chemokine expression on endothelial cells. In addition to 
these inflammatory actions of IL-6 , it also has anti-inflammatory functions, including, 
induction of anti-inflammatory cytokines such as IL-lra and acute phase reactants, 
induction of protease inhibitors in RA fibroblast-like synoviocytes, inhibition of
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cytokine production such as IL-1, TNF-a, IL-12, inhibition of adhesion molecules 
expression, and inhibition of protease expression. Levels of IL- 6  are highly elevated 
in RA, especially in the synovial fluid and tissue during active disease and correlate 
with degree of joints damage, but its direct association in joint destruction still 
controversial. In RA, IL- 6  is mostly produced by fibroblast-like synoviocytes and 
partly by other cells presents in RA synovium, such as macrophages. IL- 6  works by 
regulating the expression of immune/inflammatory genes and regulating cell 
proliferation, differentiation and survival (reviewed by Tilg et al, 1997; Ahmed et al, 
2000; Deon et al, 2001).
IL-12 has been found in the synovial membrane of patients with RA, suggesting that 
IL-12 may play an important immunoregulatory role in RA. It is a potent inducer of 
cell-mediated immunity by promoting differentiation of ThO cells into Thl type cells, 
and activating natural killer (NK) cells and CD8 + cells. In RA, IL-12 acts 
synergistically with IL-18 in the generation of Thl responses. IL-12 is produced by 
activated macrophages, dendritic cells, and to lesser extent by granulocytes. 
Interferon-y production by RA synovial tissue cells was potently and selectively 
enhanced by IL-12 (Morita et al, 1998; Sakkas et al, 1998).
Interleukin-15 serves as a powerful T-cell chemoattractant and activator and induces 
B-cell maturation and isotype switching. It activates neutrophils and NK cell 
proliferation, cytotoxicity and cytokine production, and regulates NK cell/ 
macrophage interaction. Activation of T cells by IL-15 increases their ability to 
stimulate IL-1, TNF-a, IL- 8  and MCP-1. IL-15 is produced by macrophages and 
maybe by other cells such as keratinocytes and synoviocytes, thus it may be involved
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in self-perpetuating pro-inflammatory cytokine production through re-stimulation of T 
cells. IL-15 expression is significantly increased in RA synovium and in the synovial 
fluid compared with reactive arthritis and osteoarthritis (Thurkow et al, 1997; 
Fehniger & Caligiuri, 2001). Fibroblast-like synoviocytes isolated from joints of 
patients with RA secretes large amounts of IL-15 that may be increased after 
stimulation with TNF-a and IL-1 (3 (Harada et al, 1999).
IL-17 is produced by T helper cells (Yao et al, 1995; Aaravak et al, 1999) and may 
play an important role in mediating inflammation in RA. It stimulates the production 
of IL -lp  and TNF-a from macrophages and IL-6 , IL-18, granulocyte colony 
stimulating factor (G-CSF) and PGE2 from endothelial cells and fibroblast stromal 
cells, and NO from human osteoarthritic cartilage (Attur et al, 1997), thus 
contributing to the inflammatory response. Moreover, it induces neutrophil 
recruitment through chemokine release and stimulation of granulopoiesis. 
Furthermore, IL-17 increases expression of NF-kB, a transcription factor essential for 
proinflammatory cytokine secretion. Administration of IL-17R with sTNFR and sIL- 
1RII showed a significant decrease in synovial inflammation and bone resorption in 
rats, (Jovanovic et al, 1998; Shalom-Barak et al, 1998; Shin et al, 1998; Chabaud et al, 
1999; Vervoordeldonk et al, 2002).
Interleukin-18 is a cytokine of the IL-1 family; like IL -lp the pro IL-18 lacks a signal 
peptide and requires ICE for cleavage and release of the active form (Ghayur et al,
1997). Although IL-18 and IL -lp are members of the same family, constitutive gene 
expression, synthesis, and processing are different for the two cytokines (Puren et al, 
1999; Kashiwamura et al, 2002). IL-18 mRNA expression has been identified in
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various cells, including macrophages, dendritic cells, Kupffer cells, kerotinocytes, 
chondrocytes, fibroblast-like synoviocytes, and osteoblasts. The IL-18 receptor 
consists of two subunits, a  and (3, which are members of the IL-1 receptor family 
(Torigoe et al, 1997; Bom et al, 1998; Kashiwamura et al, 2002). IL-18R is expressed 
on T and B cells, NK cells, macrophages, fibroblast-like synoviocytes, neutrophils, 
and chondrocytes. IL-18 is a strong inducer of IFN-y production by T cells and 
enhances the cytotoxicity in acquired and innate immunity. It also induces the 
production of the CC and CXC chemokines, TNF-a, IL-1 (3, GM-CSF, IL-2, IL-4, IL- 
5, IL-10, IL-13, PGE2 (Machines et al, 2000; Jablonska et al, 2001; Kashiwamura et 
al, 2002; Vervoordeldonk et al, 2002) and adhesion molecules such as ICAM-1 
(Yoshida et al, 2001). IL-18 works in synergy with IL-12 in the induction of Thl cells 
because of the reciprocal regulation of the receptors (Barbulescu et al, 1998). 
Recently, IL-18 has also been associated with Th2 response, angiogenesis and 
neutrophil activation, suggesting a broader role for IL-18 (Mclnnes et al, 2000; 
Kashiwamura et al, 2002; Vervoordeldonk et al, 2002). Moreover administration of 
IL-18 promoted the development of collagen induced arthritis. In addition to that, IL- 
18 binding protein (IL-18BP) has been described as a novel modulator of the Thl 
cytokine response. In an animal model, IL-18 blockade through polyclonal antibodies 
or recombinant human IL-1 BP significantly reduced disease activity (Plater-Zyberk et 
al, 2001). Finally, neutralizing IL-18 monoclonal antibodies have the potential to 
become valuable tools for therapeutic approaches in vivo (Lochner et al, 2002).
GM-CSF normally acts as a growth factor for monocytes as a part of haemopoiesis, 
but can also activate macrophages and monocytes and induce the expression of HLA- 
class II, thus it may contribute to the inflammatory process (Alvaro-Garcia et al,
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1989). Macrophages Inflammatory protein (M IP-la/P) are involved in the migration 
of T cells and immature dendritic cells, and may play an important role in RA and 
inflammation since it is upregulated by IL-ip and TNF-a and inhibited by IL-4 and 
IL-13 (Chabaud et al, 2001).
1.3.3 Anti-inflam m atory cytokines: IL-1 RECEPTOR ANTAGONIST
The proinflammatory effects of IL-1 are counterbalanced by IL-1 receptor antagonist 
(IL-lra). IL-lra exists in 3 primary isoforms, a secreted form of 17-kDa (sIL-lra) and 
both 18-kDa and 16-kDa intracellular forms, icIL-lral and icIL-lrall respectively. It 
has been shown that introducing IL-lra in animal models of arthritis causes reduction 
in disease severity (Burger & Dayer, 1995; Dayer & Fenner, 1996; Malyak et al,
1998). While sIL-lra and icIL-lral possess an equal IL-1R binding affinity, icIL-lrall 
is approximately 5 fold less effective at binding IL-1R (Arend et al, 1998).
The human IL-lra gene is located on the long arm of chromosome 2, close to the 
region for IL-1 a , IL-lp, IL-1RI, and IL-1RII. The gene structure for human IL-lra is 
similar to those for IL-1 a  and IL-1 p ; however, IL-lra complementary DNA (cDNA) 
contains four exons and three introns, whereas, cDNA for the active form of IL-1 a  
and IL-1 P contains three exons and two introns (Arend, 1993). The separate 5’ 
regulatory region for both soluble and intracellular form of IL-lra has been isolated, 
and some of the cis-acting DNA region involved in regulation of transcription has 
been characterized (Jenkins et al, 1997). The promoter region for sIL-lra possesses 
one inhibitory LPS response element (LRE), and additional 3 positive response- 
binding sites (LRE1, LRE2, LRE3). LRE1 was further identified as a binding site for 
NF-kB and LRE2 a binding site for PU.l (essential for LPS induced production of IL-
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Ira or other cytokines) (Smith et al, 1994 & 1998; Arend et al, 1998). LRE3 has been 
shown to bind STAT6  and mediates IL-4-induced IL-lra production (Ohmori et al, 
1996).
The production of IL-1 (3 and IL-lra is differentially regulated; stimulation with LPS 
induced both IL-lra and IL-1 (3, while IgG stimulation induced only IL-lra 
production. IL-lra is up regulated by variety of stimuli including, IL-1, IL-2, IL-3, IL- 
4, IL-6 , IL-10, IL-13, TGF-p, IFN-a, IFN-y, and direct contact with activated Th2 
cells (discussed later) (Arend et al, 1991 & 1998; Chizzolini et al, 1997).
Raised levels of plasma IL-lra have been detected in patients with juvenile arthritis 
(De Benedetti et al, 1995), RA (Chikanza et al, 1995), polymyositis (Gabay et al, 
1994), and systemic lupus erythematosus (SLE) (Suzuki et al, 1995). High levels of 
IL-lra have also been detected in synovial fluid of patients with RA. However, RA 
patients exhibit a lower IL-lra to IL-lp ratio than patients suffering from 
osteoarthritis (Chikanza et al, 1995). This indicated that a high level of IL-lra is 
essential to reduce the effect o f IL-1. In vitro experiments have revealed that an 
excess of 100 times the amount of IL-lra is required to inhibit IL -lp activity, whereas 
in vivo, 100-2000 times more IL-lra is needed (Arend, 1993; Feldman et al, 1996). 
However, IL-lra production by RA synovial cells is deficient relative to total IL-1 
production (Firestein et al, 1994).
The capacity of IL-lra to reduce in vitro and in vivo cartilage degradation, MMP 
production and the progression of inflammatory diseases such as RA has elicited 
much attention in therapeutic approaches, particularly in gene therapy (reviewed by
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Krishnan, 1999; Abramson & Amin, 2002; Dayer & Bresihan, 2002). The use of 
recombinant human IL-lra (rHIL-lra) resulted in a significant reduction in joints 
erosion, and limited decrease in inflammation was also observed. rHIL-lra was found 
to be safe and effective (Campion, 1996; Bresnihan et al, 1998 & 2001; Breedveld, 
1999; Vervoordeldonk et al, 2002). Moreover, treatment of RA with IL-lra resulted in 
reduced mononuclear infiltration of synovial membrane, which may represent the in 
vivo inhibition of biologically relevant IL-1-mediated pathogenic effects (Cunnane et 
al, 2 0 0 1 ).
1.3.4 OTHER ANTI-INFLAMMATORY CYTOKINES
In addition to IL-lra, there are several inhibitory cytokines that play a critical role in 
modulation of proinflammatory cytokines. Transforming growth factor-p (TGF-p) is 
a multi functional cytokine that exhibits both stimulatory and inhibitory effects upon a 
range of cell types. In vitro, TGF-P isoforms exert effects that can be grouped into 
three broad areas: modulation o f inflammatory cell function, growth inhibition and 
differentiation, and control of extracellular matrix production. Elevated levels of 
TGF-p have been found in the synovial fluid of RA patients. The inhibitory effect of 
TGF-P results in inhibition of T and B cell proliferation and cytokine production 
(Ranges et al, 1987; Coffman et al, 1989). Interestingly injection of TGF-p into joints 
of normal rats induced rapid leukocyte infiltration into the synovium, while the 
administration of anti-TGF-p decreased the existing inflammation (Allen et al, 1990). 
Finally, TGF-p can inhibit the induction of MMP and partially inhibits IL-1 
production, but is capable of inducing tissue inhibitor of metalloproteinase (TIMP) 
secretion (Wright et al, 1991; reviewed by Letterio & Roberts, 1998).
31
Interleukin-4 (IL-4) is a potent mediator able to shift the balance of Thl/Th2 cells, 
towards Th2 cells, and is produced specifically by Th2 cells. IL-4 antagonizes Thl 
responses by direct inhibition of IFN-y production by activated T cells. IL-4 decreases 
monocyte/macrophage cytotoxicity, cytokine production (including TNF-a, IL-1 and 
IL-6 ) and IL-15-induced cytokine production (reviewed by Burger & Dayer, 1995). In 
addition, IL-4 induces IL-lra production (Ohmori et al, 1996) and upregulates the 
expression o f the ‘’decoy receptor” thus exerting an anti-inflammatory response 
(Collotta et al, 1993). IL-4 also suppresses biosynthesis of matrix metalloproteinases 
(MMPs) in alveolar macrophages. IL-4 can also inhibit the production of superoxide 
in macrophages (Abramson & Gallin, 1990, reviewed by Burger & Dayer, 1995).
Like IL-4, IL-10 displays immunosuppressive functions, since it down-regulates the 
production of IL-1, IL-6 , IL-8 , TNF-a, GM-CSF, and the expression of MHC class II 
on monocytes/macrophages. Furthermore, IL-10 inhibits the production of MMP by 
macrophages activated with LPS and stimulates the production of TIMP. B cells, 
monocytes/macrophages and T cells (T regulatory and Th2 cells) produce IL-10. 
Substantial amounts o f IL-10 have been detected in RA synovium and synovial fluid 
but insufficient to reduce the effect of IL-1. Neutralization of endogenously produced 
IL-10 in RA synovial membrane cultures resulted in a two-to threefold increase in the 
protein levels o f proinflammatory cytokines TNF-a and IL-1 (3, and addition of 
exogenous recombinant IL-10 to the RA synovial membrane cultures resulted in a 
two-to threefold decrease in the levels of TNF-a and IL-1 (3 (Katsikis et al, 1994, 
Parry et al, 2000; Vervoordeldonk et al, 2002).
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Interleukin-11 is a pleiotropic cytokine that regulates the growth and development of 
haematopoietic stem cells and decreases the proinflammatory mediators of cytokine 
and NO production. IL-11 has several biologic functions related to inflammatory 
events in RA; it is capable of inducing B cell differentiation (Anderson et al, 1992), 
production of acute phase reactants (Baumann et al, 1991), and osteoclast 
differentiation (Blair et al, 2004). It was suggested that IL-1 and TNF-a-induced 
osteoclast activation might be partly mediated by IL-11 (Romas et al, 1996). In 
addition, IL-11 has anti-inflammatory effects, especially on macrophages and 
fibroblasts and suppresses the expression of IL-12, IFN-y, T N F -a , adhesion 
molecules, and proteases. IL-11 has been detected in the serum, synovial fluid, and 
synovial membrane of patients with RA (Okamoto et al, 1997). Treatment with 
recombinant human IL-11 (rH-IL-11) decreased the production o f TNF-a and IL- 
1P and NF-kB- binding activity in RA synovium in vitro. Blockade of endogenous 
IL-11 resulted in a 2-fold increase in TNF-a levels and the addition of IL-11 inhibited 
TNF-a, MMP-1 and MMP-3 production. In addition, IL-11 stimulated MMP inhibitor 
levels in RA synovial tissue (Hermann et al, 1998).
IL-13 can also be considered as an inhibitory cytokine since it decreases the 
production of IL-1 p, TNF-a, IL-8 , MCP-1, M IP-la, PGE2 , and epithelial neutrophil 
activating peptide-78 (ENA-78) (Woods et al, 2000). IL-13 has been detected at low 
concentration in rheumatoid synovium and synovial fluid. IL-13 has a homology with 
IL-4, and is considered as a Th2-like cytokine. IL-13 has profound effects on 
monocytes in vitro, deactivating them and acting in a complex manner to change 
monocyte morphology, phenotype, functions, and cytokine production (Woods et al, 
2000; Vervoordeldonk et al, 2002). In addition to the anti-inflammatory functions of
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IL-13 and IL-4 (mentioned above), both cytokines independently modify immune and 
inflammatory responses in several ways including enhancing monocyte/macrophage 
and endothelial cell expression of adhesion molecules, increasing macrophage 
expression of molecules associated with APC and T cell co-stimulation, and 
stimulating production of anti-inflammatory molecules such as the IL-1RII (Colotta et 
al, 1994) and IL-lra (Muzio et al, 1994).
1.4 The role of T lymphocytes in RA
The role of T lymphocytes in the production of cytokines and development of RA has 
been debated at considerable length, with disagreements over their importance in the 
initiation and progression of inflammation. Based on animal studies it has been shown 
that the first cells to infiltrate the tissue are T lymphocytes, suggesting a pathogenic 
role for these cells. However, the mechanisms underlying the extravasations of T cells 
into the joints are still unclear. Some cytokines released by T cells such as IL-4, IL- 
10, IL-13, and TGF-p have predominantly anti-inflammatory effects, this leads to the 
notion that T cells exert their pathological effect through direct cellular contact with 
monocytes-macrophages. This interaction leads to IL -lp and TNF-a production, a 
process that is potentiated by many other factors including IFN-y, IL-15, IL-17, and 
IL-18. In RA, IL -lp  and TNF-a stimulate connective tissue cells such as fibroblasts 
and synoviocytes to produces MMPs, which degrade the extracellular matrix 
component (e.g. collagens and proteoglycans). Also in RA, T lymphocytes located in 
the peripheral blood primarily express the CD45RA (naive pool) isoform, whereas, 
most synovial T lymphocytes express the CD45RO (memory pool) isoform. Also, 
increased expression of HLA-DR molecules has been associated with synovial T 
cells, although this observation remains controversial (Panayi et al, 1992; Lacraz et
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al, 1994; Summers et al, 1994; Isler et al, 1995; Chizzolini et al, 1997; Miossec and 
Berg, 1997; Vey et al, 1997; Burger & Dayer, 2002; Brennan & Foey, 2002; Miossec,
2003).
Thl cells release IFN-y, and to a lesser extent IL-2 and IL-12, promoting a 
proinflammatory response. Moreover, IL-17 (Aarvak et al, 1999) and IL-18 
(Barbulescu et al, 1998) have been associated with Thl responses. On the other hand, 
Th2 cells secrete IL-4, and sometimes IL-5, IL-6 , IL-10 and IL-13, and enhance anti­
inflammatory responses (Constant & Bottomley, 1997).
Moreover, several subsets of regulatory T cells, the Tr cells, have been identified that 
appear to be distinct in their function and phenotype from the Thl and Th2 cells. Type 
1(CD4+/CD8+) Tr cells (Trl) secrete high levels of IL-10 and IL-5 and low-to- 
moderate level of TGF-p, and little or no IL-2, IL-4, or IFN-y. Trl proliferate poorly 
following TCR stimulation, have immunosuppressive properties, and have been 
shown to prevent the development of Thl-mediated autoimmune disease. Moreover, 
functional studies indicate Trl cells and other Tr populations may help terminate Thl- 
related inflammatory response to pathogens, tumours, and alloantigens. Type 3 (Th3) 
(CD4+) cells primarily secrete TGF-p, and since this cytokine acts on multiple cell 
types, Th3 cells may be involved in many roles of immune regulation. It has been 
shown that Th3 cells inhibit immune response through cellular contact. Another type 
of regulatory T cells are called CD4+ CD25+ Tr cells. These cells also exhibit 
immunosuppressive effects, and inhibit IL-2 production via cell-cell contact and 
expression of inhibitory co-stimulatory molecule CTLA-4 (Groux & Powrie, 1999;
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Groux, 2001; McGuirk and Mills, 2002; Kidd, 2003; Foussat et al, 2003; Cottrez & 
Groux, 2004).
The differentiation of Thl cells occurs in response to a combination of IL-12 and 
IFN-y. The role of IFN-y is the inhibition of Th2 outgrowth, while IL-12 directly 
augments Thl differentiation, having no inhibitory effects upon Th2 cells (Seder & 
Paul, 1994). Th2 cell differentiation is primarily under the control of IL-4 (Swain et 
al, 1994). Both IL- 6  (Rincon et al, 1997) and PGE2 (reviewed by Harris et al, 2002) 
have also been implicated in the Th2 response, IL- 6  by stimulating IL-4 production 
from naive T cells, and PGE2 by inhibiting both the release of IL-12 from dendritic 
cells and the release o f IFN-y from T cells (Hilkens et al, 1997, reviewed by Harris et 
al, 2 0 0 2 ).
T cells may play a critical role in RA progression. In the peripheral circulation o f RA 
patients, increased numbers of activated T cells have been observed. Activated T cells 
are also present in abundance in the rheumatoid synovium. These cells express 
various cell surface molecules such as Very Late Activation Antigen (VLA-1) and 
Leukocyte Function Antigen-1 (LFA-1) at high densities. In addition to that, cells 
express the early activation antigen CD69 (Panayi et al, 1992 and 1999a; Weyand, 
2000). Additional evidence implicating T cells in the pathogenesis of RA comes from 
animal studies; in experimental models of rheumatoid-like inflammatory arthritis such 
as collagen-induced arthritis, synovitis can be generated in susceptible hosts via the 
transfer of T cells from affected animals (Holoshitz et al, 1984). Perhaps the most 
convincing evidence of the role o f T cells in RA has resulted from patient studies with 
various types of therapeutic interventions. These therapies, which involves
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elimination or interference with T cells resulted in regression of the rheumatoid 
inflammation, for example administration of anti-CD4 monoclonal antibodies resulted 
in dose-dependent reduction in disease activity that correlate with CD4+ T cells 
coating with the antibodies (Wagner et al, 1994; Moreland et al, 1997; Klimiuk et al, 
1999; Taylor, 2003). Among the subsets of T cells, CD4+ T cells have been suggested 
to play a critical role in RA. As mentioned above, these cells are present in abundance 
in the rheumatoid synovium and represent the predominant T cell subset in the 
organised perivascular cellular aggregate (Harris et al, 1990; Steiner et al, 1999). 
Further evidence implicating CD4+ T cells comes from genetic studies. Because CD4+ 
T cells recognise antigen bound to MHC class II antigens, the association of RA with 
expression of specific class II MHC molecules strongly implies a role for CD4+ T 
cells in RA (Gregersen et al, 1987&1996; Thomas & Quinn, 1996).
There is a recent demonstration implicating Thl/Th2 balance in the pathogenesis of 
RA. Several studies have demonstrated a shift towards Thl cells as determined by 
cytokine profiles and chemokine receptors present on T cells isolated from 
rheumatoid synovial joints, often accompanied by an increase in the proportion 
(relative to Thl) of Th2 cells in the peripheral blood due to preferential tissue 
infiltration by Thl cells (Dolhain et al, 1996; Miossec & Berg, 1997). As mentioned 
above, Thl cytokines (IL-2, IFN-y) favour T cells mediated cellular immunity and 
cytotoxicity, and activate monocytes, which leads to proinflammatory cytokine 
production such as IL-1(3. Th2 cytokines (IL-4, IL-5, IL-10 and IL-13) favour B cells 
mediated-humoral immunity and deactivate monocytes consequently lead to an anti­
inflammatory response (Dolhain et al, 1996; Chizzolini et al, 1997; Miossec & Berg,
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1997; Vey et al, 1997). These findings might have implication for development of 
new therapies for RA.
In addition to the production of a range of cytokines, Thl and Th2 cells differentially 
express chemokine receptors. Thl cells express CCR2, CCR5 and CXCR3, with 
CCR1 and CXCR5 expressed on a specific subset of cells. Th2 cells express CCR2, 
CCR3 and CCR4 with a subset o f cells expressing CXCR5 (reviewed by Sallusto et 
al, 1998). Chemokine receptors play a critical role in migration of lymphocytes into 
inflamed sites. In RA patients, much attention has been focused on the expression of 
CCR5, CXCR3 (Thl markers) and CXCR4 (Th2 marker) (Syrbe et al, 1999). 
Recently it has been reported that expression of CCR5 and CXCR3 is up regulated on 
the synovial T cells (Gomez-Reino et al, 1999; cited in Nanki et al, 2000).
1.4.1 T-lymphocyte activation
1.4.1.1 TCR/CD3, CD28 & CD2
Complete activation of T cells requires ligation of the T cell receptor (TCR) by 
antigen-MHC complexes together with a co-stimulatory signal, delivered by APC. 
B7-1 (CD80) and B7-2 (CD8 6 ) provide important co-stimulatory signals through 
interaction with CD28 on T cells, but other interactions including those between 
adhesion molecules and their ligands, such as intracellular adhesion molecule- 1 
(ICAM-1)/LFA-1 or LFA-3/CD2, are also involved (June et al, 1994; Guinan et al,
1994).
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Upon engagement of the TCR by antigen presented on MHC, the Src family kinase 
Lck is activated and then phosphorylates immuno-receptor tyrosine-based activation 
motifs (ITAMs) on the 8 ,8 , 7  and £ subunits of TCR. Phosphorylated ITAMs promote 
the recruitment and subsequent activation of another tyrosine kinase ZAP-70. ZAP-70 
triggers phosphorylation of LAT and SLP-70, phosphorylation of tyrosine residues on 
LAT and SLP-70 results in recruitment of a number of other proteins involved in 
activation of the Ras pathway, calcium mobilization and cytoskeletal reorganization.
One important protein that is recruited to LAT upon TCR stimulation is 
phospholipase Cyl (PLCyl). Activated PLCyl is essential for production of 
diacylglycerol (DAG) and inositol 1,4,5-trisphosphate [Ins (1,4,5) P3] (Perlmutter et 
al, 1993). DAG activates protein kinase C (PKC), PKC activates MAPK such as p38, 
JNK, and ERK1/2. Phosphorylation of MAPKs leads to activation of transcription 
factors such as NF-kB (via IkB). Activation of NF-kB is dependent on the stimulation 
of the TCR and co-stimulation via CD28. The serine/theonine kinase and MAP kinase 
kinase kinase (MAPKKKs) participate in the activation of a regulator o f NF-kB 
(IkB). IkB binds to NF-kB, phosphorylation of IkB causes release o f NF-kB to be 
moved into the nucleus and activate transcription (Weiss et al, 1984; Cope et al, 2002; 
Kane et al, 2002). Ins (1,4,5) P3 binds to its receptor on endoplasmic reticulum (ER), 
causing release of calcium to the cytoplasm from calcium stores in the ER. This event 
triggers the opening of calcium- release-activated calcium (CRAC) channels at the 
plasma membrane, allowing influx of extracellular calcium (Sorrentino et al, 2001). 
Reduced intracellular Ca2+ signalling after TCR stimulation in peripheral blood and 
synovial T cells of RA has been reported. This reduction was correlated with 
decreased IL-2 production and T cell proliferation, suggesting that the changes in
9+magnitude of the intracellular Ca signal may contribute directly to the functional 
aberration in RA T cells (Allen et al, 1995; Carruthers et al, 1996/2000), however, this 
observation still not well studied.
CD28, a 44-kDa member of the immunoglobulin superfamily, is constitutively 
expressed on the majority of CD4+ T cells as a disulphide-linked homodimer. Its 
natural ligand is B7. Various studies have shown positive effects of CD28 co­
stimulation (with TCR signal) on proliferation, cytokine production (e.g IL-2) and 
survival of T cells. This stimulation also induces secretion of other cytokines such as 
IFN-y, IL-4, IL-8 , IL-3, GM-CSF and IL2R (Guinan et al, 1994). Unlike the TCR 
signal, which depends on PKC, CD28 co-stimulation apparently does not require 
PKC; this indicates that stimulation via CD28 differs from that via TCR. However, 
like TCR signalling, CD28 activation triggers PI3 kinase activation (reviewed by 
Acuto & Michel, 2003). Association between CD28 and the NF-kB pathway has been 
suggested, by identification in the proximal IL-2 promoter of a response element 
similar to that recognised by NFkB. CD28-responsive elements, (CD28RE), confer 
responsiveness to anti-CD28 antibodies. Mutation or deletion of CD28RE abolished 
the increase in transcription mediated by CD28 (Kane et al; 2002). Finally, surface 
expression of (3 chemokine receptors CCR1, CCR2 and CCR5 are down regulated 
following CD28 stimulation (Carroll et al; 1997; Acuto & Michel, 2003).
Despite their activated phenotype, synovial T cells in RA patients show features of 
hyporesponsiveness after TCR/CD3 and CD28 stimulation. Hyporesponsiveness of 
synovial T cells has been associated with decreased levels of intracellular GSH, and 
treatment of those cells with NAC improved CD3 stimulation, while CD28
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stimulation was unaffected (Maurice et al, 1998). This indicates that CD3 stimulation 
is redox sensitive. In addition, it has been shown that the synovial T cells of RA 
patients show severely impaired phosphorylation of the adaptor protein linker for 
activation of T cells (LAT), TCR-£, and p56lck, crucial components of the TCR- 
mediated signalling pathway (reviewed by Salojin et al, 1998; Gringhuis et al, 2000; 
Cemerski et al, 2003), and also reduced protein tyrosine phosphorylation and Fyn 
expression (Ritter et al, 1997). There are several possible reasons for this 
phenomenon; the anatomy and cellular environment of the inflamed synovium are 
different from the lymph nodes, the hypoxic nature and the pH of the inflamed 
synovium has an effect on the T cells. Subcellular localization of LAT is sensitive to 
changes in the cellular levels of the antioxidant glutathione (Gringhuis et al, 2000). 
This suggests that the hypo-responsiveness of RA T cells may be due to their constant 
subjection to high levels of oxidative stress. Moreover, the cytokine milieu in RA 
synovial tissue is also different from that expressed in the lymph nodes due to primary 
interaction between macrophages and Th cells (reviewed by Cope, 2002).
Stimulation of T cells via CD2, using lectins (Phytohaemagglutinin, PHA), also 
causes a rise in cytoplasmic calcium levels, which is derived from both extracellular 
sources and from stores in the endoplasmic reticulum. CD2 stimulation follows the 
same pathway as CD3 stimulation that leads to the generation of IP3, which binds to 
intracellular membranes, causing mobilization of intracellular stores of calcium 
(Carruthers et al, 1996). Furthermore, CD2, CD3, and CD28 stimulation of RA 
patients T cells with tri-specific antibody induced higher level of IL-2 than normal T 
cells, and favours Thl cytokines (such as IFN-y). This tri-specific antibody (Tsab) 
was significantly more potent than PHA in stimulating IL-2 production by RA T cells.
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However, in normal controls IL-2 secretion was not significantly greater with Tsab 
than PHA stimulation, indicating that stimulation via CD2 is very effective in 
cytokine induction (Wong et al, 2000).
1.4.1.2 BACTERIAL LIPOPOLYSACCHARIDE (LPS)
LPS is the main constituent of the outer leaflet of gram-negative bacteria, it consists 
of a saccharide part and lipid part, termed lipid A. The hydrophobic portion of lipid A 
has been identified as the endotoxic part of LPS. Low dose of LPS may be beneficial 
for the immune system, by causing immuno-stimulation and enhancing resistance to 
infection and malignancy. LPS has been used extensively for monocyte activation, 
and will be discussed in section 1.5.1.1 in greater detail (Ulevitch et al, 1995). LPS is 
also a potent stimulator of human T cell proliferation and Thl associated cytokine 
production. It was shown that T-lymphocyte activation by LPS is strongly dependent 
on direct cell-cell contact of responding T lymphocytes with viable accessory 
monocytes, mainly represented by interaction of B7 with CD28 (Mattem et al, 1998 
&1999). It was found that LPS or lipid A was able to induce CD4+ and CD8+ 
lymphocyte activation and DNA synthesis. Further analysis of LPS-responding T 
lymphocytes found them to express CD25 on their surface, and they are in the 
memory pool (CD4+/CD45RO+) as well as naive pool (CD4+/CD45RO-). The 
response of LPS-stimulated T lymphocytes resembled an antigen-driven response 
with a low frequency of responding cells, and addition of monocytes/macrophages or 
other accessory cells such B cells or dendritic cells enhanced the response. This 
enhancement of T cell proliferation was found to be due to cell-cell contact between 
monocytes and T cells (Mattem et al, 1998). Moreover, blocking of the biological 
activity of IL-12 by a neutralizing anti-IL-12 mAb resulted in a clear reduction of T
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cell proliferation, indicating that in LPS-induced T cell proliferation not only an 
interaction by direct cell contact was necessary, but also the release of soluble factors 
such as IL-12. IL-12 alone is not able to induce proliferation in resting T cells.
One function o f monocytes during activation of T cells by LPS is to present a co­
stimulatory signal. These signals have to be presented by living monocytes since 
paraformaldehyde-fixed monocytes failing to internalise and re-express antigen did 
not support LPS induced T lymphocyte proliferation. In addition to that, the 
interaction o f LPS primed monocytes with T cells was not MHC-restricted, since 
primed autologous monocytes could be replaced effectively by primed heterologous 
monocytes and also antibodies to MHC-II had no effect in LPS-induced T cells 
proliferation. Furthermore, co-stimulatory signals through CD28 are required for 
optimal stimulation of human T lymphocytes by LPS, (Mattem et al, 1998, Brennan 
& Foey, 2002; Burger & Dayer, 2002; reviewed by Acuto & Michel, 2003). However, 
the significance of the activation of T cells by LPS, and the contribution of 
haematopoietic stem cells to this process remain to be investigated.
1.4.1.3 PHORBOL ESTER/CALCIUM FLUX
Lymphocytes can be activated by the synergistic action of protein kinase C binding 
phorbol ester (e.g. phorbol-12, 13-dibutyrate, (PDBu) and calcium ionophore (e.g. 
ionomycin), thus mimicking the action of DAG and IP3 respectively (Tmnech et al, 
1985; Berry et al, 1989). Phorbol esters mimic DAG activation of PKCs by binding 
to the same sites within the regulatory domain and inducing similar conformational 
changes. The DAG / phorbol ester binding sites have been mapped to two pairs of
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zinc fingers in the regulatory domain (CIA and C1B). Structural studies demonstrated 
that in the presence of phorbol ester, this domain forms a hairpinlike hydrophobic 
structure that mediates PKC interactions with membrane lipids, thus phorbol ester 
binding promotes conformational changes that trigger catalytic activity. Production of 
second-messenger DAG in response of physiological stimuli is transient due to the 
rapid metabolic conversion o f DAG. In contrast, phorbol esters are metabolically 
stable in most cells. As a consequence, PKC activation by phorbol esters is much 
more prolonged than the transient activation that occurs with physiological 
stimulation (Gopalakrishna et al, 2000).
Calcium ionophores such as ionomycin (Liu &Hermann, 1978) mimic Ins (1,4,5) P3. 
Ins (1,4,5) P3 binds to its receptor on endoplasmic reticulum (ER), causing release of 
calcium to the cytoplasm from calcium stores in the ER. This event triggers the 
opening of calcium-release-activated calcium (CRAC) channels at the plasma 
membrane, allowing influx of extracellular calcium (reviewed Sorrentino & Rizzuto, 
2001).
Phorbol ester/Calcium ionophore can lead to increased responsiveness to IL-2 via 
upregulation of high affinity IL-2R, and induction of IL-2 release, in combination 
with a significant proliferative response (Stoeck et al, 1987). In addition, phorbol 
ester/calcium ionophore causes activation of NFkB, a transcription factors (Baeuerle 
& Henkel, 1994).
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1.4.1.4 CD69, SURFACE RECEPTOR
CD69 has been found expressed on all peripheral blood monocytes, and is also one of 
the earliest cell surface molecules expressed after activation of T and B cells and other 
cells of haematopoietic origin (reviewed by Testi et al, 1994). It is thought to play an 
important role in production of IL -lp (Manie et al, 1993; Isler et al, 1993), and IL-15 
(Ortiz et al, 1999) in RA. CD69 can act as a potent stimulatory molecule on the 
surface of human peripheral blood monocytes (De Maria et al, 1994). Moreover, anti- 
CD69 induced TNF-a production by human monocytes (Ramirez et al, 1996).
Activation via TCR/CD3, phorbol ester such as phorbol myristate acetate (PMA) or 
PDBu or via IL-2 receptor, results in activation of the Ras protein, which 
subsequently initiates CD69 expression and cell activation. These pathways may 
involve protein-tyrosine kinases (PTKs) and/or PKC. Cross-linking of CD69 on 
activated T cells was shown to generate an extracellular calcium influx (Maria et al,
1994), and upon simultaneous PKC stimulation, to induce the expression of IL-2, 
IFN-y and TNF-a. Signal generation from CD69 in T cells requires the expression of 
the TCR/CD3, suggesting that CD69 may act in close sequence to TCR/CD3 
signalling (reviewed by Testi et al, 1994).
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1.5 The role of monocyte/macrophages in RA
The role of monocytes and macrophages in RA has been well established (Burmester 
et al, 1997; Kinne et al, 2000). Macrophages constitute a major part of both the 
normal and rheumatoid synovial lining, and are frequently filled with phagocytosed 
material (Zvaifler et al, 1995). Monocyte/macrophages have several roles that may 
contribute to the progression of RA. Synovial tissue macrophages and peripheral 
blood monocytes show signs of activation, reflected by the production of 
proinflammatory cytokines, such as TNF-a, IL-1, and MMPs. These factors play a 
crucial role in mediating joints destruction in RA. Moreover, it has been hypothesised 
that monocytes may introduce antigens into lymph nodes or joint tissue, thus it is 
possible that an antigen-incited process is not necessarily initiated in the synovial 
tissue, but rather may be imported.
Circulating autoantibodies, such as RF, anti-perinuclear antibodies and anti-keratin 
antibodies have been detected in RA (Corrigall & Panayi, 2002). Although the 
pathological role of these autoantibodies is not fully characterised, they may 
contribute to disease by forming immune complexes. Binding of IgG containing 
immune complexes to FcyRs expressed on monocytes and macrophages, leads to 
activation of these cells. This initiates a diversity of effector functions, such as 
phagocytosis, antigen presentations, antibody-dependent cellular cytotoxicity and the 
release of proinflammatory and tissue destructive mediators (Blom et al, 2000; de 
Stahl et al, 2002; Wijngaarden et al, 2003), as well as anti-inflammatory cytokines 
such as IL-lra (Arend et al, 1991).
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Macrophages in the cartilage-pannus junction also produce modest amounts of 
proteolytic enzymes, such as collagenase and stromelysin, gelatinase B and elastase. 
However, the destruction of cartilage and bone in RA is the result o f complex cellular 
interactions, in which the macrophages play a crucial role in the pathogenic cascade, 
but are not necessarily the primary effector cells of matrix destruction (Mauviel,
1993). There are multiple ways by which macrophages interact with other cells to 
trigger the formation of invasive inflammatory pannus: macrophages are the main 
source of platelet-derived growth factor (PDGF) in RA synovium. This cytokine 
causes synovial fibroblasts to grow under anchorage-independent conditions, similar 
to transformed cells (Lafyatis et al, 1989). In addition, inflammatory cytokines (TNF- 
a , IL-1 [3) contribute to the generation of proteolytic enzymes by synovial fibroblasts. 
Also it has been shown that numbers of synovial macrophages correlate with articular 
destruction in RA (Mulherin et al, 1996; reviewed by Burmester et al, 1997).
Cytokines are crucial for directing the differentiation of the monocyte/macrophage 
system, (as mentioned in section 1.3). For example, TNF-a inhibits the differentiation 
o f monocytes into macrophages and, together with GM-CSF, directs the precursor 
cells to differentiate into dendritic cells and to osteoclast cells, which greatly 
contribute to bone destruction in RA (Reid et al, 1992). Macrophages in RA synovial 
tissue are characterized by increased expression and transcription of IL-1 p and TNF-a 
reflecting the activated state. However, not only the synovial macrophages but also 
peripheral blood mononuclear cells of RA patients showed elevated levels of these 
cytokines (Firestein et al, 1990; Dayer& Fenner, 1992; Kunkel et al, 1996; Feldmann 
et al, 1996 &1999; Steiner et al, 1999).
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It is not known which factor(s) prime monocytes to subsequently locate in the specific 
organ systems. Two mechanisms may be involved: monocytes may be educated in the 
bone marrow to enter designated sites, or second, monocytes may bind to adhesion 
molecules present either physiologically or upon inflammation, and subsequently 
enter the respective tissues. Once monocytes have entered the tissue, they do not 
recirculate, but may undergo differentiation and activation events, for example, the 
formation of granulomas consisting of epithelioid and giant cells in synovial tissue or 
nodules of RA patients (Zvaifler, 1995; Burmester et al, 1997).
1.5.1 Mechanism of monocyte/macrophage activation
1.5.1.1 BACTERIAL LPS
LPS is a potent stimulant for monocytes and macrophages. It activates a cascade of 
inflammatory responses leading to increase secretion of cytokines such as TNF- 
a  (Yao et al, 1997), IL-1 (Buras et al, 1998; Schumann et al, 1998), IL-6 (Tilg et al,
1997) and IL-8 (Tanaka et al, 1997). Also it has been demonstrated that LPS activates 
caspase-1 in the monocyte cell line (THP-1), freshly isolated peripheral blood 
monocytes, and in human umbilical vein endothelial cells (HUVECs) in a time-and 
dose-dependent manner. Caspase-1 activation is associated with cleavage of the IL-1 (3 
precursor protein that is followed by release of the mature IL-lp precursor protein 
(section 1.3.1) (Schumann et al, 1998). LPS has been shown to induce acute phase 
proteins (Haziot et al, 1988), a set of functionally diverse proteins thought to increase 
host defences.
LPS binds to a serum protein called LPS-binding protein (LBP) (Tobias et al, 1993; 
Schumann et al, 1996), LBP rapidly catalyses the transfer o f LPS to membrane-bound
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CD 14 (mCD14) or soluble CD 14 (sCD14). Although CD 14 has been identified as an 
LPS receptor, it is not a transmembrane receptor and lacks intracellular domain 
(Wright et al, 1990; Ulevitch & Tobias, 1994; Pugin et al, 1998). The mechanisms by 
which CD 14 mediates a transmembrane signal have remained elusive. It has been 
hypothesised that additional transmembrane receptors must act in concert with LPS- 
CD14 complexes to initiate the signalling process leading to LPS-induced cellular 
activation. Toll-like receptor-4 (TLR-4) has been associated with LPS responsiveness. 
TLR-4 requires additional molecules, MD2, which forms a complex with the 
extracellular domain of TLR-4 for effective LPS recognition (Lein et al, 2000; Akashi 
et al, 2001; Correia et al, 2002; Zarember et al, 2002). Moreover, it has been 
documented that LPS must initially bind to CD 14 and is then transferred to the 
membrane where it associates with a complex of receptors, including TRL-4-MD2 
(Correia et al, 2002, Triantafilou M & Triantafilou K, 2002). A recent discovery 
indicated that LPS-binding site involves heat shock proteins (Hsp) 70 and 90, 
CXCR4, and growth differentiation factor 5 (GDF5), all four molecules form a 
complex after LPS ligation. Moreover, Pfeilffer et al (2001) suggested a new LPS 
activation cluster composed of CD14, TLR, CD55, CD16a, CDllb/CD18, Fcy- 
receptors, CD32 and CD64, Fcy-RIIIa, CD36 and CD81 (Pfeilffer et al, 2001; 
reviewed by Triantafilou M & Triantafilou K, 2002). In conclusion, molecules 
involves in LPS binding site are complicated and depends on the cell type, for 
example, LPS binding site on B cells has been shown to engage TRL-4, RP105 and 
MD1, whereas in mast cells the binding site is found to be TLR-4 and MD2 (reviewed 
by Triantafilou M & Triantafilou K, 2002).
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LBP is a 60kDa glycoprotein, which binds to the lipid A portion of LPS, and is a 
member of a family of lipid carrier proteins capable of transporting amphipathic 
molecules in aqueous environments. A major function of LBP is to enable LPS 
binding to either membrane or soluble CD14. LPS-LBP complex enhanced TNF- 
a a n d  NO production. LBP also enhances LPS-induced upregulation of adhesion 
molecules in polymorphonuclear cells. Depletion of this protein from plasma 
markedly reduces LPS-induced cell activation (Wright et al, 1990; Ulevitch & Tobias,
1994).
The mechanism of internalisation of mCD 14-bound LPS has not been well described. 
It may enter cells via clathrin-coated pits, or via the glycosylphosphatidylinisitol- 
anchored proteins. LPS then moves into intracellular compartments where the lipid A 
portion exerts its biological activity (Pugin et al, 1998). LPS has been shown to move 
from the plasma membrane to intracellular vesicles. There is also evidence that LPS 
may remain on the plasma membrane for long periods of time before its active form is 
released. The binding between CD 14 and LPS, and subsequent internalisation of LPS 
has been linked to both the activity of LBP and the size of LPS aggregates involved 
with larger aggregate and presence of LBP resulting in an increase rate of 
internalisation (Kitchens & Munford, 1998; Kitchens et al, 1998).
Several signal transduction pathways have been associated with LPS-CD14-TLRs 
interaction. These signals are generally alike in that they result in the activation of 
transcription factor NF-kB, which leads to proinflammatory cytokine production. It 
has been shown that LPS treatment of monocytes (Weinstein et al, 1992 & 1993) and 
HUVECs (Schumann et al, 1996) leads to increased protein tyrosine phosphorylation
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and MAP kinase activation, including ERK1/2, JNK and p38 (Weinstein et al, 1992 & 
1993).
Alternative pathways involve phosphatidylinositol-3 kinase (PI3K), activation of 
phospholipase D (PLD), and PKC (Herrera-Veilt & Reiner, 1996). Activation of 
protein tyrosine kinases (PTKs) by LPS results in activation of PI3K, followed by 
stimulation of PLD by both PTKs and PI3K. DAG activates PKC, consequently 
leading to MAPK kinase activation (Buscher et al, 1995). In addition, activation with 
LPS leads to conformational changes in the TLR-4 cytoplasmic domain and 
subsequent recruitment of an adaptor named MyD88. MyD88 recruits downstream 
IL-1 receptor-associated kinases (IRAK). IRAK is then phosphorylated and 
dissociates from the receptor complex and recruits TNF-receptor-associated factor 6 
(TRAF6) that in turn activates downstream kinases such as MAP kinases, ERK kinase 
kinase 1 (MEKK1) and NF-kB inducing kinases (NIK) (Zhang & Ghosh, 2001).
Endogenous inhibitors of LPS signalling have been discovered, 
phosphatidylinositides are capable of binding to mCD14 (utilising the action of LBP), 
and inhibit monocyte activation by preventing binding of LPS (Wang et al, 1998). 
Tissue factor pathway inhibitor (TFPI) is a plasma protease inhibitor that plays an 
important role in feedback inhibition of the coagulation cascade. It is also able to bind 
to LPS and prevent interaction with both LBP and CD 14 (Park et al, 1997). Blockade 
of NF-kB activity by excess IkB is able to completely inhibit proinflammatory 
cytokine and partially anti-inflammatory cytokine expression in response to LPS 
(Bondeson et al, 1999). This suggests that blockade o f NF-kB, or preventing its 
activation, might be a useful tool in treatment of inflammatory disease.
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1.5.1.2 1,25 DIHYDROXYVITAMIN D3
The steroid hormone 1,25 dihydroxyvitamin D3 (1,25 (OH) 2 D3) is the active form of 
vitamin D3 produced exclusively in the kidney. It is an important regulator of bone 
and mineral metabolism, and has multiple effects on cells of the immune system. It 
plays a role in controlling the growth and differentiation of several cell lines such as 
the promonocyte lines THP-1 and U937 and lymphocytes (Lemire, 1992; reviewed by 
Ross et al, 1994). O f particularly importance to the field of proinflammatory cytokine 
studies was the discovery that 1,25 (OH) 2 D3 was capable of stimulating myeloid 
cells to differentiate along a monocyte/macrophage lineage. This technique is now 
widely used in the study of proinflammatory cytokine production by promonocytic 
cell lines such as THP-1. 1,25 (OH) 2D3 induces C D llb  and CD14 expression on 
these cells and subsequently increase cytokine release such as IL-1 (3, TNF-a, and IL- 
6 in response to additional stimulation (Vey et al, 1992; Chizzolini et al, 1997; 
Landman et al, 1998). The mechanism controlling this differentiation is believed to be 
primarily due to an effect on gene expression (Obeid et al, 1990), and increased 
expression of calcium binding proteins (Roth et al, 1993).
1,25 (OH) 2D3 exerts its activity on responding cells via vitamin D receptor (VDR). 
This receptor is expressed on a wide range of cell types including monocytes and 
activated lymphocytes (reviewed by Ross et al, 1994). A number of other 
immunomodulatory and immunosuppressant roles have been determined for 1,25 
(OH) 2 D3. It inhibits the transcription and secretion of IL-2 and the transcription of 
IFN-yin T helper cells (Rigby et al, 1984), and also inhibits the generation of NK and 
cytotoxic T cells (Merino et al, 1989; Lemire, 1992). There is also a suppressive
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effect on immunoglobulin production by B-lymphocytes; this may be due to the 
inhibitory effects on the Th-cell population (Iho et al, 1986; Lemire, 1992).
1.5.1.3 OTHER INDUCERS OF MONOCYTE ACTIVATION
Monocytes/macrophages can be activated via Fc receptors (FcR), FcyR (IgG) is 
directly relevant to monocyte/macrophage activation (Sutton & Gould, 1993). FcyR 
mediate a range of activities on monocytes/macrophages, including phagocytosis, 
endocytosis, and release of inflammatory cytokines and NF-kB activation (van de 
Winkle & Anderson, 1991; Tsitsikov et al, 1995). Cross-linking of FcyRIIIa is also 
able to stimulate TNF-a secretion in monocytes (Abrahams et al, 1998). Interestingly, 
elevated expression levels of FcyRIIa and Ilia has been reported in RA (Wijngaarden 
et al, 2003) and related to the disease severity and cartilage destruction (Blom et al, 
2000; Bran et al, 2002).
Phorbol esters such as PMA trigger signal transduction cascades, due to their ability 
to mimic DAG, which activates PKC (Sharkey&Blumberg, 1985). Activation by 
phorbol esters induces expression of ICAM-1 (Dean et al, 1994; Kurosoka et al,
1998). Phorbol esters have also been used to induce differentiation of myeloid 
progenitor cells (such as THP-1) into more mature cells (Pedron et al, 1995) and 
induce proinflammatory cytokines such as IL-1 p. Calcium flux, induced for example 
by calcium ionophores such as ionomycin or A3187, also activates monocytes, and 
stimulates IL-8 expression similar to LPS (Wilson et al, 1993). Incubation of 
peripheral blood myeloid-lineage cells with ionomycin or A23187 down regulated 
CD 14 expression (Czemiecki et al, 1997).
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1.6 The principle of T-lymphocyte-monocyte co-culture
T cells and monocytes are major sources of inflammatory mediators and can 
communicate with each other as well as with other cells. This communication is 
mediated by soluble factors and by direct cell-cell contact. Interactions between T 
cells and monocyte-macrophages result in the production of cytokines such as IL-1 
and TNF-a. In RA, these cytokines stimulates connective tissues cells such as 
fibroblast-like synoviocytes to produces MMPs, which degrade the extracellular 
matrix components of the cartilage (e.g. collagens and proteoglycans) (reviewed by 
Burger & Dayer, 2002).
Direct contact with stimulated T lymphocytes is a potent mechanism which induces 
the production of pro-inflammatory factors by monocytes-macrophages, including IL- 
1(3, IL-lra (Vey et al, 1997) and TNF-a (Sampaio et al, 2000; Burger & Dayer, 2002). 
Additional experiments also detected release of MMPs from monocytes/THP-1 cells 
cultured with fixed T cells following activation with PHA, PMA and anti-CD3 
(Lacraz et al, 1994). Production of TIMP has been detected from THP-1 cells when 
incubated with PHA/PMA activated, fixed T cells (Rezzonico et al, 1998).
Furthermore, Thl and Th2 cells have different regulatory activities in cell-cell contact 
with THP-1 cells (monocyte cell line); Thl cells induce higher level of pro- 
inflammatory cytokines such as IL-1 (3, whereas Th2 cells favours anti-inflammatory 
cytokines such as IL-lra (Chizzolini et al, 1997). Moreover, direct contact between 
fixed PHA/PMA-activated T cells and fibroblast/synoviocytes inhibits the synthesis 
of type I and III collagen (Rezzonico et al, 1998). Cell-cell contact of T cells (Jurkat
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cell line) with fibroblasts induced mRNA expression of IL-17 and IL-17 receptor 
(Thiele et al, 2000). Thus cell-cell contact represents an important mechanism for 
initiation of inflammation and tissue destruction. It has been suggested that cell-cell 
contact provides a mechanism that may participate in the process of inflammation. 
This has lead to identification o f molecules on T cell surface that are involved in 
contact-dependent of monocyte-macrophage activation and cytokine production. For 
example it has been shown that activation of fibroblasts, synoviocytes and 
microvascular endothelial cells by stimulated peripheral blood T cells was mainly due 
to membrane-associated TNF-a and IL-1 a  (Burger et al, 1996; Malik et al, 1996; 
reviewed by Burger & Dayer, 2002). Monocyte/macrophage-T cell interactions 
obviously involve other surface molecules that have the ability to induce cell 
activation, for example CD40-CD40L, lymphocyte function associated antigen 
(LFA)-1/ICAM-1, and CD2/LFA-3. Ligation of CD40 (on the surface of the dendritic 
cells and macrophages) with CD40L (CD 154, in T cells) regulates production of 
certain cytokines such as IL-8, M IP-la, TNF-a, IL-12 and IL-1. Moreover, activation 
of human monocytes through CD40 induces MMP production (Malik et al, 1996; 
reviewed by Burger & Dayer, 2002; Brennan & Foey, 2002; Burger & Dayer, 2002). 
CD40 is expressed on a wide range of cells including monocytes and is involved in 
contact-dependent activation (Wagner et al, 1994; Yellin et al, 1995; Grewal & 
Flavell, 1998). CD40 and its ligand are responsible for interaction between T cells and 
B cells. This interaction leads to B cell proliferation and antibody production (Wagner 
et al, 1994). Intercellular adhesion molecule-1 (ICAM-1/CD54), a membrane 
glycoprotein, is a member of the immunoglobulin-like family with domains that play 
a role in cell-cell or cell-ECM adhesion interaction. ICAM is widely expressed on 
nonhaematopoietic cells such as vascular endothelial cells, and fibroblast and
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haematopoietic cells such as monocytes, macrophages, T cells and dendritic cells. The 
interaction o f ICAM-1 on the vascular endothelial cells with CD 11 a/CD 18 (LFA-1) 
or CDllb/CD18 (Mac-1) on leukocytes enhances the adhesion o f leukocytes to the 
vascular endothelium. Other surface molecules that have been implicated in T 
lymphocyte-monocyte interactions include CD69 and LFA-1 (Manie et al, 1993). It 
was shown that Jurkat T cells stimulated with anti-CD3, induced IL-1 production 
from THP-1 cells through cellular contact. LFA-1 was shown to be involved in this 
induction (Manie et al, 1993), and anti-CD69 inhibited IL-1 production, suggesting 
involvement of surface molecules in cytokine production (Isler et al, 1993).
1.7 The aim of the study
Proinflammatory cytokines play a central role in the progression of the inflammatory 
process in RA. Cytokine imbalance in favour of IL-1 (3 over IL-lra has been observed. 
However, the underlying mechanism controlling the production of IL-1 (3 production 
remains unclear. There has been substantial interest in the induction of monocyte 
cytokine release following T cell-monocyte interactions. Moreover, T cells in the 
synovium of RA patients are under constant exposure to oxidative stress. This may 
alter the behaviour of T cells and their interaction with monocyte-macrophages.
Previous work done in our laboratory generated Jurkat T cells resistant to hydrogen 
peroxide (HJ16). These cells stimulate induction of proinflammatory cytokines such 
as IL-1 p by differentiated THP-1 cells, compared to normal Jurkat cells (J16). The 
HJ16 cell line has now been cloned by using limiting dilution (1 cell/well), 35 clones 
were isolated. The primary aim of this study was therefore to characterize the H J16 
cells and the clones in the co-culture system using THP-1 cells or peripheral blood
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mononuclear cells (PBMCs). Thus we can investigate whether oxidative stress alters 
the behaviour o f the T cells (HJ16 and the clones) and their interaction with 
macrophages in relation to inflammatory joint disease.
It has been shown that Thl and Th2 cells induce different cytokine patterns. It has 
been observed that Thl cells induce IL-1 (3, whereas Th2 cells induce IL-lra 
production upon cell-cell contact (Chizzolini et al, 1997), therefore, J16 and HJ16 
cells might be classified into Thl or Th2 phenotype using chemokine receptors 
specific for Thl or Th2 cells.
Glutathione (GSH), depletion is associated with augmentation of oxidative stress- 
mediated proinflammatory cytokine production. Manipulation of anti-oxidants such as 
GSH in T cell lines (such as HJ16 and J16) and its effect on co-culture with a 
monocyte cell line such as THP-1 is investigated.
MAPK cascades are involved in inflammation and tissue destruction in RA. The use 
o f MAP kinases inhibitors with T cell lines (J16 and HJ16) and their effects on the 
stimulation o f IL-1 (3 production by THP-1 cells are examined.
Reduced calcium signalling and low proliferative response in the rheumatoid synovial 
T cells are manifested. This reduction may be due to constant subjection to oxidative 
stress (Carruthers et al, 1996). Therefore calcium signalling and proliferation of J16 





Chapter 2 Materials and Methods
2.1 Materials
Antibodies
Mouse anti-human CD3 (OKT3) and mouse anti-human CD69 hybridomas were 
obtained from the American Type Culture Collection (ATCC), some anti-human- 
CD3 antibody was purchased from Biocarta (Oxford, UK) and from R &D Systems 
(UK). Mouse-anti-human-CD2 antibody was purchased from CYMBUS (UK). 
Purified mouse anti-human CD 14 antibody was a kind gift from Dr D.M. Sansom. 
Goat anti-mouse IgG-FITC, and ELISA antibodies, IL-1 (3 and IL-lra were purchased 
from R&D Systems. Anti-CD28 antibody, anti-phosphorylated p38, and rabbit anti- 
horseradish peroxidase were kindly provided by Dr S.G. Ward (University of Bath).
Cell culture, ELISA and calcium signalling
Ionomycin, phorbol dibutyrate (PDBu), phytohaemagglutinin-L (PHA-L), 
lipopolysacchride (LPS, Escherichia coli), 1,25 dihydroxyvitamin D3( (1,25 (OH) 2 
D3X glutaraldehyde, foetal calf serum (FCS), bovine serum albumin (BSA), o- 
phenylenediamine dihydrochloride (OPD) tablets, Tween-20, buthionine-DL- 
sulfoximine (BSO), N-acetylcysteine (NAC), diamide, diethyl maleate (DEM), 
sodium 3’-[l-[(phenylamino)-carbonyl]-3,4-tetrazolium]-bis (4-methoxy-6-nitro) 
benzene-sulfonic acid hydrate (XTT), phenazine methosulfate, trichloroacetic acid 
(TCA), 5,5’-dithiobis (2-nitrobenzoic acid, DTNB), and P-nicotinamide adenine 
dinucleotide phosphate reduced tetrasodium salt (p-NADPH) were purchased from 
Sigma Chemical Company Ltd (Poole, Dorset).
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Streptavidin-horseradish peroxidase was purchased from Serotec. Lymphoprep (for 
PBMC separation) was obtained from NYCOMED, Norway. RPMI 1640, sodium 
bicarbonate, pencillin/streptomycin, L-glutamine, Hanks balanced salt solution 
(HBSS) were purchased from GIBCO BRL.
PD98059 (ERK1/2 inhibitor), SB203580 (p38 inhibitor), SP600125 (JNK inhibitor 
II), bisindolylmaleimide (protein kinase C inhibitor), fura-2 acetoxymethylester (fiira- 
2 AM), glutathione reductase were purchased from CalBiochem.
The human cell line THP-1 was obtained from European Collection of Animal Cell 
Culture (ECACC). The human T-lymphocyte cell line Jurkat (J16) was obtained from 
the ATCC. Hydrogen peroxide tolerant Jurkat cell line was generated in our 
department. UV-A resistant Jurkat cell line was provided by Dr C. Pourzand, 
(University of Bath, Department of Pharmacy and Pharmacology).
Molecular Biology
CCR2, CCR3, CCR4 CCR5, CXCR3 and (3-actin primers (forward and reverse 
primer), agarose and ethidium bromide were kindly provided by Dr Pauline Wood 
(Bath University, Department of Pharmacy and Pharmacology).
CCR2 sense primer sequence: CCAACTCCTGCCTCCGCTCTA,
Antisense primer: CCGCCAAAATAACCGATGTGATAC 
CCR3, sense primer sequence: TGGCGGTGTTTTTCATTTTC,
Anti-sense primer: CCGGCTCTGCTGTGGAT.
CCR4: sense primer sequence GAAGAAGAACAAGGCGGTGAAGAT 
Anti-sense sequence ATGGTGGACTGCGTGTAAGATGAG 
CCR5 sense primer sequence TGCTACTCGGGAATCATAAAAACT 
Anti-sense sequence TTCTGAACTTCTCCCCGACAAA
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CXCR3 sense primer sequence CTCCACCTAGCTGTAGCAGA 
Anti-sense sequence AGGAAGATGAAGTCTGGGAG 
(3-ACTIN sense primer sequence CTTTTCCAGCCTTCCTCC
Anti-sense sequence GCAGTAATCTCCTTCTGCATC
RNAZol was obtained from TEL-INC., PCR buffer (10x) with Mg2+, 
deoxynucleoside triphosphate set (dATP, dCTP, dGTP and dTTP), and RNAsin were 
purchased from Roche Diagnostic. Poly (T)i2-i8 were purchased from Amersham 
Pharmacia Biotech Inc.. 100-base pair DNA ladder, DNAse reaction buffer, reverse 
transcriptase (Superscript II) and DNAse 1 amplification grade were purchased from 
GIBCO, BRL.
General equipment
Tissue culture plastics were purchased from Fahrenheit Laboratory Supplies Ltd. Cell 
handling was performed in a laminar flow hood (Class II) and incubations were 
carried out in a 5% CO2 at 37°C in a humidified incubator (Gallenkamp). 
Polypropylene tubes and polystyrene flasks were used for all cell maintenance and 
culture.
Cells were counted using a cell counter (Beckman coulter counter). FACS analysis 
was performed on a Becton Dickinson FACStar Plus, using a lOOmW, 488nm argon 
laser, with light being channelled by 520nm filter (FL-1) and 580nm filter (FL-2). 
ELISA plate readings were performed on a Dynatech MR5000 spectrophotometer. 
Calcium signalling was performed on a fluorimeter (Photo-Technology International, 
PTI). The experiments under hypoxic conditions were performed using Anaerobic 
System incubators (USA), the oxygen tension was set and maintained constantly at
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1% or 2% (14mmHg) by automatically injecting mixture of 1% or 2% oxygen and 
nitrogen into the chamber.
Some of the molecular techniques were carried out in the PCR hood (PCR-640, 




The promonocytic cell line (THP-1), Jurkat T-cells line (J16), hydrogen peroxide 
tolerant cell line (HJ16), UV-A resistant Jurkat cell line (UVAR-J16) and clones of 
HJ16 (AB10, AB2, AD8 , AF4, AF8 , AGIO, AH8 , BD3, ADI 1, BB3, BG10 and BA6 ) 
were maintained in RPMI 1640 medium supplemented with foetal calf serum (see 
appendix) (at 0.3 x 106 -0 .5x l0 6 cells/ml) and cultured in 5% CO2 at 37°C. This 
standard culture medium is referred to throughout this thesis as RPMI. All cell 
manipulations were performed under sterile conditions in a tissue culture laminar flow 
hood (Class II).
2.2.2 FACS analysis of H20 2 tolerance
To determine the resistance of cells (J16, HJ16 and HJ16 clones) to H2O2, cells were 
washed once in PBS, centrifuged for 5 minutes at 1600 rpm and maintained at 1 x 106 
cells/ml. Cells were then transferred into polystyrene FACS tubes, and then washed 
again with PBS and resuspended with 1 ml of various concentration of H2O2 (0- 
30mM). H2O2 were prepared with serum free RPMI 1640 medium to avoid any 
reaction with FCS. Cells were then incubated for 4 hours at 37°C, 5% CO2 , IOOjllI of
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FCS was added to all tubes and incubated overnight at 37°C, 5% CO2 . After that, cells 
were washed twice with PBS and resuspended with 50 (il of propidium iodide (see 
appendix 1). Finally cells were analysed with flow cytometry (FL-2), using % PI 
uptake as an indication of cell death (PI binds to DNA of non-viable cells).
2.2.3 T cell-monocyte interaction and cytokine production
2.2.3.1 THP-1 cells differentiation
In order to use THP-1 cells as a model for monocyte/macrophages they were 
differentiated with 1,25-dihydroxyvitamin D3 (1,25 (OH) 2 D3). THP-1 cells were 
washed once with PBS and resuspended at 0.5 x 106 cells/ml in RPMI in a tissue
o
culture flask. 1,25 (OH) 2 D3 was added at a final concentration of 1 x 10' M in the 
dark and incubated at 37°C, 5% CO2 for 48 hours. Differentiation was confirmed by 
using CD 14 expression (detected with anti-CD 14) as a marker for mature monocytes.
2.2.3.2 T cell line activation
J16, HJ16, UVAR-J16 and HJ16 clones were washed once with PBS and resuspended 
at 1 x 106 cells /ml in RPMI. Cells were activated with phorbol dibutyrate (PDBu) 
(0.5 ng/ml) and ionomycin (1 jllM), anti-CD3 (1 or lOpg/ml), anti-CD28 (10|Ug/ml) or 
PHA-L (10pg/ml). Cells were incubated at 37°C, 5% CO2 for 24 hours. Activation 
was determined by monitoring the up-regulation of CD69 expression.
In some experiments, J16/HJ16 cells were pre-treated with BSO, DEM, diamide or 
NAC, to manipulate intracellular glutathione levels (see section 2.2.6 for detail). 
Incubation of mitogen activated protein kinase (p38, JNK, ERK1/2) or protein kinase 
C inhibitors were also used with J16 and HJ16 cells in some experiments prior to
62
activation. Cells were pre-incubated with 20|iiM PD98059 (ERK1/2 inhibitor), ljuM 
SB203580 (p38 inhibitor), 20pM SP600125 (JNK inhibitor II), 500nM 
bisindolylmaleimide (protein kinase C inhibitor), for 1 hour, and then washed once 
with PBS, resuspended in RPMI, and activated with various stimulants as mentioned 
above.
2.2.3.3 Isolation of peripheral blood mononuclear cells (PBMCs)
Peripheral blood was kindly obtained from normal donors at Bath University, 
Department of Pharmacy and Pharmacology; 50-100 ml of blood were taken from 
each donor. Blood was diluted at 1:2 with PBS and layered carefully on top of 15 ml 
Lymphoprep in polypropylene tubes. Tubes were then centrifuged at 1600 rpm for 30 
minutes. The middle layer was removed into new polypropylene tubes. PBMCs were 
then washed three times with RPMI (first wash was for 10 minutes and the further 
washes for 5 minutes, at 1600 rpm).
2.2.3.4 Enrichment of monocytes in PBMCs
PBMC were depleted of T/B cells in some experiments in order to determine if  donor 
T/B cells in the co-culture of PBMCs interfered with J16, HJ16 and HJ16 clones. 
PBMCs were suspended at 5-10 x 106 cells/ml and were then centrifuged at 1600 rpm 
for 5 min. Supernatant was removed and the cells were resuspended with 500pl of 
mouse anti-human CD3 (T cell marker), and IOOjllI of mouse anti-human CD20 (B 
cell marker). Cells were rotated at 4° C for 1 hour and then washed twice with RPMI 
1640 medium for 5 minutes at 1600 rpm. The pellet was resuspended in 1 ml of RPMI 
1640 medium and 50 pi of magnetic DYNA beads (coated with sheep anti-mouse 
IgG) was added. The tube was rotated again at 4° C for 1 hour. 10 ml of RPMI 1640
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medium was added to the tube, which was then placed horizontally on a magnetic bed 
for 2-3 minute at room temperature. This step was repeated three times. The non­
adherent cells were recovered, and then analysed by using anti-CD3 for T cells 
(expression of CD3, as T cell marker) and anti-CD 14 (expression of CD 14 on the 
mature monocytes) (section 2.2.3.5).
2.2.3.5 Determination of cell surface marker expression
Activated and unactivated J16, HJ16, UVAR-J16, HJ16 clones and THP-1 cells were 
washed once with PBS and maintained at 0.5 x 106 cells/ml. Cells were transferred 
into FACS tubes and washed once with PBS for 5 minutes at 1600 rpm and 
resuspended with appropriate antibody (anti-CD14 for THP-1 cells differentiation, 
and anti-CD69 for J16, HJ16, UVAR-J16 and HJ16 clones activation). All tubes were 
incubated at 4°C for 30 minutes. Cells were then washed once with PBS for 5 minutes 
at 1600 rpm and resuspended with 50jll1 goat anti-mouse IgG antibody and incubated 
for 30 minutes at 4°C. Cells were analysed by flow cytometry (FL-1).
2.2.3.6 T-cell / monocyte co-culture technique
Co-culture experiments were carried out in 96 well U-shaped bottomed plates. All 
treatments were carried out in duplicate. THP-1 cells were used at 1 x 106 cells/ml, T 
cell lines were used at 5 x 106 cells/ml and PBMCs were co-cultured at 2 x 106 
cells/ml. All cells were washed once and maintained at the appropriate concentration. 
In some experiments, J16, HJ16, UVAR-J16 cells and HJ16 clones (AB10, AD8 , 
BA6 , AGIO, AF4, BB3 and BD3) were fixed with 0.025% glutaraldehyde for 5-10 
minutes at room temperature. Aliquots (lOOjil) of J16, HJ16, UVAR-J16 and HJ16 
clones suspension (activated or un-activated, fixed or unfixed) were added to 1 0 0  j l l I
64
differentiated THP-1 cells/PBMC/purified monocyte suspension in 96 well plates. 
Plates were incubated for 48 hours at 37°C, after which they were centrifuged and 
supernatants were harvested into new flat-bottomed 96 well plates.
2.2.4 Enzyme Linked Immunosorbent Assay (ELISA)
ELISA was performed to determine the production of IL -ip  and IL-lra in the 
supernatant of the co-cultures. ELISA plates (Nunc Maxisorb II Immunoplate) were 
coated with 50 pl/well of monoclonal primary antibody for IL-1 (3 (mouse anti-human 
IL-(3 IgG, 17.5|ng/ml) or IL-lra (mouse anti-human IL-lra IgG, 60pg/ml) diluted in 
0.5 M carbonate/ bicarbonate buffer pH 9.6. Plates were sealed and incubated 
overnight at 4°C. Next day the plates were washed once with PBS-Tween (see 
appendix 1) and then blocked for 90 minutes with PBS containing 1% bovine serum 
albumin (BSA) and 5% sucrose. Plates were then washed 3 times with PBS-Tween 
and then either used immediately or sealed and stored at 4°C for up to one week.
Six standards for IL-1(3 (2000, 1000, 500, 200, 50, 0 pg/ml) and IL-lra (10000, 5000, 
2500, 1250, 625, 0 pg/ml) were prepared to generate standard curves. 50 |Lil/well of 
each standard were added into the first top row of ELISA plates. Culture supernatant 
samples were diluted 1:2 directly into ELISA plates with RPMI 1640 medium (25pl 
supernatant sample+25pl of RPMI 1640 medium). Plates were sealed and incubated 
overnight at 4°C. Plates were then washed 3 times with PBS-Tween. Secondary 
antibody (50|il/well) specific for anti-IL-lra or IL-1J3 (goat anti-human IL-lp; goat 
anti-human IL-lra) was added to the plates and incubated for 2 hours at room 
temperature. Plates were then washed 3 times with PBS-Tween and streptavidin-horse 
radish peroxidase (HRP) was added (50pl/well) and plates incubated for 30 minutes at
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room temperature. After that, the plates were washed 4 times with PBS-Tween and 
dried thoroughly. OPD (o-phenylenediamine dihydrochloride) tablets were prepared 
in Milli-Ro water and added to the plates (50|il/well). Plates were incubated at room 
temperature for 30 minutes. Finally, 0.5 M sulphuric acid (50pl/well) was added to 
stop the reaction, and colour development was measured spectrophotometrically on a 
plate reader (absorbance at 490 nm).
2.2.5 Analysis of chemokine receptor mRNA
Expression of chemokine receptor mRNA for CCR5, CCR3, CXCR3 and CCR4 were 
analysed by using reverse transcriptase polymerase chain reaction (RT-PCR) to help 
characterize the nature of J16, HJ16 and HJ16 clones, as Thl or Th2 like cells.
2.2.5.1 Extraction of mRNA
Messenger RNA was extracted from J16, HJ16 and HJ16 clones (AGIO, AB2, BD3, 
AF4, AB10 AD8 , BA6 , AD11, BB3 and AF8 ). Cells (5-10 x 106 cells/ml) were 
washed once with PBS (5 minutes at 1600 rpm), resuspended with 1 ml RNAzol, and 
transferred into 1.5 ml Eppendorf tubes. 100 j l l I  of chloroform was added to each tube. 
Tubes were shaken vigorously for 15 seconds, and then left on ice for 15 minutes. 
Tubes were centrifuged at 12000g for 15 minutes at 4°C and the RNA pellets were 
washed with 1 ml of 75% cold ethanol for 8  minutes at 7,500g at 4°C. Supernatant 
was removed and the pellet was air dried in the tissue culture hood, dissolved in 
RNase-free water and stored at -80°C.
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2.2.5.2 DNAse treatment of RNA
mRNA was quantified using GeneQuant and the volume of RNA solution containing 
lpg total RNA was determined. This volume was made up to 8 pl with RNase-free 
water, lp l of RNAzol (xlO) reaction buffer was added and then 1(0.1 of DNAse was 
added, the tube was mixed and left for 15 minutes at room temperature. 1 j l l I  of 25 mM 
EDTA was then added, and tubes were heated for 10 minutes at 65°C in the PCR 
thermal cycler.
2.2.5.3 Reverse transcription (RT)
Master mixture was prepared as follows: 4|li1 of 5x RT buffer, lp l of DTT 
(dithiothreitol), IjllI of dNTP (deoxynucleoside triphosphate), lp l RNAsin and lp l 
reverse transcriptase (superscript II) (total volume 8jll1 which was sufficient for one 
sample). Tubes (one duplicate, labelled as RT+) containing the DNAse-treated RNA 
were placed on ice and 2pl of poly d (T) 12-] 8 was added to each tube. RNA samples 
(RT+) were then denatured in the PCR machine at 70°C for 10 minutes. 8jll1 of pre­
prepared mixture was added to each tube and reverse transcribed by using the PCR 
machine at 42°C for 60 minutes, and at 95°C for 5 minutes and then held at 4°C. 
Samples were either stored at -20°C or carried on to the next step (PCR).
2.2.5.4 Polymerase Chain Reaction (PCR)
This step was carried out in the PCR hood. PCR master mixture was prepared as 
follows: 0.5jll1 of dNTP, 2.5pl of PCR buffer with Mg2+, 0 .125jnl polymerase, 15.9 pi 
of RNase free water, 2.5pl forward/reverse primer of a chemokine receptor/ (3-actin 
as control. This gives a total volume of 23.7 pi (for one sample).
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23.7 jj.1 of master mixture was added to new PCR tubes, labelled as RT+ or RT-. 1 p i  
of RT- sample or negative control (water) were added to appropriate tubes. The next 
step was carried out on the bench. 1 p i  of RT+ samples (from section 2.2.5.3) were 
added to appropriate tubes. All tubes (RT+ and RT-) were placed in the PCR machine 
and the RT-PCR program was run, (95°C for 5 minutes, 56° C for 30 seconds over 35 
cycles, 72°C for 30 seconds, 7 minutes at 72°C and held at 4°C).
2.2.5.5 Agarose gel electrophoresis of PCR products
Agarose gel was prepared by dissolving 5.6g of agarose in 300ml of 0.5x TBE (see 
appendix 1) (2% agarose in x0.5 TBE buffer) in a microwave. After cooling,
4 0 jll1 /100  ml of ethidium bromide was added and the gel was made and left to solidify 
at room temperature. The electrophoresis tank was filled with 0.5x TBE buffer and 
the gel was placed into the tank. 5pl of blue juice (see appendix) was added to each 
sample. Samples were loaded into the gel and electrophoresis was carried out for 90 
minutes, at 100 volts, at room temperature. Finally, the bands were detected with UV 
light.
2.2.6 Modulation of intracellular glutathione (GSH) levels in J16 and 
HJ16 cells
In order to deplete glutathione, cells (0.5 x 106 cells/ml) were incubated with various 
concentrations of buthionine-DL- sulfoximine (BSO), diamide or diethyl maleate 
(DEM), (see appendix for reagent preparation). BSO was used at 25, 50, 100 and 200 
pM for 24 hours, diamide/DEM were used at 50 and 100 pM for 2 hours and 24 
hours, or at ImM for 2hours.
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Increasing glutathione levels in J16 and HJ16 cells was achieved by incubating cells 
(0.5 x 106 cells/ml) for 24 hours with 2.5, 5, 10 mM N-acetylcysteine (NAC). 
Changes in levels of reduced glutathione were measured as described below (section 
2.2.7).
All cells were washed three times with PBS for 5 minutes at 1500rpm, then 
resuspended with RPMI 1640 at lx  106cells/ml and activated with ionomycin/ PDBu, 
co-cultured with THP-1 cells (section 2.2.3.6 ). Cells for calcium signalling were 
resuspended in HBSS, at 10-15xl06cells/ml (section 2.2.8).
2.2.6.1 Measurement of intracellular GSH
Intracellular GSH was measured in J16 and HJ16 cells before and after treatment with 
BSO/NAC. The intracellular GSH levels were measured spectrophotometrically (see 
appendix 1 for preparation of reagents): Cells were collected and washed in ice-cold 
PBS, and then resuspended in 5% TCA and kept on ice. Mixtures of 1ml phosphate 
buffer (see appendix 1), 100 pi cell suspension, 50pl NADPH, 20 pi DTNB were 
prepared, and kept in a water bath at 25°C for 10 minutes. GSH reductase (lOOpl) was 
added to the mixture and absorbance was read immediately using spectrophotometer 
at 412 nm. A standard curve was constructed, and intracellular GSH concentration 
was determined (per lx l 0 6cells).
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2.2.7 Intracellular calcium signalling
Intracellular Ca2+ signalling was measured in J16, HJ16 and UVAR-J16 before and 
after treatment with BSO, diamide, DEM and NAC (see section 2.2.6). Cells were 
washed once with PBS, resuspended in RPMI at lxlO7 cells/ml and loaded with 
l|Ltl/ml (from stock of 2.5mM in DMSO) fura2-acetoxymethylester (fura-2-AM) to 
give a final intracellular concentration of 1-1 OjllM fura2. Cells were then incubated in 
the dark for 45 minutes at 37°C to allow dye entry. After that, cells were washed three 
times and resuspended at 2 x l0 6cells/ml in HBSS containing 1% BSA and lOOpM 
calcium chloride.
Two millilitres of resuspended cells were then placed into a glass cuvette and loaded 
into a PTI spectrofluorimeter. A small magnetic stirrer placed in the bottom of the 
cuvette prevented cell sedimentation. Software provided with the system was used to 
configure the system and to set up the dual-excitation experimental method required 
for fura2 loaded-cells (fura2 excitation wavelength was driven between 340nm, 
absorption maximum of the Ca -fura complex and 380 nm, isobetic wavelength) and 
emission wavelength of 510nm.
A calibration value was generated by addition of 20jll1 4mM digitonin (in DMSO) to 
obtain Rmax (the ratio of fluorescence intensities of the dye in the Ca bound and Ca
free states at saturating amounts of Ca2+), followed by 20pl 0.5mM EGTA (Ca2+
2 +chelator) for Rmm (the ratio of fluorescence intensities of the dye in the Ca bound
and Ca2+ free states at limiting concentration of Ca2+). Absolute intracellular Ca2+
2+
concentrations were calculated by using the following equation: [Ca ]i = Kd (R- 
Rmin)/ ( R ma x - R )S f 2 /S b 2 , where Kd is the effective dissociation constant of fura- 2
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(240nM), Sf2/Sb2 is the ratio of the 510nm fluorescence intensity of fura-2-loaded
2_j_
cells at minimum and maximum saturating Ca respectively.
An initial intracellular calcium value was recorded for 50 seconds to confirm stable 
baseline, after which either PHA-L (20|Hg/ml), anti-CD3 (5|lg/ml), anti-CD28 
(5jig/ml), H202 (50pM), or a low concentration of ionomycin (500nM) was added to
o I
fura2-loaded cells to induce a Ca response. The trace was recorded for 400 seconds. 
Results were analysed using software provided with the system, which utilises the 
equation mentioned above.
2.2.8 Proliferation assay, XTT
XTT is a colorimetric assay o f cell viability, activation and proliferation, based on the 
use of tetrazolium salt. Some studies evaluated the use of XTT in human tumour cells 
and demonstrated the ability of electron coupling agents to potentiate bioreduction of 
XTT, which yields a highly coloured, water-soluble formazan product (Roehm et al, 
1991).
In this section, XTT was used with Jurkat cells to assess the differences in 
proliferation among three cell lines, normal Jurkat cells, hydrogen peroxide tolerant 
Jurkat cells (HJ16) and UV-A resistant Jurkat cells (UVAR-J16) and also to examine 
the effect o f various stimulants such as anti-CD3, anti-CD28, PHA, ionomycin, 
PDBu, and both ionomycin/PDBu. In addition, the effect of BSO, DEM, diamide (low 
GSH level) and NAC (high GSH level) on the proliferation of these cells was 
investigated (see section 2 .2 .6 ).
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Cells were washed in PBS, resuspended in fresh RPMI 1640 at 0.1 x 105 cells/ml, and 
activated with anti-CD3, anti-CD28 (lOjig/ml), PHA (10pg/ml), ionomycin (lpM ), 
PDBu, (0.5ng/ml) and both ionomycin/PDBu. Cells were plated into flat bottom 96 
well plates (lOOpl/well). The plates were incubated for 48 hours, fresh XTT-PMS 
solution (see appendix 1), was added, and after 4 hours incubation, the colour 
development was read on a spectrophotometer at 450nm.
2.2.9 Western Blotting
Cells were pre-treated with BSO and NAC for 24 hours, as described in section 2.2.6, 
to analyse any effect of GSH levels on activation of MAP kinases (p38). Cells were 
then washed in PBS, resuspended in serum-free RPMI 1640, and incubated for 2 
hours at 37°C, 5% CO2 . Cells were then activated with PDBu for 15 minutes, 30 
minutes, 1, 2.5, 5, 10 and 24 hour/s. Cells were centrifuged and washed twice in 
serum-free medium, 250jil of lysis buffer (Appendix 1) was added, the tubes were 
vortexed and kept on ice for 15 minutes. After that, tubes were centrifuged at 1000 
rpm for 10 minutes at 4°C, and supernatants were harvested into new Eppendorff 
tubes. An aliquot (5 j l l I )  was reserved for protein assay (see section 2.2.10) equal 
volume of sample buffer (appendix 1) was added to lysed cells (harvested 
supernatant) and boiled for 5 minutes.
Equal concentrations of protein of each sample were loaded onto 10% SDS- 
polyacrylamide gels, proteins bands were electrophoretically transferred onto 
nitrocellulose and the membrane was washed once in TBS-T (appendix 1) and 
blocked overnight with 1% BSA in TBS buffer, containing 10% sodium azide at 4°C, 
after that the membrane was washed three times in TBS buffer and then blotted with a
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specific antibody to phosphorylated threonine and tyrosine of p38 MAP kinase for 2 
hours at room temperature. After three washes with TBS, rabbit anti-horseradish 
peroxidase antibody was added and incubated for 1 hour at room temperature. The 
membrane was then washed five times in TBS, and incubated in ECL reagent for 1 
minute. The bands were visualised onto Kodak film.
2.2.10 Protein assay, the Bradford assay
A range of standard concentrations of BSA (0.1, 0.2, 0.5, 1.0, 2.0 mg/ml) was 
prepared in lysis buffer (appendix 1). Samples were diluted 1:5 in lysis buffer, 5)ll1 of 
diluted samples and standard were then pipetted into 5 0 0 |li1 of diluted (1:5, in Milli- 
Ro water) Bradford reagent in Eppendorff tubes, 100 Jill o f the mixture was then 
pipetted, in duplicate, into a flat-bottomed 96 well plate, and left for 5 minutes at 
room temperature. Finally the plate was read on a spectrophotometer (MR5000, 
Dynatech) at 760nm. Software provided with the system was used to calculate protein 
concentration.
2.2.11 Statistical analysis
Results are expressed as means +/- standard error of the mean. Statistical significance 
was analysed using analysis of variance (ANOVA) and student t-test. A p-value less 




CHARACTERISATION OF A HYDROGEN PEROXIDE 
TOLERANT T CELL LINE IN CO-CULTURE WITH
MONOCYTES
Chapter 3 Results
3.1 Characterisation of hydrogen peroxide tolerant T cell line in co­
culture with monocytes
A T cell line tolerant to hydrogen peroxide (HJ16) was generated by treating Jurkat cells 
(J16) with increasing concentrations of H2O2 . The HJ16 cell line was cloned by using 
limiting dilution. The main aim o f the experiments reported in this chapter was to 
characterize some of these clones and assess any differences among them in the co­
culture system.
In co-culture, J16, HJ16 cells and clones of HJ16 were incubated with differentiated 
THP-1 cells or peripheral blood mononuclear cells (PBMCs) in the presence or absence 
of lipopolysaccharide (LPS). Pro-inflammatory (IL-1(3) and anti-inflammatory (IL-lra) 
cytokines released by differentiated THP-1 cells or PBMCs co-cultured with J16, HJ16 
cells and HJ16 clones were measured.
It has been noted that Thl cells induce IL-lp, whereas Th2 induce IL-lra production 
(Chizzolini et al, 1997). Therefore, it was decided to classify J16/HJ16/HJ16 clones into 
Thl or Th2 phenotype. This was performed by identifying chemokine receptor mRNA 
associated with the Thl or Th2 phenotype.
3.1.1 FACS analysis of H2O2 tolerance
In order to assess the tolerance of HJ16 cells or the clones to H2O2, cells were challenged 
with various concentrations of H2O2 for 4 hours at 37°C. The cells were then cultured 
overnight and analysed by flow cytometry (FL-2), using % PI uptake as an indicator of
74
cell death. As shown in figure 3.1, HJ16 cells and the clones exhibited higher H2O2 
tolerance compared to J16. The ID50 o f J16 cells were approximately lOOpM, whereas, 
this value was ImM for HJ16 cells and some HJ16 clones (AB10 and BB3) and even 
higher (l-3m M ) for some other HJ16 clones, such as BD3, BA6 , AF8 , AGIO, AF4, AH8 , 
BG10 and AD 8 . AD11 and AB2 showed less resistance to H2O2 (ID50 o f 100-300pM), 
and so were discarded.
— J16 — HJ16 A A B 1 0 - * - B D 3  AF8 — AGI O — |— BB3 
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Figure (3.1): J16, H J16 and H J16 clones cell death following H 2O 2 challenge.
Death o f J16, HJ16 and HJ16 clones (AB10, BD3, AF8 , AGIO, BB3, BA6 , AD8 , BG10, 
AH8 , AF4, AD11, AB2), incubated with various concentrations of hydrogen peroxide 
(10pM-30mM) for 4 hours then washed and cultured overnight. Cell death was measured 
as increase in FL-2 fluorescence due to uptake o f propidium iodide (PI) by necrotic cells, 
determined by flow cytometry.
75
3.1.2 Differentiation o f THP-1 cells with 1,25-dihydroxyvitamin D3
In order to obtain inducible IL -ip  from the pro-monocytic cell line THP-1, these cells 
require differentiation to a mature form. This can be achieved by incubation of cells with 
1,25-dihydroxyvitamin D3 (1,25 (OH )2  D3) for 48 hours before use. Differentiation was 
determined by expression o f CD 14, a monocyte surface marker. This assay has been used 
routinely in all experiments to indicate differentiation o f THP-1 cells prior to co-culture.
THP-1 cells were washed once in PBS, re-suspended at concentration of 0.5 x 106
o
cells/ml in RPMI, 1,25 (OH )2  D 3 was added at final concentration of 10' M and incubated 
for 48 hours. The cells were then washed three times in PBS and re-suspended in RPMI. 
Cells were then analysed for CD 14 surface expression using flow cytometry. The results 
below (Figure 3.2) are representative of routine testing. Differentiation o f cells was 
exhibited as a shift in the fluorescence towards the right (figure 3.2b).
' :- Y T - i i y M |  V i  1 1 1  ■  1
i c r  i o '  10  1 0 °  11 1 0 -  1 0 '  10
FL1 -H  FL14H
Figure (3.2): D eterm ination of THP-1 differentiation by using anti-CD14 antibody.
Determination o f THP-1 cells differentiation due to l,25(OH)2D3 is measured as the level 
of FL-1 fluorescence due to binding o f FITC conjugated secondary antibody, which binds 
to CD 14 (specific primary antibody), detected by flow cytometry. Histograms of FL-1 
fluorescence, (A) -l,25(O H )2 D3 , (B) +l,25(O H)2 D3 are plotted. Background (filled 
histogram) = (-) anti-CD 14 antibody, and opened histogram= (+) anti-CD 14 antibody.
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3.1.3 Activation of J16, HJ16, and HJ16 clones and surface marker
expression
& In the co-culture system, resting J16 and H I6 cells have been shown to. provide a limited 
stimulation to THP-1 cells or PBMCs, resulting in a small increase in IL-1(3 and IL-lra 
production. In order to investigate possible methods of cell activation and the effect of 
this activation on induction of IL-lp and IL-lra production, J16, HJ16 cells and HJ16 
clones (AB10, AD8, BA6, BD3, AGIO, BB3 and AF4) were activated with 
PBDu/ionomycin or PHA-L. This activation was measured by determining CD69 
expression, one of the earliest markers of T cell activation, reaching a peak within 24 
hour and declining slowly over the course of several days.
Under resting conditions, the HJ16 cells exhibited low but detectable expression of CD69, 
indicating that these cells are slightly activated at resting conditions, perhaps due to 
chronic exposure to H2O2 . Ionomycin alone had a limited effect on CD69 expression on 
both J16 and HJ16 cells. PDBu and PHA-L (10-20jLig/ml) produced high activation, as 
manifested by CD69 expression on both cell types, as displayed in Figure 3.3a/b.
Moreover, there was a difference in the responsiveness of J16 and HJ16 cells to PHA-L: 
HJ16 cells were more responsive to PHA-L (0.1-10 pg/ml). Stimulation with 0.5-10 
pg/ml PHA-L resulted in a significant increase in both CD69 and CD2 expression 
compared to J16 cells. HJ16 cells responded at low concentration o f PHA (0.1 pg/ml), 
whereas J16 cells required concentrations above 1 pg/ml, as shown in figure 3.5. Both 
unactivated J16 and HJ16 cells express low level of CD2, but slightly higher with HJ16 
cells, addition of PHA-L increased this expression, as shown in Figure 3.5b.
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Activation with ionomycin and PDBu together has been used to characterise HJ16 clones 
in co-culture, and so CD69 expression was monitored in these cells as shown below 
(Figure 3.4). Like HJ16 cells, unstimulated HJ16 clones also exhibited low expression of 
CD69, indicating that these cells are slightly activated under resting conditions. No 




(A) Resting J16 (no CD69 expression) (B) Activated J16 with ionomycin
(low CD69 expression)
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(high expression of CD69)
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Fig (3.3a): Flow cytometry results (FL-1) of CD69 expression on J16 cells:
Investigation into the effect of various stimulants on T-cell activation, J16 cells were 
activated with ionomycin, PDBu, both PDBu/ ionomycin and PHA-L (10-20 |Ug/ml). 
Resting J16 showed no activation (A). Very low activation was achieved with ionomycin 
alone (B), PDBu (C), ionomycin/PDBu (D) and PHA-L (E) activation resulted in high 
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Fig (3.3b): Flow cytometry results (FL-1) of CD69 expression on HJ16 cells:
Investigation into the effect of various stimulants on T-cell activation, HJ16 cells were 
activated with ionomycin, PDBu, both PDBu/ionomycin and PHA-L. Resting HJ16 cells 
were slightly activated (A). Very low activation was achieved with ionomycin alone (B). 
PDBu (C), ionomycin/PDBu (D) and PHA-L (E) activation produced high expression of 
CD69 (a shift in FL-1 fluorescence to the right, open histogram).
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(F) Activated AB10 (high Expression of CD69)
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(I) Resting BA6 (low Expression of CD69) (J) Activated BA6 (high Expression of CD69)
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(K) Resting BD3 (low Expression of CD69) (L) Activated BD3 (high Expression of CD69)
Figure (3.4): Flow cytometry results (FL-1) of CD69 expression on J16, HJ16 and 
clones of HJ16 (AB10, AD8, BA6 and BD3). HJ16 cells and clones showed slight 
activation at resting phase compared to J16 cells, which showed no activation (no 
expression of CD69). All activated cells (with PBDu /ionomycin or PHA) showed 







a) Effect of PHA-L on CD69 expression on J16 and HJ16 cells
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Figure 3.5 Effect of various concentration of PHA-L on the expression of (a) CD69
and (b) CD2 on J16 and HJ16 cells. A slightly higher expression of CD69 and CD2 was 
seen with resting HJ16 cells compared to resting J16 cells. Stimulation with PHA-L (0.1- 
10 pg/ml) resulted in a significant up-regulation of both CD69 and CD2.The data is the 
mean of five experiments, +/- standard error of the mean (SEM).
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3.1.4 Expression of chemokine receptor mRNA
In this section, the expression o f chemokine receptor mRNA associated with Thl/Th2 
cells was determined in order to identify the phenotype of J16, HJ16 and the clones and 
also to examine whether the chronic exposure to H2O2 (oxidative stress) altered the Jurkat 
cells phenotype or had an effect on the expression of chemokine receptor at the mRNA 
level.
Chemokine receptor mRNA detection was performed for CCR3, CCR4 (Th2 chemokine 
receptors), CCR5 and CXCR3 (Thl chemokine receptors) and CCR2 (common receptor 
for Thl and Th2) by using RT-PCR. A positive result o f mRNA was indicated as a clear 
band, and (3-actin was used as positive control (Figure 3.6). CCR2, CCR3 and CCR5 
mRNA appear as clear bands for all types of cells tested. However, CCR4 mRNA bands 
are slightly unclear for some cells such as HJ16 cells, although a clearer band for HJ16 
CCR4 mRNA was obtained in some experiments. This may be due to technical problems, 
since the PCR technique is very sensitive and not quantitative. None of the cells 
expressed CXCR3 mRNA (Thl marker), since no bands of CXCR3 mRNA were 
observed. The experiment was repeated five times for all chemokine receptors and very 
similar results were obtained each time.
No difference was observed between J16 and HJ16 cells or the clones in the expression of 
these chemokine receptor mRNA. CCR5 may not be a specific marker of Thl cells, since 
it has been reported also as a Th2 chemokine receptor (reviewed by Sallusto; 1998). The 
pattern o f chemokine mRNA species isolated implies that the J16 cells are perhaps more 
Th2-like than Thl-like, although different experiments would be needed to justify this 
conclusion.
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Figure (3.6): RT-PCR results for some chemokine receptors of Thl and Th2. Results 
shown are a representative example of five similar results for each chemokine receptor.
L=DNA ladder, 1=PBMC (Positive control), 2=J 16, 3=HJ16, 4=AB10, 5=AF4, 6=AG10, 
7=AD8, 8=AH8, 9=AD11, 10=BA6, 11=BB3, 12=BD3, 13=AB2, 14=Negative control.
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3.1.5 Cytokine production (IL-lp/IL-lra) in co-culture
In order to investigate T cell / monocyte interactions, T cells such as J16, HJ16 cells and 
clones o f HJ16 cells (AB10, AD8, BA6, BD3, AGIO, AF4 and BB3) were cultured with 
PBMC or THP-1 cells. This co-culture technique reveals several interesting points on the 
effect o f T cells on monocytes, as illustrated below.
3.1.5.1 IL-ip and IL-lra production by PBMCs
J16, HJ16 cells and HJ16 clones (activated /un-activated, fixed or unfixed) were co­
cultured with fresh PBMCs, (with/without LPS) for 48 hours at 37°C and 5% CO2 .
Low levels of IL -lp  and IL-lra were produced by control PBMCs in the absence of LPS; 
however, this amount was increased significantly (p<0.01) after addition of LPS. Un­
activated cells (J16, HJ16 and HJ16 clones) had no significant effect on the production of 
either IL-1(3 (Figure3.7a) or IL-lra (Figure 3.7c) by PBMCs in the presence or absence of 
LPS.
Activation of T cell lines (J16, HJ16, and HJ16 clones) by PDBu/ionomycin resulted in a 
significant stimulation o f both IL-lp (Figure 3.7a) and IL-lra (Figure3.7c) production by 
PBMCs compared to un-activated T cell lines (p<0.01). Activated unfixed HJ16 cells and 
HJ16 clones (AB10, AD8, BA6, AGIO, AF4, BD3, and BB3) significantly induced 
higher levels of IL -lp compared to J16 cells in the presence o f LPS (p<0.05). Unfixed 
activated HJ16, and HJ16 clones induced slightly more IL-lra production by PBMCs than 
J16 cells.
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A significant decrease in IL-lra production by PBMCs was obtained with all fixed 
activated T cell lines. A slight stimulation o f IL -lp  and IL-lra production by PBMCs was 
generated by fixed T cell lines (Figure 3.7b, d), indicating that soluble factors may be 
mediating the production of both cytokines by PBMCs.
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with unfixed T cell line
Figure (3.7a) ELISA results of IL -ip , unfixed J16, HJ16 and HJ16 clones were cultured with fresh PBMCs. Both H Jvl6 cells and the
clones of HJ16 cells stimulated more IL -ip  compared to J16 cells. Data shown are the mean of seven experiments (+/-SEM). Each experiment
was done in duplicate, (*= Activated cells with PDBu and ionomycin, * indicates p value<0.05).
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b) Effect of fixed J16, HJ16 and HJ16 clones on the production of the IL-lp  by PBMCs
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Figure (3.7b) ELISA results of IL -ip , fixed J16, HJ16 and HJ16 clones were cultured with fresh PBMCs. Fixed T cell lines failed to
stimulate IL -lp production by PBMCs. Data shown are the mean of seven experiments (+/-SEM), (*= Activated cells with PDBu and
ionomycin).
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c) Effect of unfixed J16, HJ16 and HJ16 clones on the production of IL - lra  by PBMCs
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□  PBMC CTL
Figure (3.7c) ELISA results of IL-lra, unfixed J16, HJ16 and HJ16 clones were cultured with fresh PBMCs. No significant differences in
the stimulation o f IL-lra by J16, HJ16 cells and HJ16 clones. Data shown are the mean of seven experiments (+/-SEM), (*= Activated cells with
PDBu and ionomycin).
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□  PBMC CTL
with fixed T cell line
Figure (3.7d) ELISA results of IL -lra , fixed J16, HJ16 and HJ16 clones w ere cultured with fresh PBMCs. Fixed J16, HJ16 cells and the 
clones of HJ16 cells failed to stimulate IL-lra production by PBMCs. Data shown are the mean of seven experiments (+/- SEM), (*= Activated 
cells with PDBu and ionomycin).
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3.1.5.2 Control experiments: Comparison between fresh PBMCs and 
purified monocytes in production of IL-lp and IL-lra
PBMCs were depleted of T cells (about 80-85 % of T cells were removed), and enriched 
with monocytes (express CD 14). This was done to reduce any influence of donor T cells 
in the co-culture assay. Experiments showed a similar pattern of cytokine production by 
both PBMCs and enriched monocytes (depleted PBMCs of T cells and B cells). T and B 
cells were removed by negative selection employing anti CD3 (T cells marker) and anti- 
CD20 (B cell marker). This technique was partially successful, since % monocytes (CD 14 
expression) was increased from 9% (Figure 3.8, A2) in total PBMC to 68% (B2) in 
enriched monocytes. PBMCs showed 51% of CD3 positive cells expression (Al), 
whereas this % was decreased tol0%  (B l) after the treatment (Figure 3.8).
ELISA results of IL -lp and IL-lra produced by both PBMCs and enriched monocytes are 
shown in Figure 3.9a,b. Similar patterns were obtained in both cultures, indicating that 
any influence of donor T cells in the stimulation of monocytes to produce cytokines is 
minimal. However, the amount of cytokines released by purified monocytes was slightly 
less than by PBMCs, which may be due to subjection of the cells to several purification 
steps. J16 and HJ16 did stimulate the production o f both cytokines, and HJ16 cells were a 
better stimulant, in both experiments.
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Figure (3.8) PBMCs were depleted of T cells and B cells (purified monocytes) and 
the expression of CD3 (T cell marker) and CD14 (monocyte cell marker) were 
analysed.
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with unfixed T cell line with fixed T cell line
Figure (3.9a) ELISA results of PBM Cs and monocytes, illustrates a similar pattern o f IL-1 p produced by PBMC and purified monocytes. 
(The result represents the mean of three experiments (+/- SEM), (*= Activated cells with PDBu and Ionomycin).
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Control Experim ent: Effect of J16/HJ16 on IL -lra  production by PBMC and purified monocytes
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with unfixed T  cell line with fixed T  cell line with unfixed T  cell line with fixed T  cell line
Figure (3.9b) ELISA  results of PBM C and monocytes, illustrates a similar pattern o f IL-lra produced by PBMC and purified monocytes. The 
result is the mean of three experiments (+/- SEM), (*= Activated cells with PDBu and ionomycin).
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3.1.5.3 IL-ip and IL-lra production by THP-1 cells
J16, HJ16, HJ16 clones (activated/unactivated) (fixed or unfixed) were co-cultured with 
differentiated THP-1 cells (with/without LPS) for 48 hours at 37°C and 5% CO2 .
Like PBMCs, LPS induced the production of both IL -lp and IL-lra production in control 
THP-1 cells. In the absence of LPS insignificant amount of both IL -ip and IL-lra was 
detected. As expected, the amounts of IL-1 p and IL-lra release by THP-1 cells were 
much less than the amount released by fresh PBMCs.
In the presence of LPS, unfixed activated T cell line induced much higher level o f IL-1 P 
(Figure 3.10a) compared to fixed (Figure 3.10b) or un-activated cells. Like the pattern 
observed in PBMCs culture, activated, unfixed HJ16 and HJ16 clones were a better 
stimulant to IL -lp production by THP-1 cells compared to J16 cells (p<0.05). No 
significant differences among the clones were observed in the stimulation of IL-1 P and 
IL-lra production by PBMCs or THP-1 cells.
A reverse pattern for IL-lra was obtained, in the presence of LPS, fixed and activated T 
cell line (Figure 3.10 d) induced more IL-lra compare to unfixed cells. Unfixed T cell 
line provided limited stimulation to IL-lra production by THP-1 cells. Fixed, activated 
HJ16 cells and HJ16 clones induced slightly higher levels of IL-lra than fixed and 
activated J16 cells.
In the presence of LPS, the levels of IL-lra was significantly higher than IL-lp, in a ratio 
o f approximately 15:1
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with unfixed T cell line
Figure 3.10a: ELISA  results of IL -lp  from  various co-cultures of unfixed J16, HJ16 and H J16 clones co-cultured with differentiated 
THP-1 cells. Both HJ16 and the clones o f HJ16 cells stimulated more IL-1 (3 production by THP-1 cells in the presence of LPS compared to J16 
cells. The data shown is the mean o f seven experiments (+/-SEM), (*= Activated cells with PDBu and Ionomycin, • indicates p value <0.05).
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□  THP-1 CTL
Figure 3.10b: ELISA  results of IL -lp  from various co-cultures of fixed J16, HJ16 and H J16 clones co-cultured with differentiated 
THP-1 cells. No significant stimulation o f IL -lp  production by THP-1 cells obtained with fixed T cell line. Data shown are the mean of 
seven experiments (+/-SEM), (*= Activated cells with PDBu and Ionomycin).
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□  THP-1 CTL
Figure 3.10c: ELISA result of IL - lra  from  various co-cultures of unfixed J16, H J16 cells and H J16 clones co- cultured with 
differentiated THP-1 cells. A slight stim ulation of IL -lra  production by THP-1 cells was seen with unfixed T cells, activated HJ16 
stim ulated higher levels of IL - lra  com pared to J16 cells. Data shown are the mean of seven experiments (+/- SEM), (*= Activated cells with 
PDBu and ionomycin).
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□  THP-1 CTL
Figure 3.10d: ELISA  result of IL - lra  from  various co-cultures of fixed J16, HJ16 and HJ16 clones co- cultured with differentiated 
THP-1 cells. Activated fixed T cells stimulated significantly higher level of IL-lra compared to unfixed cells. Fixed HJ16 cells and the clones 
were more active than J16 cells in stimulation o f IL-lra production. Data shown are the mean of seven experiments (+/-SEM), (*= Activated 
cells with PDBu and ionomycin).
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3.2 Effect of various stimulants on J16 and HJ16 cells and the
production of IL-1(3 by THP-1 cells
Several T cells activation pathways were investigated in this section. J16 and HJ16 cells 
were washed once in PBS, resuspended in RPMI at lx  106 cells/ml and activated with 
ionomycin, PDBu, ionomycin/PDBu, anti-CD3, anti-CD28, and both anti-CD3/CD28 for 
24hours. Cells were then washed three times in PBS and resuspended in RPMI at 5xl06 
cells/ml and co-cultured with differentiated THP-1 cells in the presence of LPS. Results 
are presented in Figure 3.1 la,b.
Ionomycin, PDBu alone and lpg/ml CD3 showed a limited effect on the stimulation of 
THP-1 cells to produce IL-1 (3 or IL-lra compared to the combination of ionomycin and 
PDBu, anti-CD3 (10|ig/ml), combination of CD3/CD28 (10|ig/ml), and PHA-L (10 
(Xg/ml), which all significantly enhanced the production of IL-1 (3 and insignificantly IL- 
lra production by THP-1 cells. HJ16 cells at all conditions (except ionomycin, PDBu 
alone and lpg/ml CD3) provided better stimulation for the production of both IL- 
1(3 (p<0.05) and IL-lra (but not at significant levels) than J16 cells.
Activation of T cell line (J16 and HJ6 cells) with combination of CD3 and CD28 
antibodies or ionomycin and PDBu resulted in significantly higher levels of IL-1 (3 
production by THP-1 cells than activation of T cell line with PHA-L, CD3, and CD28 
antibody (p< 0.05).
1 0 1




Figure 3.11a: Effect of various stimulants on J16 and HJ16 and the production of IL-1 {3, activated (*) HJ16 cells with ionomycin/PDBu, 
anti-CD3, anti-CD28, combination of anti-CD3 and CD28 (lOpg/ml), or PHA-L significantly stimulated IL-1 (3 production by THP-1 cells 
compared to activated J16 cells (p<0.05, indicated as • ). Ionomycin, PDBu alone or lpg/ml anti-CD3 had no or limited effect on both J16 or 
HJ16 cells. Results represented as the mean value of four experiments.
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Figure 3.1 lb : Effect of various stimuli on J16 and HJ16 cells, and the production of IL -lra  by THP-1 cells, unfixed and activated (*) HJ16 
cells with various stimuli slightly stimulated IL-lp production by THP-1 cells compared to activated J16 cells or the control cells. Results 
represented as the mean value of four experiments.
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3.3 Effect of supernatants of J16 and HJ16 cells on the production of
IL-ip by THP-1 cells
In order to investigate the involvement of any soluble factor (s) produced by J16 and 
HJ16 cells during the stimulation of IL-1 (3 production by THP-1 cells, supernatants 
from activated J16 or HJ16 cells were incubated with THP-1 cells. Cells were 
activated with ionomycin/PDBu, anti-CD3 or PHA-L overnight, cells incubated with 
ionomycin/PDBu were washed three times and incubated further 24hours, cells 
activated with anti-CD3 or PHA-L were centrifuged and the supernatants were 
harvested. Supernatants of activated J16 and HJ16 cells were incubated with THP-1 
cells in the presence of LPS.
As shown in Figure 3.12, activated J16 and HJ16 supernatant enhanced the production 
o f IL -lp  by THP-1 cells. Activated HJ16 supernatant (HJ16*S) was more active, in 
term of stimulation of IL -lp production than activated J16 supernatant (J16*S). This 
was manifested by a moderate increase of IL -lp  production by THP-1 cells, but 
statistically not significant (P=0.0625).
J16*S, HJ16*S from 1 jig/ml anti-CD3 activation, had no or limited effect on IL- 
lp  production, and no stimulation of IL -lp  was observed with un-activated J16/HJ16 
supernatant. Anti-CD3 or PHA-L also had no effect on THP-1 control cells, Figure 
3.12a.
Supernatant results indicated a similar pattern to cells in previous experiments, 
suggesting that soluble factors are involved in co-culture. However, from this result, it 
seems that the soluble factors are not only factors that mediate IL-1 P production,
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hence that, the levels of IL-1 (3 produced by THP-1 cells under the stimulation of the 
supernatants of J16 or HJ16 cells are much less than that produced by THP-1 cells co­
cultured with J16 or HJ16 cells.
Supernatants of un-activated or activated J16 or HJ16 cells failed to provide 
stimulation for IL-lra production by THP-1 cells. There was no significant difference 
between the control of THP-1 cells and that with supernatants, as shown in Figure 
3.12b. This indicates that cell-cell contact is essential mechanism that mediates the 
production of IL-1 ra by THP-1 cells.
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Effect of supernatant of activated J16 and HJ16 cells on the















bno/PDBu anti-CD3 Anti-CD3 PHA J16SCTL HJ16S THP-1 THP- THP-
(1ug/ml) (1 0ug/n i) CTL CTL 1+ANTP I 
CD3
1CTL+PHA
Effect of supernatants of activated J16 and HJ16 cells on the 
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Figure 3.12a: Effect of supernatant of J16/HJ16 cells activated with ionomycin 
(l|LlM/ml)/PDBu (0.5ng/ml), anti-CD3 (lpg/ml & lOpg/ml) on the production of
(a) IL-1 (3 and (b) on IL -lra  by THP-1 cells. Supernatants of both activated J 16 and 
HJ16 cells stimulated IL-lp production by THP-1 cells, but not at significant level 
(p=0.0625), and failed to stimulate IL-lra production. Values are the mean of three 
experiments (+/-SEM), (*=activated cells).
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3.4 Study of sensitivity of J16 and HJ16 cells to PHA-L in co-culture
J16 and HJ16 cells were activated with various concentrations o f PHA-L (0.1- 
l O j L i g / m l )  for 10 hours, and co-cultured with THP-1 cells for 48 hours in the presence 
of LPS. Supernatants of the co-cultured were harvested and IL-1 P and IL-lra levels 
were measured by ELISA.
Activation of J16 and HJ16 cells with various concentrations of PHA-L augmented 
the release of IL -lp and IL-lra by THP-1 cells in a dose-dependent manner. 
Insignificant stimulation of IL -lp  (Figure 3.13a) production by THP-1 cells was seen 
with HJ16 cells activated with 0.1 |Lig/ml, and no stimulation was observed with J16 
cells activated with the same concentration or with 0.2jig/ml. However, a significant 
level (p<0.05) o f IL-1 P was obtained when HJ16 cells stimulated with 0.2 -10  |ig/ml 
PHA-L compared to J16 cells. J16 cells responded to concentration o f 0.5-10 |Xg/ml 
PHA-L (or above), but their stimulation to IL -ip production by THP-1 cells was 
significantly less than the stimulation observed with HJ16 cells at all concentration of 
PHA-L.
HJ16 cells activated with 0.1-10 |Lig/ml also induced higher levels o f IL-lra by THP-1 
cells than activated J16 cells, but this is not statistically significant (Figure 3.13b).
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a) Effect of various concentrations of PHA-L on the J16 and
HJ16 cells and their stimulation of IL-lp production by THP-1
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Figure 3.13: Effect of various concentrations of PHA-L on the production of (a) 
IL -ip  and (b) IL -lra  by THP-1 cells. HJ16 cells were more sensitive to low 
concentrations of PHA-L, manifested in better stimulation of IL-1 P (p<0.05) and IL- 
lra (not statistically significant) production by THP-1 cells. The data presented is the 
mean of three experiments +/-SEM.
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3.5 Comparison between J16 and UV-A resistant-J16 (UVAR-J16), in 
co-culture with THP-1 cells
It has been documented that UV-A irradiation decreased the ability of epidermal cells
a
to present antigen to T cells directly. This effect was accompanied by suppression of 
the expression of accessory molecules (ICAM-1, B7.1, B7.2). Also, it has been noted 
that, UVA decreased the proliferation o f lymph node cells, (Iwai et al; 1999).
In these experiments, UV-A resistant Jurkat cells (UV-A-R-J16) were used in 
comparison with the normal Jurkat cell line, to assess the effect o f UV-A on these 
cells and their stimulation to IL -lp  and IL-lra by THP-1 cells.
Cells were activated with ionomycin/PDBu overnight, washed and co-cultured with 
THP-1 cells. In contrast to HJ16 cells, no significant difference was seen between J16 
and UV-A-R J16 cells in stimulation o f IL -lp and IL-lra production
All fixed cells were better stimulants of IL-lra production than unfixed cells. 
However no significant difference between fixed J16 and fixed UVAR-J16 was seen 
in the stimulation o f IL-lra production by THP-1 cells (Figure 3.14).
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a) Effect of J16 and UVA-RJ16 cells on the production of IL-ip by
THP-1 cells.
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Figure 3.14: Comparison between the effect J16 and UVAR-J16 cells on the 
production of (a) IL-lp and (b) IL-lra by THP-1 cells. No significant difference 
between UVAR-J16 and J16 in stimulation o f both IL-1 p /IL-lra, (*=Activated cells 
with ionomycin/PDBu). The data is the mean o f three experiments, +/- SEM.
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3.6 Effect of Hypoxia (1% and 2 %  oxygen) on the production of IL- 
lp  and IL-lra by PBMCs
Hypoxia is a common modification of the extracellular environment that can affect 
cellular function. Hypoxia induces the expression of certain cytokines such as IL-1 (3 
and IL-lra (Naldini, et al; 2001). The effect of hypoxia (1% and 2% O2) on the 
production of IL-1 P and IL-lra by PBMCs and their stimulation was investigated. In 
order to asses the effect o f hypoxia on T cells and their stimulation to IL -lp and IL- 
lra production by PBMCs, J16 and HJ16 cells were incubated with PBMCs in low 
oxygen, 1% or 2% 02, 5% CO2 , and normal oxygen, (20 % O2, 5% CO2). The 
production of cytokines was measured in the harvested supernatants, and the results 
were expressed as the mean value of three experiments.
A significant reduction in IL -lp  and IL-lra production was observed in cells 
incubated under 1% O2 (hypoxia) compare to 20% O2 (normoxia) (p<0.01). However, 
J16 and HJ16 cells provided PBMCs with slight stimulation with respect to controls, 
but no significant difference between J16 or HJ16 cells stimulation at 1% 02 , Figure 
3.15a,b. In contrast, 2% O2 significantly (p<0.01) enhanced IL-lp and IL-lra 
production by PBMCs in the presence of LPS, and due to substantial increase in IL-1 P 
and IL-lra in control cells (PBMCs), it was difficult to determine whether J16 or 
HJ16 cells provided stimulation to PBMCs to produce IL-lp and IL-lra, Figure 
3.15a,b. A slight increase in both IL-lp and IL-lra production by PBMCs in the 
absence o f LPS was generated by hypoxia (2% 02).
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Figure 3.15a: Effect of 1 & 2 % O 2 in the production of IL-1 P by PBMCs. A significant increase in IL-1 [3 production was observed with 2% 
O2 . The results expressed as the mean value of three experiments (+/-SEM).
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Figure 3.15b: Effect of 1 & 2 % O 2 in the production of IL -lra  by PBMCs. A significant increase in IL-lra production was observed with 
2% O2 . The results expressed as the mean value of three experiments (+/-SEM).
CHAPTER 4
RESULTS
MANIPULATION OF THE INTRACELLULAR 
ANTIOXIDANT, GLUTATHIONE, IN J16 AND HJ16
CELLS
Chapter 4 Results
4.1 Manipulation of the intracellular antioxidant, glutathione (GSH), 
in J16 and HJ16 cells
Glutathione (GSH) is the main intracellular defence against oxidative stress, and 
regulates the redox potential. Modulation of intracellular GSH levels has previously 
been shown to influence a variety of cell functions. For example, L-buthionine (DL)- 
sulfoximine (BSO) treatment to decrease GSH levels augmented TNF-ocand IL-6 
production by epithelial cells (Haddad et al; 2001 & 2002). Moreover, 
hyporesponsiveness of synovial T cells in rheumatoid arthritis was associated with 
decreased intracellular levels of GSH and increased levels of thioredoxin (another 
major cellular antioxidant) (Maurice et al, 1998).
Here we are investigating the effect of decreasing or increasing of GSH levels in J16 
and HJ16 cells and their ability to stimulate IL -lp  and IL-lra production by THP-1 
cells.
BSO, diethyl maleate (DEM) and diamide were used to decrease GSH, and NAC to 
increase GSH in J16 and HJ16 cells. Experiments using trypan blue exclusion tests 
were always performed in order to exclude any toxicity of these drugs.
4.1.1 Measurement of glutathione (GSH) on J16 and HJ16 cells
In order to manipulate intracellular GSH levels, J16 and HJ16 cells were incubated 
with BSO to deplete GSH, and NAC to increase GSH. Cells were washed once in 
PBS, resuspended in RPMI at 0.5 x 106cells/ml, various concentrations of BSO or
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NAC were added, cells were incubated overnight, and intracellular GSH levels were 
measured.
Interestingly, the HJ16 cell line showed significantly higher GSH content than J16 
cells (p<0.01). The mean value of three experiments of GSH levels was 6.7 jlM for 
HJ16 cells and 4.2 |nM for J16 cells. Addition of 2-100 |nM BSO significantly 
decreased GSH levels in both cell lines in a dose-dependent manner. A slight decrease 
was seen with both cell types treated with l|iM  BSO. As expected, NAC treatment 
(2.5, 5 and 10 mM) significantly increased GSH levels in both cell lines (Figure 4.1). 
However, GSH concentrations in HJ16 cells remained higher than J16 cells at all 
treatments.
115
a) In tracellu lar GSH levels in J16 and H J16 cells afte r 
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Figure 4.1 In tracellu lar GSH content of J16/H J16 cells. Cells were treated with 
various concentration of a) BSO or (b) NAC for 24 hours and presented for 
biochemical determination o f intracellular GSH. Results shown are the mean o f three 
separate experiments (+/-SEM).
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4.1.2 Investigation into the effect of depletion of GSH in J16 and
HJ16 cells and their stimulation of IL-lp/ IL-lra production by THP-
1 cells
GSH levels were decreased in J16 and HJ16 cells by incubating them with various 
concentrations of BSO, DEM and diamide. The cells were then washed three times 
and activated with ionomycin/PDBu for 24 hours. They were co-cultured with 
differentiated THP-1 cells in presence of LPS for 48hours, supernatants were 
harvested, and IL-1 (3 and IL-lra production was measured by ELISA. The results are 
presented as the mean value of several experiments, each performed in duplicate.
Interestingly, depletion of GSH with BSO (50, 100 and 200 fiM) in activated J16 and 
HJ16 cells significantly enhanced the stimulation of IL -lp and production by THP- 
lcells (p<0.05) compared to untreated cells. A moderate increase in IL-lra production 
by THP-1 cells was also seen after BSO treatment of J16 and HJ16 cells, but not 
statistically significant. No significant difference was observed between BSO-treated 
J16 and HJ16 cells in the stimulation of IL -lp and IL-lra production by THP-1 cells 
(Figure 4.2a,b).
To assess the effect o f increased GSH levels, cells were incubated with NAC (2.5, 5 
and 10 mM) overnight, washed and activated with ionomycin/PDBu, after that cells 
were washed and co-cultured with THP-1 cells for 48 hours. IL-lp and IL-lra levels 
were measured in the harvested supernatants. Unlike BSO-treatment, NAC treatment 
of these cells resulted in a slight reduction of IL-1 P and IL-lra production by THP-1 
cells. This reduction was better seen with J16 cells than HJ16 cells (Figure 4.3a,b).
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Although this reduction is not significant, it reveals that there was no enhancement of 
stimulation of IL -lp or IL-lra production by THP-1 cells co-cultured with the NAC- 
treated T cell line.
In order to confirm that the enhancement of the stimulation o f IL -lp and IL-lra 
production was due to the effect o f depletion of GSH levels, diamide and DEM were 
used as alternative methods to deplete GSH levels in J16 cells. Both methods of 
depletion of GSH levels resulted in similar results to those obtained with BSO-treated 
J16 and HJ16 cells. Depletion of GSH with DEM (ImM  and 100 pM, for 2 or 24 
hours) and diamide (lOOpM) resulted in a significant increase in the stimulation of IL- 
ip  and to lesser extent IL-lra production by THP-1 cells (Figure 4.4a,b).
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b) Effect of BSO- treated J16 and HJ16 cells on the stimulation of IL- 
lra  by THP-1 cells
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Figure 4.2: Effect of BSO-treated J16 and HJ16 cells on the stimulation of (a) IL-
lp  and (b) IL -lra  production by THP-1 cells. J16 and HJ16 cells were treated with 
various concentrations of BSO for 24 hours. BSO treated cells significantly enhanced 
IL-lp production by THP-1 cells. Low increase in IL-lra production was obtained. 
The results presented are the mean value of 5 different experiments (+/-SEM), (*= 
activated cells with ionomycin/PDBu, •  indicates p value< 0.05).
119
a) Effect of NAC-treated J16 and HJ16 cells on the production 
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4.3: Effect of NAC-treated J16 and HJ16 cells on the stimulation of (a) IL-1(3 and
(b) IL -lra  production by THP-1 cells. J16/HJ16 cells were treated with various 
concentrations of NAC for 24 hours. NAC-treated cells resulted in a slight reduction 
in both (a) IL-1 (3 and (b) IL-lra production by THP-1 cells. The data presented is the 
mean of five different experiments, +/- SEM, (*= Activated cells ionomycin/PDBu).
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a) Effect of DEM/Diamide-treated J16 cells on the production of IL-
1P by THP-1 cells
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Figure 4.4: Effect of depletion of GSH on J16 cells and their stimulation to (a) 
IL-1 P and (b) IL -lra : a significant increase in IL-lp and IL-lra after depletion of 
GSH with DEM/diamide. The results are the mean value of four experiments, +/- 
SEM, *= activated cells ionomycin/PDBu.
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4.2 Effect of MAP kinase inhibitors on J16 and HJ16 cells and their
stimulation of IL-lp and IL-lra production by THP-1 cells
The availability of chemical compounds that can specifically block one or another 
signal transduction pathway has greatly contributed to the study of the role of MAP 
kinases. A newly discovered inhibitor, SP600125, is used to inhibit JNK. It has been 
shown that SP600125 completely blocks IL-1-induced expression of c-Jun and 
collagenase mRNA and prevents the accumulation of phosphorylated-Jun in cultured 
synovial cells (Han et al; 2001). PD98059 can specifically inhibit MEK1/2, two 
enzymes that phosphorylate and activate ERK1/2. Moreover, P38 can be inhibited by 
SB203580, addition of this inhibitor blocks the cytokine-induced matrix 
metalloproteinase release from chondrocytic cells (Vincenti et al; 2001).
Treatment of cells with PDBu leads to activation of protein kinase C (PKC), which is 
essential in T cell signalling. PKC is also sensitive to oxidants (Gopalakrishna et al; 
2000), and can be inhibited by bisindolylmaleimide (BIM) (Toullec et al, 1991).
The effect of these inhibitors on J16 and HJ16 cells before and after treatment with 
BSO (manipulation of intracellular redox) and their stimulation of IL-1 P production 
by THP-1 cells was investigated. IL-lra was excluded due to the low level produced 
by THP-1 cells co-cultured with unfixed Jurkat cells (see chapter 3). J16 and HJ16 
cells were incubated with BIM (500nM), PD98059 (20|iM), SB203580 (l)iM), 
SP600125 (20pM), and various combination of PD98059, SB203580, and SP600125 
for 1 hour prior to activation with ionomycin/PDBu for 24 hours, (concentrations of 
these compounds were recommended by the suppliers). Cells were then washed in 
PBS, resuspended at 5xl06cells/ml in RPMI and co-cultured with THP-1 cells in the
1 2 2
presence of LPS. Supernatants were analysed for IL -ip and IL-lra production by 
ELISA (Figure 4.6).
Interestingly, both activated J16 and HJ16 cells pre-treated with PD98059 inhibitor 
showed a significant reduction in the stimulation of IL -lp by THP-1 cells (p<0.05) 
compared to untreated cells. However PD98059-treated HJ16 showed slightly higher 
stimulation of IL -ip than  PD98059-treated J16 cells, indicates that HJ16 MAPK 
ERK1/2 may be up- regulated.
Using SB203580 or SP600125 alone and BIM with J16 and HJ16 cells resulted in a 
slight decrease in IL-ip production by THP-1 cells. Combination of SB203580 and 
SP600125 in both cell lines significantly reduced IL -lp production by THP-1 cells 
(p<0.05). HJ16 cells showed a better stimulation of IL -lp production in the presence 
or absence of the inhibitors, indicating of up-regulation of these MAPKs.
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Effect of MAP kinase inhibitor on J16 and HJ16 cells and IL -ip production by THP-1 cells
Figure 4.6: Effect of MAP kinase inhibitors on J16 and HJ16 cells and their stimulation of IL-1 (3 production by THP-1 cells. A
significant reduction in IL-ip production by THP-1 cells co-cultured with J16 or HJ16 cells treated with ERK1/2 inhibitor (PD98059), and the 
combination of SB203580 + SP600125. Treatment of J16 and HJ16 cells with SB203580, SP600125, and BIM resulted in a slight reduction in 
IL-ip production by THP-1 cells. (PD=PD98059 (20pM), SB=SB203580 (lpM), SP=SP600125 (20jnM), PD+SB=PD98059+SB203580, 
PD+SP=PD98059+SP600125). The results expressed as the mean value of five experiments +/-SEM, (* activated cells with ionomycin and 
PDBu, • indicates p value <0.05).
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4.2.1 Effect of BSO and MAPK inhibitors on the J16 and HJ16 cells,
and their stimulation of IL-1 P production by THP-1 cells.
Redox regulation of MAPK-mediated cytokine biosynthesis has not been well 
characterized. However, it has been reported that pre-treatment with BSO facilitated 
TNF-a-induced MAPK p38 activation (Hashimoto et al; 2001). Previously in this 
thesis, it was shown that pre-treatment of J16 and HJ16 cells with BSO increased IL- 
lp  production by THP-1 cells in co-culture (section 4.2). The effect of BSO and 
MAPK inhibitors on J16 cells was analysed.
Treated or untreated J16 cells (with BSO) were incubated with MAPK inhibitors for 1 
hour, prior to activation for 24hours, and co-cultured with THP-1 cells with LPS. IL- 
ip  production by THP-1 cells was measured and the results were expressed as the 
mean value of three experiments.
Treatment of J16 and HJ16 cells BSO enhanced the production of IL-1 P by THP-1 
cells (Figure 4.7). However, PD98059 inhibitor significantly reduced IL- 
ip  production (p<0.05) in the presence or absence of BSO. However, BSO treated 
cells showed slight increase in the stimulation of IL -lp  production after ERK1/2 
inhibitors compared to untreated cells.
BSO-treated J16 cells augmented IL-lp production in the presence or absence of 
SB203580, SP600125 and SB203580/SP600125 inhibitors (p<0.05).
From previous results, (Figure 4.2a) the levels of IL -lp  from the co-culture 
supernatant was higher in BSO-pre-treated J16 and HJ16 cells, than control cells,
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indicating that pre-treatment o f BSO facilitated LPS/PDBu/ionomycin-induced IL-1 (3 
production. Since activated p38 MAP kinase is an important signal, which regulates 
cytokines production, the enhancement of p38, MAP kinase activation by BSO might 
result in the facilitation of IL-1 (3 production. To test this possibility, cells that had 
been treated with BSO or NAC were stimulated with PDBu and LPS for 15 minutes. 
As shown in Figure 4.8, BSO enhanced p38 MAP kinase phosphorylation, after PDBu 
and LPS activation, and NAC had no effect on p38 activation.
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Effect of MAPK kinase inhibitors on J16 before and after
treatment with BSO, and IL-ip production by THP-1 cells
□  J16*
■  J16*+100uM BSO
CTL PD98059 SB 203580 SP600125 SB/SP THP-1 CTL
Figure 4.7: Effect of MAP kinase inhibitors on J16 before and after treatment 
with BSO and stimulation of IL -ip  production by THP-1. BSO enhance the 
production of IL-lp in the presence or absence of MAPK inhibitors. PD inhibitor was 
potent in both treated and untreated cells. BSO enhanced IL-ip production in the 
presence or absence of SB203580, SP600125 and the combination of both SB203580 
and SP600125. The result presented is the mean of three experiments, (+/-SEM), (* 
=activated cells with ionomycin/PDBu).
J16* J16*BSO J16*NAC
Figure 4.8: BSO up-regulates phosphorylated p38 MAP kinase activation, (with





THE EFFECT OF MODULATION OF GLUTATHIONE 
LEVELS ON CALCIUM SIGNALLING AND CELL 
PROLIFERATION OF J16, HJ16 AND UVA-R-J16 CELLS
Chapter 5 Results
5.1 The effect of modulation of glutathione on calcium signalling and 
cell proliferation of J16, HJ16 and UVAR-J16 cells
T cells in the inflamed joints of RA patients show features of hyporesponsiveness.
This hyporesponsiveness is reflected by low proliferative responses, both in vivo and
in vitro, as well as low calcium responses upon stimulation (Maurice et al; 1997).
Glutathione (GSH) is an important constituent of intracellular antioxidant defences, 
acting to reduce the toxic effects induced by free radicals. T lymphocytes isolated 
from the synovial fluid of RA patients contain decreased levels of GSH compared to 
T lymphocytes isolated from peripheral blood, (Carruthers et al; 1996, Maurice et al; 
1997).
5.1.1 Intracellular calcium signalling in J16, HJ16 and UVAR-J16 
cells
Intracellular calcium signalling in J16, HJ16 and UVAR-J16 was examined after 
stimulation of the cells with PHA-L (25 pg/ml), anti-CD3 (10 |Hg/ml), anti-CD28 (10 
pg/ml), ionomycin (500nM) and hydrogen peroxide (50pM).
The peak and the plateau rise in intracellular calcium signal from baseline were 
calculated using a program provided with the system. All three cell types (J16, HJ16 
and UVAR-J16) showed a rapid rise in intracellular calcium signal to a peak followed 
by a lower plateau signal (Figure 5.1). No significant differences were observed in the 
baseline of intracellular calcium signal of all three cell types. The range of values of 
the baseline of J16, HJ16 and UVA-J16 was between 15-50nM. For HJ16 and
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UVAR-J16 cells the peak and the plateau was less than the peak and the plateau of 
J16 cells. There was a significant reduction (p<0.05) in both the peak rise and the 
plateau of HJ16 (the median of the peak lOOnM for the plateau 40) and UyA-R-J16 
cells (the median of the peak 125, and for the plateau 45 nM) compared to the J16 
cells (the median of the peak 200 nM, and for the plateau 60) (Figure 5.1). This 
significant reduction in the peak and plateau of HJ16 cells intracellular calcium 
signalling was also seen in experiments involved different stimulants such as anti- 
CD3, (Figure 5.2), anti-CD28 (Figure 5.3), low concentration of ionomycin (500nM) 
(Figure 5.4), and H2O2 (Figure 5.5). Moreover, no significant difference was observed 
in the peak or the plateau of intracellular calcium signalling between PHA-L and anti- 
CD3 or anti-CD28 stimulation. Addition of low dose of ionomycin (500 nM) caused a 
sudden rise in the peak in a time less than 10 seconds after addition o f ionomycin in 
both J16 and HJ16 cells, whereas, other stimuli gave peaks of intracellular calcium 
signal after 100-140 seconds after addition of the stimuli. As expected, the peak value 
(the median 450nM for J16 cells and 250 for HJ16 cells) obtained with ionomycin 
was significantly higher (p<0.05) than the peak value of intracellular calcium signal 
obtained with other stimuli (the median 200 for J16 and 100 for HJ16 cells). No 
significant differences were obtained in the plateau for all stimuli, except for H2O2 .
No plateau of intracellular calcium signalling o f both J16 and HJ16 cells was obtained 
after addition of H2O2 . Addition of 50joM H2O2 resulted in a significant increase in 
intracellular calcium signalling of J16 cells compared to HJ16 cells, which showed no 
effect (Figure 5.5). This continuous increase in intracellular calcium signal in J16 
cells was observed for 400 seconds, and no plateau was achieved. This may be due to 
an adverse effect o f H2O2 on the cells. However, the highest value recorded of
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intracellular calcium signalling of J16 cells (about 60nM after 400 seconds) was 
significantly less than those obtained with other stimuli.
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Intracellular calcium signalling in J16, HJ16 and
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Figure 5.1: Representative example of in tracellu lar calcium signal tha t were seen 
with J16, HJ16 and UVA-J16 cells loaded with Fura-2 and stim ulated with 
25pg/ml PHA-L (indicated as ^  ) .  The baseline, peak, and plateau o f intracellular 
calcium were recorded on the PTI flourimetry system. A significant reduction in 
intracellular calcium was seen in HJ16 and UVAR-J16 cells compared to J16 cells. 
(p<0.01, statistic was done on the peak values o f 10 experiments of J16 and HJ16 and 
5 experiments o f UVA-J16).
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Figure 5.2: Representative example of the 5 patterns of in tracellu lar calcium 
signalling in J16 and H J16 cells afte r anti-CD3 stim ulation. A significant 
reduction in intracellular calcium with H J16 was recorded.
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Figure 5.3: In tracellu lar calcium signalling in J16 and H J16 after CD28 
stim ulation, HJ 16 exerted a reduced intracellular calcium signalling compare to J16. 
(Representative example o f 5 patterns).
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Figure 5.4: In tracellu lar calcium signalling in J16 and HJ16 afte r addition of 
ionomycin (500nM), HJ16 exhibited reduced intracellular calcium signalling 
compare to J16, (Representative example o f 5 similar patterns).
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Intracellular calcium signalling in J16 and HJ16 cells, after 
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Figure 5.5: Effect of 50pM of hydrogen peroxide (H2O2) in intracellular calcium
in J16 and HJ16 cells, no effect o f H 202 was seen in HJ16, intracellular calcium 
signalling was enhanced in J16, (Representative example o f 3 similar patterns).
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5.1.2 Investigation into the effect of depletion of GSH on intracellular 
calcium signalling
BSO, DEM and diamide are widely used to lower GSH levels, and micromolar 
concentrations of BSO decrease intracellular calcium responses after anti-CD3 
stimulation (Staal et al; 1994). J16 and HJ16 cells were treated with various 
concentrations of BSO (25 - 200 ftM), 10 0 |liM  DEM and 100pm diamide. 
Experiments using trypan blue dye exclusion were always performed in order to 
exclude any overt toxicity of these drugs.
Treatment of J16 cells with 25-200pM of BSO resulted in a significant decrease in the 
peak and the plateau of intracellular calcium signalling (Figures 5.6a). No significant 
differences in the base line were observed. However the peak and the plateau of J16 
cells treated with 200mM BSO was higher than the peak and plateau of J16 cells 
treated with 25-1 OOpM BSO. This reduction in calcium signalling was best seen with 
25-100pM BSO, (P<0.05). Slight reduction in intracellular calcium signalling of J16 
was also observed with 200pM BSO. DEM and diamide treatment also resulted in 
significant decrease in calcium signalling in J16 (p<0.05) (Figure 5.7).
Depletion of GSH in HJ16 cells resulted in slight decrease in intracellular calcium 
signalling (Figure 5.6b). This slight reduction in intracellular calcium signal was seen 
in the base line, the peak and the plateau.
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Figure 5.6a:GSH regulates the PHA-L-induced in tracellu lar calcium in Ju rk a t 
cells (J16). PHA-L induced calcium flux is significantly decreased in BSO-treated 
Jurkat cells, (representative example of five similar experiments).
Effect of depletion of GSH on the in tracellu lar calcium 
signalling of HJ16 cells
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Figure 5.6b:GSH regulates the PHA-L-induced in tracellu lar calcium in HJ16 
cells. PHA-L induced calcium flux is insignificantly decreased in BSO-treated HJ16. 
Representative example o f five similar experiments.
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Effect of DEM/Diamide on calcium signalling of J16 cells
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Figure 5.7 T reatm ent of J16 cells with lOOpM DEM or diam ide to deplete GSH 
resulted in decrease in tracellu lar calcium signalling afte r PHA-L stim ulation.
(Representative example o f three similar experiments).
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5.1.3 Effect of N-acetylcysteine on intracellular calcium signalling
N-acetylcysteine (NAC) is a GSH precursor, so it has been used to enhance GSH in 
cells. Normal Jurkat cells (J16) and H2O2 tolerant cell line (HJ16) were treated with 
2.5, 5, 10 mM NAC for 24 hours. PHA-L induced calcium flux was analysed in both 
J16 and HJ16 cells. Treatment of J16 cells with lOmM NAC enhanced the base line, 
peak, and the plateau of intracellular calcium signalling but not statistically 
significant. 2.5 and 5mM NAC had no significant differences in intracellular calcium 
signalling of J16 cells (Figure 5.8a). NAC treatment of HJ16 cells showed no 
significant differences in the base line, the peak, or the plateau of intracellular calcium 
signalling, compared to untreated cells figure 5.8b.
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Figure 5.8:GSH regulates the PHA-L-induced in tracellu lar calcium in (a) J16 
and (b) H J16 cells. PHA-L induced calcium flux is increased in J16 cells treated with 
lOmM NAC for 24hours, no significant differences were observed with other 
concentration in both J16 and HJ16 cells. Representative example o f three similar 
experiments.
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5.1.4 Investigation of proliferation of J16, HJ16 and UVAR-J16 cells
and the effect of GSH levels
In order to investigate the proliferation rate in J16, HJ16 and UVAR-J16 cells and the
e
effect o f GSH levels, the XTT assay was performed to assess any differences in these 
cells. Briefly, cells were pre-treated with various concentrations of BSO/DEM/ 
diamide or NAC, washed and resuspended at lx l0 5 cells/ml; 100 jul of each sample 
was plated into 96 well plates and incubated for 48 hours with various stimulants- 
anti-CD3 (10 pg/ml), PHA-L (10 pg/ml), ionomycin; (1 pM), PDBu, (1 pM), and a 
combination of ionomycin/PDBu. The results were expressed as the percentage of 
absorbance to J16 (as 100%).
In the control cells, a significant decrease in proliferation was seen with HJ16 cells 
and UVAR-J16 cells compared to normal J16 cells (p<0.05) (Figure 5.10). Activation 
of cells with anti-CD3, PHA-L, ionomycin, PDBu and ionomycin/PDBu markedly 
decreased the proliferation of all cells. However, PHA-L (10 pg/ml) activation 
promoted a significant reduction of proliferation in all three-cell types compared to 
other stimulants. This is clearly manifested with HJ16 cells (p<0.01), therefore, the 
effect of PHA-L on the proliferation was studied further, and low concentrations (0.1- 
lOpg/ml) were used, (Figure 5.12). H J16 cells were sensitive to low concentration of 
PHA (0.1 pg/ml). This was manifested by the decline in proliferation, which started at 
concentration of 0.1 pg/ml, whereas J16 cells at 1 pg/ml, so there is about 10 fold 
difference in the sensitivity of these cells.
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Depletion of GSH with various concentrations of BSO (50, 100 and 200 |llM), DEM 
(50, lOOpM and ImM) and diamide (50,100 (liM, and ImM) exerted markedly 
reduced proliferation, (p<0.01). No significant differences among these drugs or 
concentrations were seen, all resulted in significant reduction in the proliferations of 
J16, HJ16 and UVAR-Jlo cells. NAC treatment (2.5, 5 and lOmM) showed a 
significant increase (p<0.05) in proliferation of J16 cells and much greater for HJ16 
and UVAR-J16 cells (Figure 5.12).
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Figure 5.9: proliferation of J16, HJ16 and UVAR-J16. HJ16 and UVAR-J16 cells showed a substantial decrease in proliferation.
Stimulation o f cells with anti-CD3, PHA, ionomycin, PDBu, and ionomycin/PDBu caused reduction in proliferation o f all three-cell lines. (The 
presented data is the mean o f the absorbance of three experiments. • indicates p<0.05, or • • p<0.01.
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Figure 5.10 Effect of various concentrations of PHA-L on J16 and HJ16 cell 
proliferation. HJ16 cells were sensitive to 0.1 pg/ml PHA, whereas J16 cells at 1 
pg/ml. Sensitivity are measured by reduction in proliferation o f the cells. The data 
shown is the mean absorbance of three experiments (+/- SEM).
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Figure 5.11: M odulation of GSH by BSO, DEM, diam ide and NAC influences proliferation of J16, HJ16 and UVAR-J16. Depletion of 
GSH, with BSO, DEM or diamide, significantly reduced proliferation. Increase of GSH with NAC enhanced proliferation o f J16 cells and 





6.1 Characterisation of a hydrogen peroxide tolerant T cell line 
(HJ16) in co-culture with monocytes
The results reported in chapter 3 showed that unfixed activated HJ16 cells and HJ16 
clones were much more active in co-culture, in terms o f stimulation of IL- 
ip  production by PBMCs (Figure 3.7a) and THP-1 cells (Figure 3.10a), compared to 
J16 cells. Also, HJ16 cells were sensitive to low concentrations o f PHA-L manifested 
by higher expression of CD2 and CD69 (Figure 3.5), stimulation of IL -ip production 
by THP-1 cells than J16 cells (Figure 3.13), and inhibition of proliferation (see 
section 6.3). Chronic exposure of J16 cells to oxidative stress (HJ16 cells) up- 
regulates complexes of proteins and transcription factors essential for cell activation 
and cytokine production or cell surface expression. PHA-L activates cells via CD2, 
and induces a high production of cell signalling molecules such as DAG (Pelassy et 
al, 1991). All unfixed activated T cells (J16, HJ16, and HJ16 clones) stimulated much 
higher level of IL -ip by both PBMCs and THP-1 cells, compared to fixed T cells, 
indicating soluble factors may be involved. Fixed activated T cells stimulated more 
IL-lra production by THP-1 cells, but not by PBMCs.
The presence of hypoxia and oxidative stress in RA synovium has been well 
documented. Hypoxia favours proinflammatory cytokine production by monocytes, 
which may be due to an effect on T cells (Mapp et al, 1995). Our results with HJ16 
cells, which have been exposed to oxidative stress (H2O2), are in good agreement with 
this observation. Under resting conditions, HJ16 and HJ16 clones (AB10, AD8, BA6 
and BD3) showed slight activation, manifested by the expression of CD69, whereas
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normal J16 cells did not show any activation (Figure 3.3a,b, and Figure 3.5a). 
Previous work by Isler et al showed that CD69 might be involved in the induction of 
proinflammatory cytokines (Isler et al, 1993). However, stimulation with PDBu alone 
resulted in up-regulation of CD69 (Figure 3.3a/b), but does not correlate with the 
stimulation of IL -lp and IL-lra production by THP-1 cells in co-culture. No 
significant production of IL-lp and IL-lra was obtained when THP-1 cells were 
cultured with J16 or HJ16 cells activated with PDBu alone (3.11a/b). This result 
provides no support for a CD69 mediated effect in the co-culture system. Further 
work is required to confirm this observation; Isler et al demonstrated that blocking of 
CD69 with antibodies could partially inhibit contact induction of cytokine release 
during co-culture, although other uncharacterised surface proteins are also required 
for contact activation (Isler et al, 1993). Recently, it has been found that high-density 
lipoprotein (HDL)-associated apolipoprotein A-I (apo A-I) inhibits cellular contact 
between T cells and monocytes, and consequently, inhibits IL -iP and  TNF-a 
production (reviewed by Burger & Dayer, 2002).
As mentioned above, unfixed activated HJ16 cells and the clones induced 
significantly higher production of IL-lp by both PBMCs (Figure 3.7a) and THP-1 
cells (Figure 3.10a) in the presence of LPS compared to J16 cells. This supports the 
hypothesis for a role of redox imbalance in the production of proinflammatory 
cytokines. These findings suggest that H2O2 induced changes in HJ16 cells, which in 
some way lead to higher induction of IL-lp. Cells respond to oxidative stress by a 
tightly controlled sequential process. The sequence of events begins with the sensing 
of the environmental changes at the cellular level via a signalling mechanism 
involving the extracellular matrix and cell surface sensor molecules. The sensor then
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transduces the signal to the intracellular environment through second messenger 
systems that subsequently activate transcription factors (such as hypoxia inducible 
factor-1, Hif-1) and initiate specific transcriptional events. Moreover, it has been 
found that oxidative stress or hypoxia activates transcription factors such as NF-kB 
and AP-1, that are involved in the production o f IL-lp. These transcription factors are 
directly subjected to redox regulation through their cysteine residues such that a 
reduced state in these cysteine residues is essential for their activity (reviewed by 
Ginn-Pease & Whisler, 1998; Kamata & Hirata, 1998; Haddad, 2002b). In addition, 
oxidative stress regulates certain protein tyrosine kinases and phosphatases, which 
may leads to the production of proinflammatory mediators. H2O2 rapidly induces 
substantial increases in c-jun and c-fos mRNA levels as well as increases in DNA 
binding of transcription factor AP-1 (reviewed by Kamata & Hirata; 1998). Moreover, 
oxidative stress such as exposure to H2O2 can rapidly induce marked increases in 
tyrosine phosphorylation in Jurkat cells (Whisler et al; 1995). Human T and B cells 
treated with millimolar concentration of H2O2 exhibit increased activity of protein- 
tyrosine kinase (PTK) (such as p56,ck and p72syk), MAPK and S6 peptide kinase 
(Whisler et al; 1995, reviewed by Kamata & Hirata; 1998). Thus exposure of HJ16 
cells to H2O2 might influence cellular signalling pathways, and render them more 
active in co-culture.
All unfixed activated T cells stimulated more IL -lp  production by PBMCs and THP-1 
cells than fixed activated T cells. There are several explanations for this outcome: 
soluble factors other than IFN-y or IL-17 (see below) may contribute to the production 
of such cytokines, hence, the supernatants of activated J16 and H I6 cells showed a 
slight stimulation of THP-1 cells to produce IL -lp  (Figure 3.12a), but this increase
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was not statistically significant. This may require high concentration of the 
supernatants or more cells could be used. The effect o f IL-17 on our co-culture system 
is excluded, because no IL-17 release by J16 or HJ16 cells was detectable.
Alternatively, T cells may mediate their effect through cellular contact rather than 
soluble factors. T cell cytokines such as IL-4, IL-10, IL-13 and transforming growth 
factor (TGF)-p have predominantly anti-inflammatory effects, IFN-y and IL-17 
display a weak activation capacity in terms o f IL-1 (3 and TNF-a induction, suggesting 
that soluble factors produced by T cells are not pathological mediators of RA. 
Therefore, T cells might exert a pathological effect through direct cellular contact 
with monocyte-macrophages (reviewed by Burger & Dayer, 2002; Dayer, 2003). In 
this work, fixed T cells were used to study the effect of cellular contact without 
soluble factors involved. However, fixation of T cells with glutaraldehyde is very 
artificial and may cause changes or alteration of cell surface molecules essential for 
the stimulation of IL -lp  and IL-lra production by PBMCs or THP-1 cells. Therefore, 
we do not exclude the effect of cellular contact with unfixed T cells co-cultured with 
PBMCs or THP-1 cells and stimulated IL -ip and IL-lra production. It should be 
noted the co-culture was performed in 96 well U-shaped plates, where T cell and 
monocytes are in close contact. It has been documented that direct cell-cell contact 
between monocyte-macrophages and stimulated T cells can induce different patterns 
of cytokine production, depending on the T cell type and stimulus. This suggests that 
multiple cell surface molecules are involved in the contact-mediated activation of 
monocytes. Imbalance in the production of proinflammatory versus anti-inflammatory 
cytokines has also been observed. A study performed by Chizzolini et al (1997) 
demonstrated that cell membranes from antigen-stimulated, but not from resting, T
147
cells induced dose-dependent cytokine production by THP-1 cells, and Thl cells 
induced higher levels of IL-1 (3 production than Th2. In contrast, Th2 cells favour IL- 
lra production by THP-1 cells, via direct cell-cell contact. A similar pattern was 
obtained in our study in that fixed T cells (Th2-like cells, see below) induced higher 
levels o f IL -lra than IL-lp by THP-1 cells, but not by fresh PBMCs. Moreover, Vey 
et al (1992) demonstrated that direct contact with stimulated T cells favours the 
production o f IL -ip  over that o f IL-lra in both PBMCs and THP-1 cells. In contrast, 
soluble factors release by stimulated T cells favour the production of IL-lra (Vey et 
al, 1992). Our results showed that unfixed T cells stimulated both IL -ip  and to lesser 
extent IL-lra production by PBMCs. However, fixed T cells were better inducers for 
IL-lra production by THP-1 cells but not by PBMCs. Thus it can be concluded that, 
direct cell-cell contact with activated T cells is a potent mechanism, which induces 
not only IL-lra production but also proinflammatory cytokines such as IL-ip, TNF-a, 
IL-6 and MMPs (Vey et al, 1992; Isler et al, 1993; Lacraz et al, 1993). Several 
receptors and ligands have been implicated in mediating contact-dependent 
phenomena, including membrane-associated cytokines such as TNF-a, LFA-l/ICAM- 
1, CD40/CD40L, lymphocytes activation antigen (LAG-3), CD69 and CD2/LFA3 
(Wagner et al, 1994; reviewed by Burger & Dayer, 2002; Dayer, 2003). CD69 and 
CD2, however, are up regulated on HJ16 cells compared to J16 cells, before and after 
activation with PHA-L (Figure 3.5). Up-regulation of such molecules (other than 
CD69) may explain why HJ16 cells were more active in terms of stimulation of IL-lp 
and IL-lra production by PBMCs and THP-1 cells. The significant reduction in the 
production o f IL -lp by both PBMCs (Figure 3.7b) and THP-1 cells (Figure 3.10b) 
cells after fixation of T cells may be due to negative affects of glutaraldehyde on 
surface molecules that are essential in the stimulation of IL -ip production.
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It has been shown that T cell subsets (Thl, Th2) may determine the type of cytokines 
that can be produced by monocytes (Chizzolini et al, 1997). Thus, we attempted to 
classify J16 and HJ16 cells and the clones by using chemokine receptors (Figure 3.6). 
The results revealed that J 16, HJ16 and the clones are perhaps more Th2-like. Further 
confirmation is required for this classification. Moreover, there was no apparent 
difference in the expression of CCR2, CCR3, CCR4, CCR5 and CXCR3 at mRNA 
level between J16 and HJ16 cells or the clones. However the percentage of CD3+ 
lymphocytes expressing CCR2, CCR4, CCR5, and CXCR1 was significantly elevated 
in RA peripheral blood compared with that in normal peripheral blood, while the 
percentage of CD3+ lymphocytes expressing CCR5 was significantly enhanced in RA 
synovial fluid compared with that in normal and RA peripheral blood (Ruth et al, 
2001).
Many co-cultures of T cell and monocyte cell lines (THP-1 cells) or PBMCs were 
carried out in the presence of LPS. LPS has profound effects on the production of 
cytokines (IL-lp and IL-lra) by monocytes-macrophages. Interestingly, it has been 
demonstrated that T lymphocyte activation by LPS is strongly dependent on direct 
cell-cell contact of responding T lymphocytes with viable accessory monocytes 
(Mattem et al, 1994), mainly represented by interaction o f B7 with CD28 (Mattem et 
al, 1998). Therefore, the use of LPS in our co-culture system may provide co­
stimulation to the T cell line (J16 and HJ16 cells) as well as directly stimulating the 
monocyte cell line (THP-1 cells) or PBMCs.
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The ratio of IL-lp to IL-lra was approximately 1:15 at all treatments. Endogenous 
production o f IL-lra is an important anti-inflammatory mechanism both in animal 
models and in human disease. In the rheumatoid synovium, an imbalance exists in this 
system, such that levels of IL-lra are not adequate to effectively block the 
proinflammatory effects of IL-1 (IL-lra binds to IL-1RI with an avidity equal to that 
of IL-1), a high level of IL-lra is essential to reduce the effect of IL-lp. In vitro 
experiments have revealed that an excess o f 100 times the amount of IL-lra is 
required to inhibit IL -lp activity, whereas, in vivo, 100-2000 times more IL-lra is 
needed (Arend, 1993; Firestein et al, 1994; reviewed by Arend; 1996/2001).
The pattern of IL-lra production was different in THP-1 cells and PBMCs. Fixed J16, 
HJ16 cells and HJ16 clones resulted in higher production of IL-lra by THP-1 cells, 
but not by PBMCs (Figure 3.10d) in the presence of LPS compared to unfixed cells 
(Figure 3.10c). Fixed HJ16 cells and the clones induced higher IL-lra production than 
fixed J16 cells, although this was not statistically significant. This may be due to the 
binding efficiency of these cells. It has been reported that exposure of Jurkat cells to 
H2O2 increased the binding to THP-1 cells. The membrane binding sites on the 
oxidized Jurkat cells were found to be sialylated poly-N-acetylgalactosaminyl sugar 
chains (Beppu et al, 2000). The difference in the patterns of IL-lra generation 
obtained with THP-1 cells and PBMCs may also be due to the difference in the 
response to LPS. LPS-induced expression of the human sIL-lra gene in macrophages 
is controlled by at least two PU.l (a transcription factor) binding sites. The proximal 
PU.l site, binds both NF-kB and GA-binding protein (GABP). This site overlaps the 
previously identified NF-kB binding site and thus represents a novel composite NF- 
kB/PU.I/GABP binding site. Mutation that disrupted either NF-kB or PU.l had no
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effect on the LPS response. However, a mutation that disrupted both NF-kB and 
PU.l-binding resulted in a greater than 50% decrease in the LPS response. Mutation 
of the distal site resulted in an approximately 50% decreased in the activation of the 
promoter in response of LPS. Thus LPS-induced regulation of sIL-lra gene 
expression is a complex event potentially involving the interaction of three different 
transcription factors (NFkB/PU.I/GABP) (Smith et al, 1998). Expression of these 
receptors and transcription factors on THP-1 cells (which are biologically different 
from fresh PBMCs) and PBMCs might be different, which could explain why a 
different pattern of IL-lra was obtained. Furthermore, it has been found that the rate 
of internalisation of LPS by THP-1 cells slowed significantly after a few minutes of 
exposure to LPS (Kitchens & Munford, 1998). Furthermore, LPS has been shown to 
initiate multiple intracellular signalling events, including the activation of NF-kB, 
which ultimately lead to the synthesis and release of a number of proinflammatory 
mediators, including IL-1, IL-6, TNF-a and IL-8 (Zhang et al, 1999). Similarly LPS 
might have a different effect on IL-lra inducing-pathways on both THP-1 and 
PBMCs. It has been shown that molecules involves in LPS binding site are 
complicated and depends on the cell type, for example, LPS binding site on B cells 
has been shown to engage TLR-4, RP105 and MD1, whereas in mast cells the binding 
site is found to be TLR-4 and MD2 (reviewed by Triantafilou M & Triantafilou K, 
2002). This provides further support to the hypothesis that the response of cells, such 
as monocytes and THP-1 to LPS may be heterogeneous and the interaction of a group 
of transcription factors with a single cis-acting element may depend on the relative 
affinities and the concentration of proteins as well as their localization within the 
nucleus (Arend et al, 1995; Smith et al, 1998).
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The production of IL-1 (3 (Figure 3.15a) and IL-lra (Figure 3.15b) by PBMCs 
increased significantly after exposure to 2% O2 in the presence of LPS and slightly in 
the absence of LPS, indicating that co-stimulus is required to enhance IL -ip or IL-lra 
generation. This is in agreement with previous studies showing that hypoxia induces 
IL-1 release in mononuclear cells stimulated by LPS (Ghezzi et al, 1991; Naldini et al, 
2001). The potentiation of IL-1 P and IL-lra production by 2% O2 indicates a 
mechanism of regulation of cytokine production by hypoxia. This mechanism could 
be important in many pathologic conditions. A significant reduction in the production 
of IL ip  and IL-lra by PBMCs co-cultured under 1% O2, this may be due to that 1% 
O2 was lethal to the cells and affected their viability.
No significant difference was found between J16 and UVA-R J16 cells in their 
stimulation of IL -lp  and IL-lra production by THP-1 cells (Figure 3.14). This 
indicates that UVAR-J16 cells are biologically different to HJ16 cells, and different 
oxidative stresses may result in different responses. Further investigation of the 
effects of oxidative stress caused by H2O2 and UVA on Jurkat cells is needed to 
explain why UVAR-J16 cells are similar to J16 in co-culture, whereas, HJ16 cells are 
more active. Further work is being undertaken by other researchers in our laboratory 
to explore the nature of HJ16 cells, UVAR-J16 and the effect of redox balance in the 
activation of transcription factors such as NF-kB.
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6.2 Manipulation of the intracellular antioxidant, glutathione (GSH)
in J16 and HJ16 cells and their stimulation of IL-lp and IL-lra 
production
The contribution of redox imbalance, which often results from enhanced ROS 
formation, to the molecular events that lead to the inflammatory response, is not well 
understood. Cells possess several antioxidants or reductants that maintain the 
intracellular redox environment in a highly reduced state. Glutathione (GSH) is a 
major cellular reductant, involved in the elimination of ROS such as H2O2 . Recently 
accumulating evidence has indicated that cellular redox plays an essential role not 
only in cell survival, but also in cellular signalling systems (redox regulation) 
(reviewed by Kamata & Hirata, 1998; Haddad, 2002b).
HJ16 cells displayed certain characteristics not associated with RA synovial fluid 
cells. HJ16 cells exhibit increased GSH level compared to normal J16 cells (Figure 
4.1), whereas synovial T cells have depleted GSH (Maurice et al, 1998). Moreover, it 
has been demonstrated that levels of GSH are reduced in erythrocytes from RA 
patients (Chilles et al, 1990), and that reduced GSH may be responsible for the 
differentiation of T cells towards a Thl phenotype (Peterson et al, 1998). This 
difference in GSH levels in HJ16 cells and RA synovial fluid T cells may be due the 
acute and chronic exposure to oxidative stress. HJ16 cells have been exposed to a 
chronic oxidative stress resulted in high GSH level, whereas RA synovial fluid T cells 
are in subjected to acute oxidative stress continuously (Mapp et al, 1995).
Interestingly, BSO, DEM, and diamide treatment to deplete GSH in J16 and HJ16 
cells enhanced the stimulation of IL -lp and IL-lra production by THP-1 cells
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(Figures 4.2 and 4.4). It is not clear whether the up-regulation o f IL-lra production 
was due to a direct effect of depletion of GSH on T cells or is due to the increase of 
IL -lp  levels. Further investigation is required to determine the effect of GSH levels 
on IL-lra production. In contrast, NAC treatment resulted in a slight reduction in the 
stimulation of IL-1 p and IL-lra production (Figure 4.3). Our results, in agreement 
with previous studies on epithelial cells (Haddad, 2001), showed that depletion of 
GSH with BSO augmented proinflammatory cytokine production. In vitro the 
regulatory effect o f BSO on proinflammatory cytokine production has been studied. 
Growing evidence implicates an association between redox signalling and the 
regulation of proinflammatory cytokine production, thereby placing more importance 
on the utilization of intracellular GSH. The GSH biosynthesis is blocked by BSO, a 
specific inhibitor of y-glutamylcysteine synthetase. Consequently, the capacity of T 
cells (J16 and HJ16 cells) to replenish intracellular stores of GSH is dramatically 
affected, thereby modulating the equilibrium necessary to evoke a defence strategy in 
pathophysiology (Hayes & McLellan, 1999). Depletion of GSH is associated with 
generation of ROS, leading to augmentation of proinflammatory cytokine production. 
This may be mediated at least in part by the activation of redox-sensitive transcription 
factors such as NF-kB (Ginn-Pease & Whisler, 1998, Kamata & Hirata, 1999). The 
pathway mediating BSO-induced up-regulation of pro-inflammatory cytokines by T 
cells is a complex process and involves several mediators. BSO is capable of inducing 
intracellular accumulation of ROS, GSH is involved in H2O2 reduction (a major 
source of OH ) in epithelial cells, and GSH depletion results in H2O2 accumulation 
and increased OH' production (Hayes & McLellan, 1999).
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Furthermore, GSH depletion in murine APCs decreased the secretion of IL-12 and led 
to polarization from the typical Thl cytokine profile towards Th2 response patterns, 
suggesting that GSH levels in APCs play a central role in determining whether a Thl 
or Th2 cytokine response predominates (Peterson et al; 1998). It has been reported 
that IL-12 production is regulated by the redox potential of murine peritoneal 
macrophages. “ Reductive”  macrophages with elevated GSH levels produced IL-12, 
whereas ‘’oxidative”  macrophages with a reduced level o f GSH did not (Murata et al, 
2002).
On the other hand, NAC treatment of J16 and HJ16 cells resulted in a slight reduction 
in IL-1 (3 production by THP-1 cells (Figure 4.3), although this reduction is not 
statistically significant. On the other hand, there is no enhancement of IL -lp and IL- 
lra production. Thus NAC treatment has an effect, which is opposite to that of BSO- 
treated cells. It has been reported that NAC reduced LPS-mediated secretion of TNF- 
a  and IL-6 and blocked the phosphorylation/activation of MAPK p38 in epithelial 
cells (Haddad, 2002c). The effect of NAC on cytokine production is still 
controversial. A recent study suggested that NAC-dependent regulation of IL-1 p is 
tightly regulated by NF-kB, and showed elevation in IL -ip  production following 
incubation with NAC and LPS (Parmentier et al, 2000). Other investigators, however, 
have reported an antagonist effect of NAC on proinflammatory cytokine biosynthesis 
and NF-kB regulation (Ginn-Pease & Whisler, 1998, Verhasselt et al, 1999). We 
cannot exclude the possibility, however, that a NAC-mediated inhibitory effect on 
soluble factors released by NAC-treated J16 or HJ16 cells may be linked with the 
IkB/NF-kB pathway.
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The synovium of RA is hypoxic and contains several different cell types, including 
macrophages and T cells; these cells are in close contact. The hypoxic nature of the 
synovium alters the intracellular GSH levels. It has been found that synovial T cells 
have depleted intracellular GSH levels (Maurice et al, 1997). As mentioned above T 
cells might exert a pathological effect through direct cellular contact with monocyte- 
macrophages. BSO treatment of J16 and HJ16 cells may enhance the expression of 
cell surface molecules involved in contact mediated monocyte activation, as well as 
their counter-ligands. It has been postulated that T cell membrane-associated TNF-a 
may be involved in macrophage activation. Hence, depletion of GSH with BSO 
(cellular thiol status) and oxidative stress (H2O2) promote NF-kB activation, and may 
also up-regulated membrane-associated molecules on J16 or HJ16 cells, consequently 
enhancing cellular contact and cytokine production. Moreover, it has been found that 
depletion of intracellular GSH increased neutrophil adhesion to human umbilical vein 
endothelial cells via up-regulation of ICAM-1, P-selectin, and E-selectin. NAC 
treatment attenuated this adhesion (Kokura et al, 1999).
In addition, MAPK pathways are also sensitive to GSH levels and contribute to the 
increase in cytokine production. It has been shown that BSO facilitated TNF-a 
induced p38 MAP kinase activation in human epithelial cells (Hashimoto et al; 2001). 
Our preliminary results showed up-regulation of phosphorylated p38 after BSO 
treatment o f J16 cells (Figure 4.8). MAPKs in HJ16 cells and in BSO treated J16 and 
HJ16 cells seem to be up-regulated, hence the effect of MAPK or PKC inhibitors 
(PD98059, SB203580, SP600125, and bisindolylmaleimide) had less effect on these 
cells compared to J16 or untreated cells (Figures 4.6 and 4.7). It is well documented 
that cellular redox changes are involved in the activation of the MAPK superfamily
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(reviewed by Kamata & Hirata, 1998). Our results are in agreement with previous 
observations. MAPKs (p38, ERK1/2, and JNK) are likely to play a critical role in the 
pathogenesis of RA, for example JNK enhances transcriptional activity of AP-1, a key 
regulator of MMP production. IL-1 is a potent inducer of JNK phosphorylation. 
Initially, it was believed that JNK and p38 pathways alone were responsible for 
mediating responses to inflammatory cytokines. These kinases act in part by 
phosphorylation and activating the transcription factors c-Jun and ATF2. Upon 
activation, these transcription factors can induce the promoters of multiple genes, 
including those for MMPs. In contrast ERK1/2 were thought to be responsible for 
transducing growth factor-dependent proliferative signals. However, chemical 
inhibition of the ERK1/2 pathway with PD98059, (which inhibit MEK1 and MEK2, 
two enzymes that phosphorylate and activate ERK1/2) has raised additional issues: it 
has been shown that when fibroblast-like synovial cells are treated with this 
compound and stimulated with serum, phorbol ester, or growth factors, the 
proliferative responses are blocked, as well as activation of MMP-1. Inhibition f  these 
kinases in T cells seem to block the stimulation of IL-1 (3 production by co-cultured 
monocytes (Rincon et al, 2000; Han et al, 2001; reviewed by Vincenti, et al 2001). 
Our results showed inhibition of IL -lp production after incubation of J16 or HJ16 
cells with ERK1/2 inhibitors (PD98059), JNK inhibitor (SP600125), p38 inhibitor 
(SB203580), and PKC inhibitor (bisindolylmaleimide). This confirms the broader 
roles of these MAPKs (especially ERK1/2), at least in cultured cells.
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6.3 The effect of modulation of glutathione on calcium signalling and
cell proliferation
The results presented in chapter 5 demonstrated that HJ16 cells compared to J16 cells 
have a reduction in the peak and plateau of intracellular calcium signalling in 
response to PHA-L (Figure 5.1), anti-CD3 (Figure 5.2), anti-CD28 (Figure 5.3), and 
even ionomycin (Figure 5.4). A similar pattern has been observed in synovial fluid 
(SF) and peripheral blood T cells from patients with RA compared to normal controls 
(Allen et al, 1995, Carruthers et al, 1996 & 2000). A change in the pattern of the 
intracellular signal in cells may influence subsequent activation events at the nuclear 
level, thus affecting the functional outcome of such stimuli, including cytokine 
production. T cell activation requires sustained threshold intracellular calcium, and 
the necessary level varies from cell to cell (reviewed by Berridge et al, 2000). 
However, reduction in intracellular calcium signalling does not correlate with 
stimulation of IL -lp and IL-lra production by PBMCs and THP-1 cells in the co­
culture system reported in chapter 3. However, it does correlate with the proliferation 
assay reported in chapter 5.
Oxidative stress has an effect on the cellular metabolism and structural elements of 
cells; such effects can change the calcium signal and modify essential pathways. It has 
been reported that oxidants such as H2O2 causes a rapid increase in calcium 
concentration in the cytoplasm of diverse cell types (Wang & Joseph, 2000). Addition 
of low concentration of H2O2 to J16 cells, but not to HJ16 cells resulted in continuous 
increase in intracellular calcium (Figure 5.5). It seems that this increase can be due to 
both calcium release from internal cellular stores such as the ER/SR, and calcium 
import from extracellular spaces. Similarly, Roveri et al observed that mild oxidative
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stress caused by moderate H2O2 levels transiently increased cytoplasmic calcium 
levels even in calcium free medium, but failed to do so if  calcium was first depleted 
from the ER/SR (Roveri et al 1992).
There are several possible explanations as to why HJ16 cells have a reduction in 
intracellular calcium signalling: Oxidants can directly attack membranes forming lipid 
peroxides, which can activate phospholipase A2 (PLA2). The products of PLA2 
actions (arachidonic acid and hydroxyl fatty acids) are known as mediators of such 
important physiological processes essential for immune responses and inflammation. 
It has been demonstrated that lipid peroxides alter calcium homeostasis, which in turn 
can modulate PLA2 activity in endothelial cells (Elliott et al, 1992). In addition, 
elevated calcium levels in the cytoplasm can induce other enzymes that produce free 
radicals such as nitric oxide synthase (Lynch & Dawson, 1994). Thus, by elevating 
cytoplasmic calcium levels, oxidants can also indirectly cause more oxidant 
production and further escalate calcium levels. HJ16 cells were subjected to alteration 
in the membrane forming lipid and intracellular enzymes and proteins essential for 
calcium binding (buffering system). For example calcineurin activity (an important 
enzyme in calcium dependent eukaryotic signal transduction pathways) is sensitive to 
cellular redox state, it has been found that H2O2 can completely abrogate calcineurin- 
mediated NF-AT trans-activation in response to stimulation (Reiter et al, 1999; 
reviewed by Berridge et al, 2000). Further investigation of the calcium binding 
proteins is required to elicit their nature in HJ16 cells.
IP3 which is the recognised second messenger releasing calcium from intracellular 
stores (ER/SR), may induce a second independent effect by enhancing calcium influx
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through plasma membrane permeable channels. Once initiated, the process leads to 
the activation of PKC and to a wide variety of cellular responses, which culminate in 
cytokine production and cell proliferation (see below). Oxidants, however, also can 
regulate production of IP3 and calcium release from ER/SR as a consequence (Doan 
et al, 1994). These stores in HJ16 cells may have depleted levels of calcium due to 
exposure to H2O2 . Moreover, H2O2 can effectively inhibit calcium transport by sarco- 
endoplasmic reticulum calcium transporting ATPases (SERCA), in smooth muscle 
(Grover et al, 1992). SERCA are ATP-dependent calcium pumps that transport 
calcium against its concentration gradient into the lumen of ER/SR, thus antagonising 
the function of IP3 by reducing free cytoplasmic calcium levels and accumulating 
calcium in ER/SR. It has been found that SERCA can be inhibited by oxidation of its 
sulphydryl groups and also by direct effect of oxidants on the ATP binding site 
(Castilho et al, 1996, Xu et al, 1997). Furthermore, hypoxia alters Na2+/Ca2+ 
exchangers (essential in equilibrium of calcium in the mitochondria) causing more 
calcium to be transported into mitochondria instead of its release from mitochondria 
(Griffiths et al, 1998).
It can be concluded that oxidants such as H2O2 and duration of exposure could 
dramatically change calcium signalling and even reverse its direction from stimulative 
to repressive (or vice versa). Hence chronic exposure to H2O2 rendered HJ16 cells 
with reduced calcium signalling, and addition of H2O2 to J16 cells increased calcium 
signalling. However, addition of H2O2 to J16 cells resulted in continuous increase in 
calcium signalling and no peak or plateau was obtained, this may be due to membrane 
damage caused by H2O2 .
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The intracellular GSH concentration in T cells provides mechanisms for modulating 
responses elicited by antigens and cytokine signals. Depletion of GSH in J16 cells 
resulted in a significant decrease in intracellular calcium signalling (Figure 5.6a), but 
only a slight decrease with HJ16 cells was observed (Figure 5.6b). GSH depletion 
induces an imbalance in the antioxidant defence, including the activity of such 
enzymes as superoxide dismutase, catalase and glutathione peroxidase. Glutathione 
peroxidase for example has been found to be decreased significantly after BSO 
treatment (Thanislass et al, 1995). Diminished GSH concentration affects the 
regulation of reductive process by the GSH redox pathway (Reed, 1986). Moreover, 
protein-thiols are essential for a number of membrane functions, such as enzyme 
activities (e.g. Na, K ATPase) and the transport system. It has been shown that some 
protein thiols are essential for calcium transport in mitochondria and microsomes and 
that loss of such protein thiols can lead to perturbations of cellular calcium 
homeostasis (Kramer et al, 1987). In addition, the sulfhydryl groups are involved in 
calcium retention and their oxidation causes the depression of calcium sequestration 
in liver microsomes and mitochondria. The loss in calcium retention appears to be 
related to alterations in the status of GSH, which in turn, affects the permeability 
mechanisms (Thanislass et al, 1995). This could be a possible reason for the observed 
decreased intracellular calcium signalling after GSH depletion, but confirmation 
requires further study.
The rates of proliferation of the HJ16 and UVAR-J16 cells are significantly reduced 
compared to J16 cells (Figure 5.9), which may be due to exposure to oxidative stress 
and reduced calcium signalling in these cells as mentioned above. Calcium is one of 
the key regulators of cell proliferation (reviewed by Berridge et al, 2000). However,
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all cells (J16, HJ16, and UVAR-J16 cells) showed a high proliferation rate in resting 
conditions. In normal T cells the induction of proliferation is dependent on the co- 
stimulatory signals (Suthanthiran et al, 1990), however our results showed that 
treatment of J16, HJ16, and UVAR-J16 cells with anti-CD3, PHA-L, ionomycin, 
PDBu, and combination of ionomycin and PDBu resulted in a reduction in 
proliferation of all cells (Figure 5.9). This reduction was seen most dramatically with 
HJ16 cells stimulated with PHA-L. HJ16 cells were more sensitive to PHA-L 
stimulation (Figure 5.10). This is not only due to up regulation of CD2 (PHA-L 
receptors) expression, but may be due to up regulation of intracellular molecules 
essential in cell signalling via CD2 or other PHA-L binding receptors. In normal T 
cells, anti-CD2 mAb alone failed to induce cell proliferation (Sunthanthiran et al, 
1990). It has been documented that oxidative stress induces T cell 
hyporesponsiveness, manifested by impaired expression of some TCR-proximal 
signalling molecules such as TCR-£, p56, LAT (Cermerski et al, 2003) and ZAP-70 
(Chakravarti & Abraham, 2002). Signalling through the CD2 molecules was shown 
to employ similar signalling molecules as the TCR (Bonin et al, 1998), thus exposure 
of J16 cells (HJ16 cells) to H2O2 , may have had an effect on these molecules that 
consequently affected the CD2 signalling pathway.
Pretreatment of J16, HJ16, and UVAR-J16 cells with BSO, DEM, and diamide 
dramatically inhibited cell proliferation, and no significant differences between these 
cells were observed. This permits the interpretation that depletion of GSH in these 
cells is associated with a profound inhibition of their proliferative potential. Previous 
observations showed that decreased intracellular levels o f GSH in T cells affected
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both calcium responses and proliferation after anti-CD3 stimulation (Suthanthiran et 
al, 1990; Staal et al, 1994; Maurice et al, 1997).
In contrast to the effect of BSO on cell proliferation, NAC treatment increased the 
proliferation of J16, HJ16 and UVAR-J16 cells, maybe due to enhancement of GSH 
levels. It has been found that GSH enhanced T cell proliferation activity and increased 
IL-2 production (Liang et al, 1989). This suggests that the effect of GSH on the 
replication of activated T lymphocytes is partially, if  not mainly, due to its influence 
on the production of IL-2. GSH may interact with IL-2 directly by reducing the 
disulfide bond of IL-2. However, this explanation is unlikely since the reduced form 
of IL-2 is less potent than the non-reduced form. This lead to an alternative 
explanation; GSH may affect the IL-2 activity indirectly through its effect on the 
target cells (Liang et al, 1989; Park et al, 2000). Blockade of surface SH groups on T 
cells causes a marked inhibition of mitogen-induced cell proliferation, due to down- 
regulation IL-2 receptors and interference with IL-2 binding to high-affinity receptors 
complex (Smith et al, 1992).
From the discussion above, it can be concluded that the intracellular GSH 
concentration in T cells performs a central role in modulating responses elicited by 
antigen and cytokine signals. At higher concentrations of GSH, proliferation will be 
favoured, whereas at lower concentrations of GSH, inflammatory-type responses that 
involve the induction of transcription factors NF-kB and AP-1 are more likely to 
occur. That is, when GSH levels are high, T cells respond poorly to stimulation in 
terms of calcium signalling and proliferation. In contrast, when GSH levels are low 
(after treatment with BSO), T cells fail to flux calcium or to proliferate. Instead, they
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respond strongly in co-culture, with changes in cellular protein phosphorylation and 
induction of transcription factors such as NF-kB and AP-1.
In addition, long-term exposure to oxidants might lead to chronic changes in the 
delicate balance o f the pro-oxidant and antioxidant status of the T cell, and 
consequently, counteract the initial effects of oxidative stress. Depletion of 
antioxidants may have a role in the development of autoimmune diseases such as RA. 
Treatment of RA patients with potential aliphatic thiols with strong reducing 
properties has been used for a long time, and shown to be beneficial (Halliwell et al, 
1988).
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6.4 SUMMARY AND CONCLUSION
Expression of CD69 showed that HJ16 and the clones are activated in resting 
conditions, presumably due to the exposure to H2O2 . A slight up-regulation of CD2 
was also seen with HJ16 cells in resting conditions and significantly after PHA-L 
activation compared to J16 cells.
Unfixed activated HJ16 cells and HJ16 clones significantly induced IL -lp production 
by PBMCs and THP-1 cells in the presence of LPS, compared to normal J16 cells. All 
unfixed and activated T cell lines (J16, HJ16, and clones o f HJ16 cells) enhanced the 
production of IL -lp by both PBMCs and THP-1 cells, indicating soluble factors may 
be involved, as well as cell-cell contact. Fixed T cell lines promoted the production of 
IL-lra by THP-1 cells but not by PBMCs.
Depletion of GSH in J16 and HJ16 cells augmented their stimulation of IL -lp  and to 
lesser extent IL-lra production by THP-1 cells. Enhancement of GSH levels in J16 or 
HJ16 cells had no effect on the stimulation of IL-lp or IL-lra production by THP-1 
cells.
HJ16 cells exhibited low intracellular calcium signalling and low proliferative rate. 
Depletion of GSH decreased intracellular calcium signalling and proliferation of both 
J16 and HJ16 cells. Increased GSH levels in J16 and HJ16 cells had no significant 
effect on intracellular calcium signalling, but significantly increased the proliferation 
o f these cells.
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In addition, the intracellular GSH concentration in T cells provides a central role for 
modulating responses elicited by antigen and cytokine signals. At higher 
concentration of GSH (after NAC treatment, but not after exposure to oxidative 
stress), proliferation will be favoured, whereas, at lower concentrations of GSH, an 
inflammatory-type response is more likely to occur. Moreover, when GSH levels are 
low, T cells fail to flux calcium or to proliferate. Instead, they respond strongly to 
inflammatory cytokine stimulation with changes in cellular protein phosphorylation 
and induction of transcription factors.
These results suggest a possible role of hypoxia and the interaction between T cells 
and monocytes in the rheumatoid synovium, which leads to the enhanced production 
of proinflammatory cytokines and perpetuation of inflammation.
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6.5 FUTURE DIRECTION
ROS accumulation in J16 and HJ16 cells can be measured before and after treatment 
with BSO or NAC, with effect on MAPK and transcription factors (such as NF-kB) 
essential for cytokine production and cell surface molecules expression and their 
ligands.
Cell-cell contact is a potent mechanism, which induces both anti-inflammatory and 
pro-inflammatory cytokines. Several receptors have been shown to be involved in this 
including, CD40, CD40L, CDllb-CD18, and CDllc-CD18, CD23, CD69, LFA-1 
and others. These molecules can be investigated on HJ16 cells.
Further investigation of the T cells and soluble factors (other than IL-17) involved in 
the co-culture could be highly productive. Modulation of antioxidants (with BSO or 
NAC) on soluble factors released by T cells or monocytes can be studied.
Moreover, calcium signalling in HJ16 cells and the BSO-treated T cell line was 
significantly reduced, molecules involved in calcium signalling such as IP3 and 
calcium-binding proteins can be investigated in HJ16 cells and related to chronic 
exposure to oxidative stress.
Finally, the different patterns of IL-lra achieved by THP-1 cells and fresh PBMCs 
can be studied further. This may involve cell surface molecules expressed on THP-1 




Culture Media, solutions and Buffers 
R P M I1640
Milli-Q water 400 ml
RPM I(lOx) 50 ml
FCS 50 ml
Penicillin (lOOOIU/ml/Streptomycin (1000 pg/ml) 5 ml 
Sodium Bicarbonate (7.5% w/v) 15 ml
L-Glutamine (200 mM) 5 ml
Soudium Hydroxide (10 M) 800 pi






Alternatively, for tissue culture work, 5 tablets (Oxoid) in 500 ml Milli-Q water.
ELISA Solutions
Coating buffer: 0.5 M carbonate-bicarbonate buffer, pH 9.6.
Blocking buffer: 1% BSA, 5% sucrose in PBS, pH 7.4.
W ash buffer: 0.05% Tween 20 in PBS, pH 7.4.
Tris diluent: 0.1% BSA, 20 mM Trisma base (2.42 g/1), 150 mM NaCl (8.76 g/1), pH 
7.3.
Stop solution: 0.5 M Sulphuric Acid.
Proliferation assay
Phenazine methosulfate (PMS): 1.53 mg/ml in PBS (5 mM stock solution stable at 
4C° for 3 months), protect from lighlt.
XTT: 1 mg/ml in RPM I medium, make up fresh a t time of assay, dissolve at 37C° 
XTT-PMS:
To 1 ml of the XTT mixture, add 5 pi of PMS stock.
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SDS-PAGE gel solutions (western blot)
5x TBE Buffer
Tris base 54 g
Boric acid 27.5 g
0.5 M EDTA (pH 8) . 20 ml
Milli Q water to 1000 ml
Blue Juice
Bromophenol blue 50 mg
Ficoll 400 3 g
Milli Q water 20 ml
Reservoir Buffer
25 mM Tris 3.03 g
192 mM glycine 14.4 g
0.1% SDS (Lauryl sulfate) 1 g
Milli-Q water 1000 ml
Semi-dry transfer buffer
48 mM Tris 5.81 g
39 mM glycine 2.93 g
SDS 0.375 g
Methanol 200 ml
Milli-Q water 800 ml
Wash/Blocking buffer (TBS-T, lOx) (pH 7.5)
10 mM Tris 
100 mM NaCl 
0.1% Tween-20 
Milli-Q water
For blocking add 5% non-fat powder or 1% BSA
4x Resolving gel buffer (pH 8.8)
1.5 M Tris 
0.4% SDS 
Milli-Q water
4x Stacking gel buffer (pH 6.8)





Resolving gel buffer (pH 8.8) 5 ml
Bis-Acryl (30%) 6.67 ml














Milli-Ro water 6.85 ml
Stacking gel buffer (pH 6.8) 3 ml
Bis-Acryl (30%) 2 ml
10% AMPS 150 |il
TEMED 10 pi
Lysis Buffer (pH 7.5)
20 mM Tris 0.242 g
137 mM NaCl 0.801 g
NaF (500 mM stock) 2 ml
ImM EDTA100 mM stock 1 ml
1% Glycerol 10 g
1% NP-40 (IGEPAL) l g
Milli-Q water make up to 100 ml
The following reagents must be added immediately prior to use:
1 mM sodium orthovanadate (500 mM stock) 0.2 pl/ml
1 mM PMSF (500 mM stock in DMSO) 2 pl/ml
Aprotinin 2 mg/ml stock 2 pl/ml
Leupeptin 2 mg/ml stock 2 pl/ml
Pepstatin A 5 mg/ml stock 0.4 |il/ml
2x Sample buffer (pH 6.8)
125 mM Tris 1.51 g
4% SDS 4 g
10% Mercaptoethanol 10 ml
20% Glycerol 20 g
0.04 % Bromophenol 0.04 g
Milli-Q water make up to 100 ml












0.5 M EDTA 
(Filter in the hood)
DTNB (prepare fresh each time of experiment)
DTNB
0.5% sodium bicarbonate (NaHCC>3)
Dissolve at 37°C for 20 minutes, and sonicate in 
minutes, protect from light.
GSH reductase
0.1M Phosphate buffer ImM EDTA 2 ml
GSH reductase (stock) 17.3 pi
p-NADPH: prepare a stock solution of 5 mM in 0.5% NaHCC>3, protect from light 
and store at -20°C.
Buthionine-DL-sulfoximine (BSO), diethyl M aleate (DEM), and diamide: prepare 
fresh at 50 mM working solution with RPMI.




Sodium bicarbonate 5 ml (to give pH 7.4)
Propidium  iodide: lmg/ml (Milli-Ro water).
3 mg 
2 ml
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